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 Abstract 
This research aimed to examine the relationship between dietary interactions, health and 
disease and the effects of nutritional intervention on metabolic phenotype.  High 
throughput proton nuclear magnetic resonance spectroscopy and liquid chromatography 
mass spectrometry analytical platforms coupled with multivariate statistical methods 
were utilised to identify metabolic changes in biological fluids related to nutritional 
status and intervention. These metabonomic approaches were applied initially to an 
animal study and subsequent human studies. 
 
The aims of this research were tackled by examination of a preliminary animal study to 
assess the effects of methyl eugenol, a natural dietary flavour component that is 
genotoxic, on rat metabolic phenotype by analysis of urinary metabolic profiles. Methyl 
eugenol alterations of urinary metabotype at relatively low doses (1-50mg/kg bw/day) 
could not be discriminated, however discrimination based upon age, sex and 
administration method (orogastric gavage vs. dietary matrix) could be seen. 
 
A second study examined the effects in humans of dietary fat and carbohydrate 
composition on the development of metabolic syndrome by analysis of urinary and 
faecal water metabolic profiles.  Dietary intervention did not produce statistically 
significant alterations of human urinary and faecal water metabotype. Furthermore, 
regression analyses of bacterial population numbers to 
1
H-NMR spectroscopic data of 
both urine and faecal water also did not produce statistically significant modelling of the 
datasets. This study highlighted the need to limit inter-subject variability particularly in 
human nutritional intervention studies.  
 
The third metabonomic study investigated the effects of cruciferous vegetable, meat 
meal and caffeine dietary intervention on the human urinary metabolic phenotype by 
1
H-NMR spectroscopy and UPLC-MS analysis.  Chemometric analysis of the 
1
H-NMR 
spectral dataset, use of two-dimensional NMR experimentation and synthetic standard 
urine spiking experiments identified S-methyl-L-cysteine-sulphoxide (SMCSO) and N-
acetylated-SMCSO as urinary biomarkers of cruciferous vegetable consumption in man.  
Multivariate statistical analysis of the 
1
H-NMR spectral dataset identified post-prandial 
biomarkers of meat meal consumption and bacterial co-metabolite excretion in human 
urine. Targeted interrogation and multivariate statistical modelling of the UPLC-MS 
database identified 36 tentative biomarkers of cruciferous vegetable, meat and caffeine 
dietary interventions. 
 
This research demonstrated the successful application of metabonomics to the study of 
nutritional intervention and the identification of biomarkers of dietary exposure. Also 
highlighted were the challenges of biomarker identification particularly in UPLC-MS 
datasets and the need to limit both experimental and inter-subject variations in 
metabonomic studies of human biofluids.  
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Chapter One – Introduction 
 
1.1 Nutrition in health and disease 
Diet and nutrition are known to be very important factors in the prevention of many 
chronic disease conditions and the maintenance of good health. The nature of the links 
and mechanisms between diet and health and as determinants of chronic disease are of 
prominent scientific and public health interest. Chronic diseases such as obesity, 
diabetes, cardiovascular diseases, cancer and many others are deemed preventable or at 
least ameliorated by alteration of diet and/or lifestyle. Chronic diseases are largely 
deemed preventable; however more research is required to elucidate the mechanisms 
which link diet to health and a reduction in disease incidence and the dietary 
components which contribute both detrimentally and beneficially to health. In the 
interests of the public, the favoured course of action is prevention by dietary 
intervention, which is seen as being more cost-effective and sustainable than the use of 
medical treatments.  
 
Although age, sex and genetic factors can determine the incidence of chronic disease, 
many risks are due to environmental and lifestyle choices such as diet, physical 
inactivity, smoking, alcohol consumption and the impact of environmental toxins 
through inappropriate food choices. Also biological factors such as dyslipidaemia, 
hypertension, obesity and hyperinsulinaemia impact on chronic disease incidence. 
Traditional plant-based diets around the world have largely been replaced by processed 
high-fat, energy dense diets with substantial content of animal products. It is known that 
diets rich in fruits, vegetables and plant materials can prevent the onset of many chronic 
diseases in man, particularly cancer 
1-4
. The mechanisms whereby bioactive plant 
components offer protection are a major focus for understanding the relationship 
between diet and disease.  
 
The incidence of chronic diseases related to diet is rapidly increasing, accounting for 
60% of the 56.5 million total reported deaths worldwide in 2001 
5
.  Almost half of these 
are associated with cardiovascular disease (CVD), obesity and type II diabetes. 
Estimates suggest around half the women and a third of the men in UK are clinically 
obese (http://www.food.gov.uk/). Furthermore around 25% of the UK population 
demonstrate symptoms of metabolic syndrome (MS) 
6, 7
. MS is a condition 
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characterised by an increased risk of coronary heart disease (CHD), type II diabetes and 
many forms of cancer. Symptoms of this metabolic condition are dyslipidaemia, 
hypertension, insulin resistance and increased bodily fat ratios. There is evidence that 
the amount and type of dietary fats and carbohydrates in the diet directly influence 
blood lipid profiles, insulin sensitivity, endothelial function and blood pressure 
8, 9
.  The 
quality and quantity of carbohydrates in the diet, particularly the glycaemic index (GI), 
are also known to have an impact on the development of many chronic diseases. The GI 
is the ranking system (low 0-100 high) of carbohydrates based upon how rapidly they 
are converted to simple monosaccharides and absorbed into the blood stream. High GI 
carbohydrates such as refined simple sugars typical of industrialised diets cause spikes 
and instabilities in the blood sugar level, leading to hyperinsulinaemia, type II diabetes 
and there is also clear evidence of increased risk of CVD 
10, 11
. 
 
A diet containing substantial quantities of fruit, vegetable and fibre has been shown to 
be protective against many forms of cancer and conversely a diet rich in animal 
products causative of cancers such as colon, bowel, lung and prostate 
12-17
 and also the 
development of CVD 
18, 19
.  
 
The relationship between diet and disease and particularly the chemoprotective 
properties of many compounds derived from fruits, vegetables and plants commonly 
consumed in the human diet are subject to substantial research focus. 
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1.2 Diet and Cancer risk factors 
Humans are exposed to a vast array of environmental chemicals and behaviours that can 
affect the incidence of cancer, both in a beneficial and detrimental way.  
 
The major environmental causes of cancer are thought to be smoking, dietary 
(carcinogenic food components, macro- and micronutrient imbalances), chronic 
bacterial and viral infections such as HPV (human papillomavirus) in cervical cancer 
and also hormonal factors 
20. The most important factor on an individual‘s risk of cancer 
is lifestyle choice. For example, smoking increases the risk of lung, larynx, nasal, 
bladder and oesophageal cancers. Tobacco smoke contains many chemical carcinogens, 
tumour promoters and co-carcinogens eg. Aromatic amines, phenols, aldehydes and 
polycyclic aromatic hydrocarbons. Other than exposure to tobacco smoke, the human 
diet is known to contain a vast array of compounds which increase the risk of cancer 
such as the cooked red meat heterocyclic amines PhiP (2-Amino-1-methyl-6-
phenylimidazo[4,5-b]pyridine) and MeIQX (2-Amino-3,8-dimethylimidazo[4,5-
f]quinoxaline) 
21
, edible plant flavanoids, alkenylbenzene derivatives 
22
, food additives 
and contaminants such as the fungal mycotoxins aflatoxin B1 and PAH 
23, 24
.  
 
It is known from epidemiologic studies that an unhealthy diet can be the primary cause 
of between 10-30% of cancer deaths
25
. 
 
Although the chemical food components which can cause cancer are known, there are 
hardly any specific foods which convincingly increase or reduce cancer risk. This is 
thought to be attributable to the fact a person‘s diet consists of many different foods, 
nutrients and chemicals which can affect risk and the actual establishment of a person‘s 
diet is confounded by the problems of accurate reporting and recall
26
. 
 
The consumption of fibre has been demonstrated recently to be inversely correlated with 
bowel cancer in a large European epidemologic study the European Prospective 
Investigation into Cancer and Nutrition (EPIC) 
27
. It was shown that the people who had 
the highest fibre consumption were 15-40% less likely to develop bowel cancer. There 
have been conflicting reports on the incidence of bowel cancer and fibre consumption in 
other investigated populations
28, 29
, but this is confounded by studies in American 
populations where fibre consumption is very low by comparison would not detect this 
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correlation. It is thought that fibre protects against bowel cancer incidence by 
encouraging fermentative bacteria to produce short chain fatty acids
30
 including butyrate 
which has been shown to inhibit in vitro cancer cell growth
31
. 
 
It is reported that increased fruit and vegetable consumption can prevent the risk of 
development of mouth, oesophageal, stomach and lung cancers
32, 33
 but no association 
has been identified with prostate, ovarian or kidney cancers
34-36
. Specificially the 
highest consumers of fruits and vegetables could reduce their incidence of 
oesophageal
37
 cancer by a third and lung cancer by a quarter
38
. 
 
Although, fruit and vegetables are undoubtedly a good source of vitamins, essential 
minerals and fibre the exact components responsible for the associated reduction of 
cancer risk is unclear and in isolation many micronutrients can actually exacerbate 
cancer risk
39
. It is most probable that variation in fruit and vegetable consumption and 
the synergistic effects of all micronutrient components are essential for the 
chemoprotective effect observed in large cohort epidemiologic studies
40
.  
   
The effect of eating red and processed meat and cancer risk is well documented and is 
known to influence bowel cancer risk and that high consumers, particularly of processed 
meats were particularly at a greater risk
4, 15
. Red meat consumption has also been linked 
to the development of pancreatic
41
 and stomach cancers
42
. However, there is no strong 
evidence that eating white meats can increase risk in the same way as red and processed 
meats
43
. 
 
It has been suggested that haem present in red and processed meats is responsible for 
the difference in effect of red and white meats on cancer risk. Haem has been 
demonstrated to be metabolised by gut microbes into N-nitroso compounds which are 
known to be carcinogenic
44
. Haem may also cause irritation and inflammation of the gut 
mucosa promoting carcinogenic processes
45
. However, chlorophyll present in green 
vegetables may ameliorate the effects of haem in red and processed meats
46
. It is also 
believed that nitrite compounds used as preservatives in processed meats may also 
contribute to stomach cancer incidence
47
. The nitrites have also been shown to be 
converted into N-nitroso compounds in the gut
48
. 
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Cancer risk is also known to increase due to deficiency of many essential micronutrients 
such as folic acid, vitamin B12, iron, selenium, vitamin E, folic acid, vitamin C, vitamin 
D, and calcium 
49
. 
 
1.3 Plant phytochemicals- Janus properties 
Commonly consumed vegetables, fruit and plant materials contain a range of low-
molecular weight secondary metabolites, which serve to protect the plant against attack 
by predators or pathogenesis of microbes, in the interaction of the plant with its 
environment, seed dispersal and flower pollination. Plants rely on their diversity of 
secondary metabolites, enzymatic defences and their cell walls, in the absence of the 
proteinaceous immune system found in animals, as a form of protection against 
physiological stress and attack 
50
. 
 
Several hundred different plant species are regularly consumed by humans as food, 
which has placed selection pressure on varieties low in toxic compounds, and the 
promotion of the content of secondary metabolites with beneficial properties, such as 
reducing undesirable chemicals such as tannins, alkaloids, terpenoids and phenolics. In 
spite of this reduction of the plants endogenous defences due to cultivation practices, 
significant levels of biologically-active plant metabolites have evolved concurrently 
with humans. Many chemicals contained in the matrix of commonly consumed 
vegetables and plants are potentially toxic and can act as modulators of gene or protein 
expression 
51
, as genotoxins 
24
,  as carcinogens 
52
, as metabolic inhibitors 
53
 or as 
enzyme inactivators 
54
. Any diet in which plant foods are consumed will contain 
chemicals which have potentially negative effects on health. These compounds are 
primarily absorbed in the gut and metabolised in the liver where they may be activated 
by phase I and II enzymes. The compounds themselves or their metabolites can disrupt 
homeostatic regulation by interference with the biochemistry of human cells. In the past 
research focus was upon toxic secondary metabolites such as cyanogenic glycosides in 
cassava 
55
, the glycoalkaloids in potatoes and tomatoes 
56
 and goitrogens 
57
. 
Overwhelming epidemiological evidence of an inverse relationship between plant 
material consumption and many forms of cancer and chronic disease has changed this 
research focus 
3
. However, there are many plant secondary metabolites that are still of 
public health concern, particularly those that are manufactured and utilised as additives 
in food and cosmetics such as the flavanoids and alkenylbenzene compounds 
22, 58
.  
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Many bioactive food compounds have been found to have antinutritive value (ie. goitrin 
in livestock) 
59, 60
. These plant compounds can possess outright toxic effects and in 
some instances carcinogenic potential 
61
. Plant phytochemicals can possess ‗Janus‘ 
properties of having both beneficial and detrimental effects to health dependent on 
concentration, cell type and secondary metabolite formation. Such phytochemicals can 
have procarcinogenic, anticarcinogenic and co-carcinogenic properties 
62
.  
 
For example, following biotransformation the alkenylbenzene derivative methyl 
eugenol (commonly consumed as a food additive, flavouring agent and found in varying 
amounts in basil, mace, nutmeg, tarragon, bananas and clove oil) has been demonstrated 
to have genotoxic effects in animal models and is carcinogenic 
63, 64
. The evaluation of 
the potential carcinogenic properties and toxicity of such commonly consumed plant 
phytochemicals is of great importance to public health. 
 
However evidence overwhelmingly suggests a strong connection between vegetable and 
plant consumption and a reduction in incidence of many chronic diseases; such as 
cardiovascular disease 
2
, type II diabetes 
65
, Alzheimers 
66
 and an inverse relationship 
with many forms of cancer 
3, 67
.  
 
It is generally agreed that diets in which there is a high consumption of a variety of 
fruits and vegetables is beneficial to human health, however the extent to which plant 
secondary metabolites contribute to this effect, as opposed to antioxidant vitamins and 
other essential micronutrient components, is the subject of debate 
68-70
. 
 
The way in which plant phytochemicals reduce the incidence and severity of many 
chronic diseases is not fully understood. It is believed that the health benefits of 
consumption of vegetables and plant materials are additive and synergistic and involve 
combinations and interactions of plant phytochemicals in humans 
39
. 
 
Amongst the most studied and potent phytochemicals identified are the hydrolysis 
products of the glucosinolates found in many varieties of the cruciferae, over 120 
different vegetable glucosinolates have been identified 
71
. It is believed that the 
abundance of glucosinolates is responsible for the epidemiological evidence of an 
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association of cruciferous vegetable consumption with a decreased risk of lung, 
stomach, colon and rectal cancer 
17
. 
 
The active forms of many phytochemicals are limited by their bioavailability, 
concentration and ability to reach the relevant sites of the body. The concentration of 
dietary phytochemicals varies between cultivars and is highly dependent on storage and 
growing conditions. The liberation, absorption, distribution, metabolism and excretion 
(LADME) of bioactive compounds are all important considerations when interpreting 
epidemiological studies identifying a relationship between diet and health 
72
. It is 
normally the metabolites of the parent compounds of dietary phytochemicals that are 
responsible for the observed effect in in vitro, in vivo and epidemiological studies. 
These active metabolites are either produced by action of vacuole bound enzymes 
within the plant material released following disruption of the cell wall ie. 
mastication/processing or by extensive phase I metabolism in the liver and intestine in 
the human body.  In view of this many in vitro studies of plant phytochemicals need to 
be tentatively interpreted and use of parent compounds, plant extracts or metabolites in 
organ-specific cell cultures do not represent the complexity of the biological interaction 
in vivo.  
 
Humans are exposed to an enormous diversity of plant phytochemicals in their diets 
with beneficial or sometimes detrimental effect on health and incidence of chronic 
diseases. The mechanisms of dietary food components are difficult to predict in the 
context of studies of dietary intervention but are of great importance to preventative 
medicine and reducing the incidence of many chronic diseases.  
 
1.4 Methods of assessing the relationship between diet and health 
The assessment of the relationship of specific dietary components and health outcomes 
and the use of experimental dietary interventions in human subjects is extremely 
challenging. The optimisation of specific foods and their bioactive compounds 
represents a sensible, non-invasive and cost-effective method of reducing the global 
burden of cancer and other chronic diseases 
73
. However the identification of dietary 
compounds which are critical to human health is compounded by the thousands of 
compounds which are introduced into the human body by diet 
39
. There also exists a 
lack of dietary exposure quantitation for many compounds commonly consumed in the 
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human diet, which makes extrapolation of actual contribution to health outcomes 
difficult to assess. For example humans consume over 5000 different flavanoids, of 
these only a few individual compounds have been assessed for their beneficial health 
properties 
73
.  Many plant phytochemicals remain entirely uninvestigated and the 
individual treatment of phytochemical components of food in isolation can lead to 
confusion of the role of diet and health. A holistic approach to the investigation of diet 
and beneficial/detrimental human health outcome is essential, particularly as it is 
thought that synergistic interactions among food components are crucial to their 
beneficial effects and many isolated components do not always result in the similar 
outcomes as in the intact plant material 
71, 74
.  
 
In many cases in vitro empirical evidence is directly extrapolated from the laboratory 
bench to a supposed effect in vivo in humans. The observed effects should be used as an 
indication of potential in vivo effect and as a guide to further complete study within 
human subjects. Proposed mechanisms of action within cell culture is not necessarily 
true within the complex endogenous and microbiotic metabolism of a human 
―superorganism‖ 75. Pleiotrophic factors influence the absorption, bioavailabilty, 
exposure and action within human subjects.   
 
For example, the majority of evidence concerning the anticarcinogenicity of cruciferous 
vegetables and their glucosinolate hydrolysis products comes from in vivo animal 
studies and in vitro cell cultures in which the ITC or indole has been used in isolation 
76
. 
In animal models and cell systems, combinations of ITCs have been shown to confer 
protection against genotoxic agents better than individual ITCs 
77
. The focus on the 
individual components ignores the potential for chemical interactions and 
chemoprotective contributions from other compounds found in the normal matrix of 
cruciferous vegetables. Inter-species differences and the use of doses of the hydrolysed 
glucosinolate and carcinogenic compounds far in excess of the estimated levels in a 
normal human diet hinder extrapolation of the results of animal studies in relation to 
humans. Quantities of  ITC‘s utilised in in vitro studies are usually far in excess of  
human exposure levels and cause acute cellular stress which may promote apoptosis and 
cell cycle arrest and may not be a relevant effect in human subjects 
78
.  
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However, in vivo human studies have strongly supported the beneficial effects of CV at 
high but realistic consumption levels 
16, 79-82
. This is in accordance with the 
epidemiological evidence of the negative correlation between high cruciferous 
vegetable consumption and the incidence of diet-related cancers 
71
.  
 
The design of scientific experiments assessing the effects of dietary interventions in 
humans and experimental animals is crucial to establish correct nutritional advocation, 
addressing the relationship of diet and disease and acquiring a holistic picture of the 
interactions of plant phytochemical and other dietary components 
83
. The limiting factor 
remains the design of well defined nutritional interventions that assess the long-term 
effects of bioactive food components and foods, particularly the speed of discovery and 
cost of set-up. 
 
Further problems arise in nutritional intervention studies in humans where dietary 
restrictions and incomplete or falsified food diaries/food questionnaires can confound 
data interpretation and produce false positive or negative results.  Estimation of dietary 
intake is prone to error as many people‘s diets are extremely complex and consist of 
many different foods which are consumed intermittently. The two most commonly used 
form of dietary assessment are food frequency questionnaires (FFQ) and 24hr dietary 
recalls. The FFQ is a convenient and inexpensive way to measure an individual‘s 
dietary intake over a long period of time, however they are prone to incorrect dietary 
―self-reporting‖ 84 with an under-reporting of energy and protein intake by 20-50% 85. 
This is even more detrimental when considering dietary components consumed at 
concentrations several orders of magnitude lower, such as plant phytochemicals and 
micronutrients. Twenty-four hour dietary recalls provide more in depth information but 
yet again when a dietary intervention is based on restriction or a reduction of 
consumption of certain foodstuffs, these can be falsified and intake on a single day is a 
poor predictor of long-term intakes. These methods of assessment are also costly both in 
time and financially 
86
. 
 
The compositional analysis of food also presents analytical problems where a great 
variation in macro- and micronutrient contents exists. The specific cultivar and growing 
conditions of plants can determine a great variation in the content of many 
phytochemicals and micronutrients. For example the concentration of glucoraphanin in 
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broccoli is known to vary by as much as 25 fold depending on the cultivar 
87
.  Also the 
selenium content of many plants is affected by the selenium content of the soil 
88
.  
 
The method of food processing is also very important in the absorption of dietary food 
components, as has been observed in increased lycopene availability in tomatoes 
following cooking and processing 
89
 and the decreased enzymatic activity reducing the 
cancer-protectant properties in heated garlic 
90
.  
 
The quantification of dietary components is essential to a scientifically sound dietary 
intervention study, however the methods of processing and cooking should also be 
considered. These factors can all affect the absorption, metabolism, distribution and 
excretion of dietary food components and therefore exposure of the compound to the 
target organs and tissues of interest. It is of great interest to combine the assessment of 
dietary intake, the interplay of genetic factors, the influence of the gut microbiota, the 
pharmacokinetics, pattern of intakes and effects of other environmental factors in 
nutritional intervention studies. This represents one of the major challenges of 
modelling ―mammalian biocomplexity‖ and the effects of dietary components in both 
health and disease 
75
. 
 
1.5 Biomarkers of nutritional intervention 
Biomarkers of exposure, effect and susceptibility can potentially circumvent the 
aforementioned problems associated with assessing the relationship between diet and 
detrimental/beneficial health outcomes and the efficacy of dietary interventions. 
 
A biomarker is any substance which can be monitored in tissues or biofluids which 
either predicts or influences health, the exposure to dietary components or can influence 
the incidence or behaviour of a disease 
91
. Biomarkers which are able to account for the 
variations in physiological state and which truly predict diseases states and outcomes 
have rarely been absolutely identified and usually represent biomarkers of an increased 
risk of detrimental/beneficial health outcomes 
92
. There is little distinction between the 
requirement for biomarkers which identify the effects of beneficial phytochemicals and 
food components and biomarkers for environmental toxins and factors detrimental to 
health; in both cases these are equally elusive 
74
. 
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Biomarkers which are able to determine exposure to specific foods or components and 
also to inform on specific biological effects and inter-individual differences in effect, 
exposure and metabolism are needed for nutritional intervention studies. The selection 
and validation of potential biomarkers relies upon the ability to easily and reliably 
identify them in response to specific dietary intervention or disease state. 
 
The use of molecular biomarkers to assess dietary exposures is highly desirable to 
identify predictors of dietary intake and as a means to quantify dietary exposure to a 
particular food stuff or dietary component. These could also potentially provide further 
insights into the mechanisms of action of beneficial/detrimental dietary components and 
be used to assess correlations between dietary exposure of certain foods and population 
epidemiological studies of disease incidence and risk and have important implications 
for disease prevention and public health. 
 
As an example mercapturic acid conjugates of the hydrolysis products of glucosinolates 
are the most commonly studied biomarker of CV consumption. However,  the excretion 
of these biomarkers is highly dependent on inter-individual genetic differences, 
metabolic differences, abundance of the particular glucosinolates in the vegetable 
consumed, cooking method, bioavailability, level of absorption, bacterial metabolism 
and the rates and specific metabolic endpoints of myrosinase hydrolysis in the plant 
material 
93
. A more specific, predictable and stable biomarker of CV consumption is 
desirable for assessment of epidemiological data, dietary intervention study adherence 
and dietary assessments in human populations. There remains great need for non-
invasive biomarkers in both humans and animal experimental models related to dietary 
intervention. 
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1.6 Metabonomics 
Any alteration in physiological state in an organism can lead to perturbations of the 
levels of endogenous compounds involved in important biochemical pathways. This 
causes a disturbance in the cell; in order to return to a state of homeostasis a cell must 
alter its biochemical composition and this is reflected in the surrounding biofluid. 
Therefore dynamic changes in biofluid composition can indicate the underlying 
molecular mechanisms involved following physiological changes. These subtle 
perturbations can be examined by high-resolution spectral techniques such as 
1
H-NMR 
spectroscopy and can yield information of particular metabolic pathways involved in 
disease states, toxicology, drug metabolism studies and nutritional interventions 
94-96
. 
 
This study of dynamic changes in low molecular weight metabolites in biofluids such as 
urine, faecal water, blood serum, cerebral spinal fluid, saliva etc. and also in cells and 
tissues is known as Metabonomics. Metabonomics is defined as ―the quantitative 
measurement of the dynamic multiparametric metabolic response of living systems to 
pathophysiological stimuli or genetic modification‖97 and it relies heavily on high 
resolution spectroscopy and on chemometric techniques to interpret the complex 
multivariate spectral data. 
 
Individual patterns of metabolite changes represent the fluxes and alteration of the 
concentrations of the low molecular weight components of biofluids in response to 
homeostatic perturbation. Metabonomics analyses provide a time-related snap shot of 
the metabolic state of an individual. The metabotype is defined as the ―probabilistic 
multiparametric description of an organism in a given physiological state based on 
analysis of its cell types, biofluids or tissues‖ 98. By taking serial measurements, the 
dynamics of such perturbations can be evaluated. Metabonomics can be applied to the 
process of biomarker discovery. Due to its sensitivity subtle perturbations of biofluids 
resulting from dietary interventions can be determined 
96
. 
  
 13 
 
1.7 Application of metabonomics to nutritional intervention studies 
The concept of metabonomics has largely been developed within toxicology and drug 
metabolism studies. However, the role of diet in metabolic outcomes in toxicology 
studies has been recognised as crucial for some time. The study of cadmium chloride 
utilising 
1
H-NMR in rats observed that acute caloric restriction increased levels of 
plasma creatine 
99
. 
 
Food-specific biomarkers that are present in the blood serum or urine can either be 
exogenous compounds whose mere presence indicates consumption of the food stuff or 
a significant change in an endogenous metabolite effected either by an increase or 
depletion by the dietary intervention concerned. In many cases, these compounds are 
phytochemicals or non-nutrients which are unmetabolised, or they represent secondary 
metabolites which can be eliminated by the same routes as many xenobiotic compounds 
by glucoronidation, sulphation or glycosylation. However, foodstuffs unlike drugs 
represent a complex matrix of exogenous constituents rather than a specific known 
compound. In spite of this complexity when considering dietary intervention 
Metabonomic techniques can be applied to the determination of the subtle metabolic 
consequence of dietary intervention and for the purposes of biomarker discovery. This 
has been demonstrated in a number of studies where low molecular weight biomarkers 
of dietary intervention were found to predict exposure to different dietary components.  
  
Notably discrimination has been achieved in several human studies contrasting 
vegetarian, high and low meat diets with metabolites characteristic of both meat 
exposure and vegetarian metabotype reported 
100-102
 and in metabonomic studies of 
dietary standardisation in humans, intersubject variations were found to be most 
reduced within urine, in contrast to saliva and blood serum 
103
. Endogenous metabolite 
concentration changes in lactate, alanine and citrate have also been reported in human 
urine samples attributable to a carbohydrate-rich diet
104
. Discriminatory urinary 
metabolites related to the effects of cooking protein
105
 and blood serum metabolites of 
cooking of vegetables (alpha-carotene)
106
 have also been identified.  During the heat 
treatment of protein-containing foods, the amino acid lysine is most prone to undergo 
chemical reactions in the course of amino acid cross-linking or Maillard reactions. 
Among the reaction products formed, lysinoalanine, N-fructoselysine and N-
carboxymethyllysine were found to be metabolites in increased concentration in rat 
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urine 
105
. The effects of cooking onions in a dietary in intervention study in humans 
identified diagnostic urinary biomarkers (quercetin, methyl quercitin and quercitin 
glucuronides) by HPLC-tandem MS/MS analysis
107
. Urinary metabolic changes 
characteristic of consumption of other protein sources have also been identified in 
milk
108
 (increased hippurate) and fish
109
 (trimethylamine and trimethylamine-N-oxide). 
 
Metabonomics has also successfully characterised the effect on metabolic phenotypes of 
chamomile 
110
, ethyl glucoside as a biomarker of alcohol dietary intervention 
111
, in soy 
isoflavone dietary intervention which was found to have effect on osmolyte and energy 
metabolic pathways 
112
. The effect of epicatechin, a phytochemical founds in many 
foods such as green tea and dark chocolates, has also been examined using 
1
H-NMR 
spectroscopy coupled to metabonomic chemometric analyses in Sprague-Dawley rats. 
Urinary profiles showed decreased concentrations of 2-oxoglutarate, citrate, 
dimethylamine and taurine attributable to epicatechin intake. These were concluded to 
be attributable to shifted energy metabolism from carbohydrate to lipid/amino acid 
metabolism and highlighted the ability of the metabonomic method to study the 
bioactivity of dietary plant phytochemicals 
113
. 
 
Mennen et. al. 
114
 report a number of urinary metabolites which are characteristic of 
polyphenolic rich foods utilising HPLC-MS analysis such as wine (gallic acid and its 
metabolite 4-O-methylgallic acid), coffee (chlorogenic and caffeic acids), apple 
(phloretin), orange (hesperetin) and polyphenolic naringenin is reported to be diagnostic 
of both grapefruit
114
 and cacoa comsumption
115
. 
 
There are a number of studies that have reported metabolites associated with black tea 
consumption specifically gallic acid and its metabolite 4-O-methylgallic acid 
114
  
A comparison of the effects of green tea and black tea consumption in humans using 
metabonomic analysis of urine and blood serum revealed gut-bacterially derived 
metabolic endpoints of tea consumption, hippurate and 1,3-dihydroxyphenyl-2-O-
sulphate in urine. Most interestingly green and black teas were found to have a 
differential effect on the excretion of endogenous human metabolites. Green tea was 
shown to decrease concentrations of several urinary citric acid cycle intermediates and 
black tea blood serum levels of lipoproteins, glucose and acetate. This study revealed a 
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possible effect of tea consumption on energy metabolism and biosynthesis in humans 
116
. 
 
Recently a novel metabolic profiling strategy for food biomarker discovery combined a 
nutritional intervention with citrus fruits and validation with a large-scale 
epidemiological study 
96
. Proline betaine a biomarker of citrus fruit consumption was 
identified in a human citrus fruit dietary intervention study by 
1
H-NMR spectroscopy. 
The plant origin of this osmolyte was then identified in citrus fruits by targeted 
1
H-
NMR spectroscopy. Finally, the putative biomarker was validated by profiling in 
1
H-
NMR spectra of urine in citrus fruit consuming and non-consuming UK participants of 
the INTERMAP study (International
 
Collaborative Study of Macronutrients, 
Micronutrients, and Blood
 
Pressure). Citrus fruit consumers in the study were shown to 
consume lower proportions
 
of fats, have lower urinary sodium-potassium ratios, and 
consume higher proportions
 
of vegetable protein, fibre, and most micronutrients than 
non-citrus consumers. This citrus fruit biomarker identification strategy was successful 
in correlating presentation of this biomarker in human urine in a large scale 
epidemiological study and healthier eating patterns. 
 
It is known that, particularly within human subjects a high genetic, environmental and 
dietary diversity exists within a population. This is particularly confounding within 
multivariate statistical analyses of human biofluids. The limitation of this inherent inter-
subject variability is essential to successful metabonomic analysis, particulary dietary 
intervention which in most instances does little to provoke a dramatic perturbation of 
homeostatic regulation. The biofluids of humans are also thought to be affected by 
pleiotrophic physiological factors unrelated to diet such as hormonal status, diurnal 
cycles and most importantly the inter-individual specificity of the gut microbial 
populations 
75
. Metabonomic technologies represent a powerful tool for the elucidation 
of the effects of dietary intervention. However inter-subject variation particularly within 
human subjects requires consideration, particularly the gut microbiota which is thought 
to be one of the greatest determinants of inter-subject variability. 
 
Diet-induced phenotypic responses are known to be highly individual-specific and are 
influenced by genetic factors (nutrigenetics), gene expression (epigenomics and 
transcriptomics), protein expression and activity (proteomics), fluxes and alterations of 
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small molecular weight compounds (metabolomics/metabonomics) and gut microbial 
contributions to metabolism (microbiological metabonomics) 
117-120
. The effect of 
nutritional intervention and disease incidence is collectively described by the interplay 
of systems biology ―-omics‖ and the identification of biomarkers is made in the context 
of the human ―super-organism‖ 75. 
 
A study examining caloric restriction in mice undertook a systems biology approach 
looking at and correlating blood plasma metabolic changes with genomic transcriptional 
changes in mice. It was found that caloric restriction induced a change in gene 
expression away from lipid biosynthesis towards fatty acid catabolism, β-oxidation and 
gluconeogenesis. Metabonomic changes revealed increasing lactate, 3-hydroxybutyrate, 
cholesterol and low-density lipoproteins with increased creatine and several glucogenic 
amino acids; methionine, glutamine, alanine and valine as a result of acute caloric 
restriction. These results indicated metabolic switching to energy conservation and 
gluconeogenesis due to caloric restriction and successfully illustrate the utility of 
metabonomics within a systems biology approach to metabolic consequences of dietary 
change in experimental animals 
121
. Metabonomic analysis has also been used to 
examine the effects of controlled gene expression on metabolic profiles in a mouse 
model (mnd) of motor neuron degeneration and the effects of vitamin E 
supplementation on blood serum and solid-state MAS 
1
H-NMR spectroscopic profiles 
of cerebral tissue 
122
.
 
 
Metabonomic analysis is still challenged by the difficulty of modelling responses to 
diets or foodstuffs in biologically complex organisms like humans and the ability to 
distinguish between the effects of nutritional intervention and normal physiological 
variation. 
 
1.8 The human gut microbiota 
There are believed to be between 10-100 trillion bacteria inhabiting the human gastro-
intestinal tract with an estimated biomass of ~1.5kg, and they are thought to outnumber 
the individual mammalian cells in the human body 
123
. 
 
There are 500-1000 different gut microbial species co-existing in stationary phase. 
These bacteria are ultimately responsible for physiological and pathological processes, 
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nutrient cycling and syntrophy of food components in the intestinal tract, trophic effects 
on the intestinal epithelia and the immune system and also compete against pathogenic 
bacteria in the intestinal lumen 
124
. It is estimated that 99% of all active genes within the 
human body are microbially derived and as such understanding the symbiotic 
relationships between humans and the gut microbiota is crucial in systems biology 
125
.  
 
The homeostasis of the gut microbiota is influenced by many factors including genetics, 
nutrition, age, stress and sex 
126
. The GI tract is colonised immediately at birth by 
Lactobacilli and Bifidobacteria which assumes an adult colonisation pattern when solid 
food is introduced into the diet 
127, 128
. The microbial composition of the GI tract is 
determined by the transitional decrease in the oxygen level between the upper and lower 
GI tract. Aerobic gut bacteria are thought to utilise oxygen in the upper GI tract which 
supports a favourable environment for facultative and obligate anaerobes further along 
the GI tract 
129, 130
. The complex relationships of human commensual bacteria with other 
species and host have made it extremely challenging to culture individual anaerobic 
species in in vitro assays and will continue to be a barrier to further understanding of the 
proportions of the total component species. However assiduous studies are currently 
being performed to characterise the genetic and metabolic components of the human gut 
microbiota as part of the human microbiome project 
131
. 
 
The human gut bacterial species which are found in the highest proportions have been 
characterised and include obligate anaerobes Bacteroides spp. Provetella, 
Porphyromonas, Bifidobacterium spp., Peptostreptococcus spp., Clostridium spp.,  
Eubacterium spp. and facultative anaerobes Enterobacteriaceae, Streptococcus spp., 
Enterococcus spp., Staphylococcus spp., Lactobacillus spp., and fungi 
131
. 
 
It is known that many metabolites seen in human biofluids are exclusively or 
predominantly microbially derived such as p-cresol and its precursor p-
hydroxyphenylacetate. P-cresol is formed from tyrosine via transamination to p-
hydroxyphenylacetate by P.vulgaris which is then decarboxylated by C.difficile and 
lactobacillus species 
132
. Interestingly, high proportions of anaerobic gut microbes such 
as C.difficile and a depletion of P.vulgaris can indicate poor diet and can lead to a build 
up of p-hydroxyphenylacetate in the urine. The increase in urinary concentration of 
bacterial associated metabolites such as p-cresol is related to amino acid absorption by 
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the gut mucosa, short-chain fatty acid concentration and bacterial activity in the gut by 
species Clostridium difficile 
132
 lactobacilli sp. 
133
 and Clostridium scatologenes 
134
. 
Following p-cresol reabsorption in the intestinal lumen, sulphation occurs 
predominantly in the liver and subsequent excretion of p-cresol sulphate in the urine 
along with many other phenolic bacterial co-metabolites 
135
.   
 
Bacterial metabolites are commonly observed in human biofluids and are related to 
tryptophan transamination, glycine benzoate conjugation (hippurate) and glutamine 
acetylation (phenylacetylglutamine). It has been suggested that the excretion of these 
metabolites serves as an alternative to urea for removal of waste nitrogen 
136
. The 
human colonic microbiota plays a role in human lipid metabolism through the 
production of short chain fatty acids, deconjugation of bile acids and cholesterol 
assimilation in the colon 
137
. Recent studies looking at the metabolic interactions 
between the gut microbiota of and the mammalian host have highlighted the role of the 
gut bacteria in the enterohepatic recirculation and in systemic lipid metabolism 
138
.  
 
It is believed that diet influences the composition and activity of the gut microbiota 
139
. 
In particular, a diet rich in both soluble and insoluble fibres promotes the growth and 
fermentation of some bacterial populations in the colon 
140, 141
. 
 
Evidence suggests that humans and their microbiota have co-evolved to such an extent 
that we cannot survive without them and many commensuals produce essential 
metabolites which humans cannot produce endogenously 
142
. The highly adaptive nature 
of the gut microbiota is highlighted by opportunistic bacteria such as (Entero 
Pathogenic E.coli EPEC) which can assume pathogenic characteristics under stress 
conditions 
143
. Clostridium difficile is also known to become pathogenic in geriatric 
wards where long term low dose antibiotics are used and bacterial resistance emerges 
144, 145
. 
 
Understanding how these symbiotic relationships contribute to metabolic variation in 
nutritional intervention studies is important to understanding the complex interplay of 
nutrition and human health. 
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1.9 Aims and Objectives 
Diet is of crucial importance to health and the prevention of many chronic diseases of 
significant public health concern. Understanding the relationships between food 
components both detrimental and beneficial to health and disease is of vital importance 
to preventative medicine.  
 
There exists a need for non-invasive biomarkers of dietary exposure in both humans and 
animal experimental models for interpretation of epidemiological studies, estimation of 
dietary intakes and exposures and for elucidating the pharmacokinetics of dietary food 
components. 
  
This thesis addressed the hypothesis that application of metabonomic technologies to 
nutritional intervention studies can identify biomarkers of health and disease. 
Specifically I have examined cohort datasets as part of a systems biology approach to 
understanding dietary interactions in: 
1. A dietary intervention study in rats examining the effect of methyl eugenol a 
genotoxic carcinogen on the rat urinary metabolic phenotype. 
2. A dietary intervention study in humans examining the effect of alterations of 
dietary fat composition and GI of carbohydrates in subjects at risk of developing 
the MS on the urinary and faecal water metabolic phenotype. 
3. A dietary intervention study in humans examining the effects on the urinary 
metabolic profile of a CV, meat meal and caffeine dietary interventions.
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Fig. 1.1 Flowchart of thesis structure. 
Chapter 2: Analytical Methods
Chapter 3: Chemometric Methods
Chapter 4: The Effects of the Naturally Occurring Food-Derived
Genotoxic Carcinogen Methyl Eugenol on Rat Metabolic Phenotype
Chapter 5: Changing Dietary Fat Composition and Carbohydrate
Glycaemic Index in Subjects at Risk of Developing the Metabolic
Syndrome
Chapter 6: The Effects of High Cruciferous Vegetable Consumption on
Human Metabolic Phenotypes
Chapter 7: Discussion and Future Work
Chapter 1: Introduction
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Chapter Two:  Analytical Methods 
2.1 An Introduction to Spectroscopy  
2.1.1 Biological Nuclear Magnetic Resonance (NMR) Spectroscopy 
The initial theoretical principle of nuclear magnetic resonance spectroscopy (NMR) was 
first proposed in 1924 by Austrian-Swiss physicist Wolfgang Pauli. He formulated the 
Pauli Exclusion Principle, which stated that no two electrons could exist in the same 
quantum state. This quantum degree of freedom resolved inconsistencies between 
observed molecular spectra and the developing theory of quantum mechanics. Kronig, 
Uhlenbeck and Goudsmit further developed this idea of degree of freedom in 1927 to 
the idea of spin. Certain nuclei possessing spin characteristics would exhibit split energy 
levels when exposed to an applied magnetic field. Pauli also derived the first observed 
spectrum of the hydrogen atom. 
 
2.1.2 Principles of NMR Spectroscopy 
Subatomic particles within an atom possess spin on their axes; in many atoms these spin 
states are paired such that the nucleus has no overall spin. If the neutrons and protons 
are even then the nucleus has no spin. However in 
1
H and 
13
C for example the nucleus 
possesses a net spin. For 
1
H spin is created by the presence of a single proton and no 
neutron, the nucleus has a half integer spin possessing two possible orientations. 
Without an external magnetic field, these orientations have equal energy. When a 
magnetic field is applied, the energy levels of the nuclei in a population split into a 
lower and higher energy level. Initial populations are determined by thermodynamics 
described by the Boltzmann distribution. The application of electromagnetic radiation, 
in this case the magnetic field, will excite nuclei in the lower energy level to the higher 
level. The frequency of radiation needed is determined by the difference in energy 
between the two energy levels, the transitions between nuclear energy levels occur by 
absorption of electromagnetic radiation in the radiofrequency range. 
    
   ΔE=hv 
 
h is Planck‘s constant and v is the frequency of the absorbed radiation. The Larmor 
frequency is defined as the frequency of radiation that causes a spin state transition (ΔE) 
in the nuclei and is dependent on the interaction between the applied magnetic field B0 
and the nuclei.  
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Either nuclei are aligned against the magnetic field in the low energy state, or with it in 
a high energy spin state. The precise amount of energy needed for this transition 
depends on the nucleus in question and strength of the external magnetic field. 
  
   v=γB0/2π 
 
Where v is the frequency and γ is the gyromagnetic ratio a nuclide specific constant that 
provides a measure of the ‗magnetic strength‘ of a nucleus. The intensity of the signal in 
an NMR spectrum is determined by area under the resonance line and proportional to 
the number of nuclei responsible for the NMR signal. This is useful in structural 
determination of the number of protons in each functional group contributing to a peak 
in a 
1
H-NMR spectra.  
 
2.1.3 Relaxation times  
Signal is detected within the radio frequency range; this causes perturbations in the 
magnetisation field. In static magnetic fields nuclei precess about the field with random 
distribution of spin orientations; this is known as the bulk magnetisation vector (Mz), or 
the sum of the individual vectors (Fig 2.1).  
 
Fig. 2.1 Bulk magnetisation vector (Mz) 
The application of a 90º radiofrequency pulse causes the magnetisation of the nucleus of 
interest to tilt perpendicular to the applied field B0 in the x-y plane (Fig. 2.2). Following 
this perturbation the nucleus goes through a relaxation process returning to the Z-axis in 
alignment with the applied field. There are two types of relaxation process, Spin-lattice 
transverse relaxation T1 and spin-spin longitudinal relaxation T2.  
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z
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Fig. 2.2 Effect of 90° pulse tilting magnetisation into the x-y plane 
 
The nuclei within an NMR sample are in vibrational and rotational motion creating a 
complex magnetic field. The sample in which the nuclei are held is known as the lattice. 
The relaxation time T1 is dependent on the magnetogyric ratio of the nucleus and the 
mobility of the lattice (Fig 2.3). This represents the average lifetime of nuclei in the 
higher energy state and a return to equilibrium population levels. 
 
 
Fig. 2.3 T1 spin relaxation 
 
Spin-spin relaxation is the interaction between neighbouring nuclei with identical 
processional frequency but differing magnetic quantum states. Nuclei can freely 
exchange quantum states. This causes no net change in the populations in the different 
energy states but causes a decrease in the lifetime of a nucleus in the excited state. The 
T2 is the time constant for the decay of magnetisation in the perpendicular plane (x-y) to 
the applied field B0 (Fig 2.4). 
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Fig. 2.4 Spin-spin (T2) relaxation, time taken for all protons in the observed sample to 
decay in the x-y plane to the applied magnetic field B0. 
 
The variations between T1 and T2 that exist between protons of different molecules are 
very important for NMR spectroscopy as they can be manipulated by the radiofrequency 
pulse programs used. 
 
2.1.4 Chemical shift 
Chemical shift is a function of the level of nuclear shielding in proportion to the applied 
magnetic field B and is a function of the nucleus and its environment. The chemical 
shift is measured relative to a reference compound which is tetramethylsilane in the case 
of 
1
H-NMR.  
 
Electrons around the nucleus act as a shield to the applied field. The difference between 
the applied magnetic field and the magnetic field of the nucleus is termed nuclear 
shielding. Circulating electrons in S-orbitals produce a magnetic field opposing the 
applied field. A diamagnetic shift is required for the nucleus to absorb at its transition 
frequency. Electrons in p-orbitals however have no symmetry, which in turn produces a 
paramagnetic shift due to large magnetic fields at the nucleus. In 
1
H-NMR, there are no 
p-orbitals, therefore there is a small range of observable chemical shifts as a molecule 
becomes increasingly electronegative, electron density around the proton decreases, and 
resonance occurs at lower field strengths.  
 
Following radiofrequency pulse application, a time domain decay signal is detected by 
the spectrometer between the pulse intervals. This represents the emission of energy as 
the nuclei gradually relax between the two energy transitions and process back to 
population equilibrium. This presents as oscillations that gradually decay and is known 
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as the free induction decay (FID). The FID represents a series of frequency components 
that are manipulated mathematically by fourier transform to a frequency domain signal. 
This gives the NMR spectrum showing protons in all of the different chemical 
environments. 
 
The process of shimming is performed to correct any inhomogeneity in the applied 
electromagnetic field. This involves the adjustment of small electromagnets located 
around the sample within the superconducting magnet. This is very important as 
inhomogeneity of the magnetic field leads to line broadening of the resonance peaks 
within the spectrum.  
 
2.1.5 Spin coupling 
Spin-spin or scalar coupling occurs when neighbouring nuclei within a compound cause 
a splitting of spin states into a fine structure. The influence of a methyl group containing 
three protons upon a neighbouring single proton is to split the NMR resonance into a 
quartet of four peaks. As a rule of thumb, resonances are split by the number of 
neighbouring protons within three bonds distance +1. However exceptions occur with 
chiral molecules where AB and ABX spin systems can occur resulting in a more 
complex splitting pattern. Spin-spin coupling is very useful for structure elucidation and 
assignment in NMR spectra.  
 
2.2 NMR pulse programs 
The basic pulse program involves a simple system of improving the signal to noise 
ratio. The basic program consists of pulsing the sample acquiring the FID and allowing 
a delay to avoid saturation and allow relaxation. Dummy scans are also performed at the 
beginning of the acquisition to allow the applied magnetic field to stabilise to a steady 
state or in decoupling experiments where the high power irradiation increases the 
sample temperature. They are also performed to reach steady state conditions for T1 
relaxation if the recycle delay is shorter than four times the T1 value of the nucleus 
measured. The serial collection of FIDs gives a signal to noise improvement equivalent 
to the square root of the number of FIDs acquired. Therefore the acquisition of 100 FID 
scans provides a 10 fold improvement in the signal to noise ratio.  
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2.2.1 Water pre-saturation 
Water pre-saturation is obtained using a two pulse NMR programme first with a low 
energy pulse from the RF coil which selectively saturates the single large water signal 
in the NMR spectra using a highly specific frequency. This can also be applied to other 
solvents within the field of the NMR spectrum; this is followed by a non-specific 90º 
pulse to excite all of the other desired resonances. The result of this pulse sequence is a 
spectrum with a reduced water signal and improved signal to noise ratio for the 
metabolite resonances of interest and a reduction in the distortion of the spectrum 
baseline.  Suppression of the water peak also allows an increase in the available gain. 
 
2.2.2 Standard 1D pre-saturation pulse sequence 
The standard 1D pulse sequence consists of three consecutive 90° pulses with water 
presaturation pulses applied between each 90° pulse. The magnetisation vector flips in 
the x-y plane, into the z-axis and finally back into the x-y plane. This has the effect of 
improving the signal to noise ratio and amplifying the returning signal by suppressing 
all signals that are not in the 90° orientation before acquisition of the FID. Field 
inhomogeneity in B1 results in the edges of the sample volume not experiencing the 
applied field in totality. These regions normally contain residual solvent, this leads to 
improved solvent suppression in aqueous samples.   
 
2.2.3 Carr-Purcell-Meiboom-Gill (CPMG) 
The purpose of the Carr-Purcell-Meiboom-Gill (CPMG) sequence (Meiboom and Gill 
1958) is to manipulate the T2 (time constant for the decay of magnetisation in the x-y 
plane perpendicular to the applied field B0) of protons to reduce contributions from 
proteins, lipids and other macromolecules found within tissue extractions and normal 
matrices of biofluids such as blood serum. The CPMG pulse sequence is a modification 
of the Hahn spin-echo sequence generating signals weighted according to T2. The 
sequence begins with a 90° pulse which tilts the proton magnetisation into the xy-plane; 
different nuclei possess B0 heterogeneity and process at different frequencies. This 
results in ‗fanning-out‘ of the magnetisations. In contrast to the Hahn sequence, 
following the delay time T2 (the spin-echo delay), the CPMG pulse sequence applies a 
second 180° pulse to the y‘-axis rather than the x-axis, the magnetised components 
subsequently invert echoes forming along the same direction improve 180° pulse 
accuracy. The influence of the applied magnetic field Bo causes the components to 
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precess at the same frequency and arrive at the Iy‘I-axis. This produces an echo signal at 
time T2 after the pulse sequence. To minimise signal loss mechanisms a series of 180° 
pulses is applied to improve detection of the signal.  
 
Within the context of this thesis the CPMG pulse sequence was applied to aqueous 
vegetable extracts to clearly observe the water soluble components and to reduce the 
broadening seen within the 
1
H-NMR spectra due to macromolecular components and to 
give clear representation of the lower molecular weight components of interest.  
 
2.3 Two-dimensional NMR spectroscopy 
The application of two-dimensional (2D) NMR spectroscopy is to elucidate the 
structure of complex unknown molecules by dispersion of the intensity of NMR signals 
plotted along two frequency axes or dimensions. 2D NMR spectroscopy provides 
information on the correlations/relationships between different spins within the same 
molecule. 2D pulse programs consist of a series of preparation and mixing pulses the 
induced magnetisation precesses within the subsequent evolution and detection time 
phases. The detection period provides the 1D time-domain data from the Fourier 
transformed FID, the evolution phase consists of repeated NMR pulses with 
increasingly longer time periods.  This creates the second time-domain (Fig. 2.5).  
 
 
 
 
 
 
Fig. 2.5 Schematic of a typical 2D NMR pulse sequence 
 
 
2.3.1 J-Resolved 
1
H-NMR spectroscopy 
In standard 1D 
1
H-NMR spectra chemical shift and spin-spin overlapping multiplets can 
obscure coupling information. In a 2D J-resolved experiment the chemical shift and 
coupling information are separated and displayed on different axes of the 2D matrix. On 
the F2 axis only chemical shift information is presented and on the F1 axis only spin-
spin coupling information. A 2D 
1
H J-resolved spectrum, when projected onto the F2, 
 
 
Preparation Mixing 
Evolution t1 
Evolution t1 
t2 
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gives a proton decoupled spectrum, each appearing simply as a singlet. 2D J-resolved 
spectroscopy is based on a repetition of the spin echo sequence varying the delay period 
to allow J modulation effects to evolve. This experiment is particularly useful for 
deconvolution of crowded areas of a 
1
H-NMR spectra 
146
.   
 
2.3.2 Correlation spectroscopy (COSY) 
The homonuclear COSY experiment utilises coherence or magnetisation transfer within 
the COSY90°. The second 90° pulse causes magnetisation transfer through adjacent 
directly J-coupled bonds.  Frequency axes both contain chemical shift information and 
the 1D intensity peaks are seen along the diagonal, cross-peaks in the spectrum 
represent nuclei which are spin-spin coupled.  
 
2.3.3 Total correlation spectroscopy (TOCSY) 
In homonuclear TOCSY spectra correlations are seen between directly coupled nuclei 
within a molecule as in COSY spectra. However, correlation is also seen within nuclei 
within an unbroken spin system. The diagonal on TOCSY spectra represents the intense 
peaks which match the 1D spectrum; the cross peak multiplets represent correlations of 
nuclei in an unbroken spin system of up to 5 or sometimes more bonds. AB spin 
systems or a carbonyl for example would constitute an interruption of a chain of 
TOCSY correlated nuclei. This form of 2D NMR spectroscopy is complimentary to 
COSY spectra in elucidating correlations between protons within unknown metabolites 
 
2.3.4 Heteronuclear Multiple Bond Coherence (HMBC) and Heteronuclear 
Single Quantum Coherence (HSQC) 2D 
13
C NMR experiments 
These heteronuclear 
1
H-
13
C 2D NMR experiments are very useful and complimentary 
experiments for identifying unknown compounds, particularly those for which there is 
little structural information based on the 1D-NMR spectrum ie. unknown singlet peaks. 
Heteronuclear refers to the use of both 
1
H and another nucleus possessing spin usually 
13
C, but correlation with other isotopes is also possible such as 
31
P. The HMBC 
experiment utilises the stable 
13
C isotope which constitutes approximately 1.1% natural 
abundance of carbon. This experiment shows correlations between protons in a 
molecule and carbons over long range J-coupling of 2,3 or sometimes more bonds by an 
inverse detection experiment. Peaks from protons attached to 
12
C are removed by the 
pulse sequence implemented. HSQC on the other hand utilises 
1
H protons to observe 
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13
C which are directly coupled and usually of no more than one bond length in distance. 
HSQC provides the chemical shift of directly bonded 
13
C to the proton observed in the 
1
H NMR spectrum. The identification of metabolites can be made based on comparison 
of the carbon 13 and proton chemical shifts to literature sources or authentic standards. 
This is because the 
13
C chemical shift is relatively insensitive to pH and sample 
concentration, and it can be used to compare different biological matrices. Due to the 
low abundance of 
13
C high resolution NMR spectroscopy and upwards of 200 scans are 
required for low concentration samples. A chromatographic concentration of the 
unknown is desirable prior to conducting this experiment to aid structure elucidation eg. 
Solid phase extraction. 
 
2.4 Preparation of Biological Samples 
2.4.1 Flow Injection Urine Sample Preparation 
A 1ml aliquot of each of the urine samples was taken for 
1
H-NMR spectroscopy. To 
reduce pH induced chemical shift variability in the urine samples a 400μl aliquot of 
urine samples was combined with 200 μl of 100 mM phosphate buffer solution (pH 
7.4). The samples were allowed to stand for 10mins before centrifugation at 13,000 g 
for 10 mins to remove insoluble materials. Aliquots (500 μl) were transferred in a 
randomised order and with controls inserted every fifteenth sample to a 96 deep-well 
plate and the samples were mixed with 50μl of TSP/D2O solution (3-trimethylsilyl 
2,2,3,3-tetradeuteropropionate in deuterium oxide, 1 mM final concentration). TSP is an 
internal chemical shift reference (δ1H 0.0) and D2O provides a lock signal for the NMR 
spectrometer. 
 
The completed plates were covered with adhesive film and mixed carefully before being 
stored at 5˚C. Immediately prior to NMR analysis the plates were centrifuged at 3,000 g 
av for 5 mins. Push solvent (1g NaN3 in 1000 ml dH2O) was used for NMR automation. 
 
2.4.2 Solid Phase Extraction (SPE) 
Solid phase extraction is a chromatographic technique that is used for the concentration 
and purification of samples. This is particularly useful for the elucidation of unknowns 
from low concentration/large sample volume biological samples such as urine. SPE 
normally utilises a C18 reversed phase column containing a prepacked sorbent which 
consists of chemically bonded n-octadecylsilane, an alkane with an 18 carbon chain to a 
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silica matrix. The column is first conditioned and washed with the appropriate solvent 
and the sample is then loaded onto the column. Analytes within the urine are Van der 
Waals bounded to the sorbent bed and are eluted by disrupting the interaction of analyte 
and solid phase by sequential washes of increasingly concentrated solvent. Analytes are 
eluted or retained on the column based on their polarity and therefore the corresponding 
fraction of elution provides information on the polarity of an unknown constituent of 
urine. In a reverse phase the polarity of the stationary phase is less than the mobile 
solvent phase which usually consists of methanol equilibrated with water. Increasing 
concentration of methanol decreases polarity of the solvent phase across the column.  
 
2.4.2.1 Solid Phase Extraction method 
Urine (2 ml) was acidified to pH 2 with 1 M HCl and extracted with a C18 bonded 
cartridge (Isolute, 200 mg, supplied by International Sorbent Technology Ltd, Hengoed, 
UK).  The cartridges had previously been activated by washing twice with 5ml 
methanol. The fractions were eluted with, 5, 10, 20, 40, 60, 80 and 100% methanol/H2O 
solutions (pH 2). All samples were freeze-dried and reconstituted in 600 µl LC-MS 
grade H2O (Sigma-Aldrich, UK). An aliquot (500 μl) was transferred into a 5 mm NMR 
tube prior to NMR spectroscopic analysis and 100μl was utilised for MS/MS analysis.  
 
2.5 
1
H-NMR Spectroscopy Methodology 
2.5.1 Flow Injection Experiment 
NMR spectra were acquired in the stop-flow mode using a Bruker AMX600 
spectrometer (operating at 600.13MHz 
1
H frequency at ambient probe temperature (298 
± 1 K)) with a 5mm single cell 
1
H/
13
C inverse detection flow probe with an active 
volume of 250μl. Sample transfer from the 96-well plate to the probe was automated by 
a Gilson (Middleton, WI, USA) XL233 sample-handling system interfaced to the 
XWinNMR data system for control and timing. For each sample, 450μl was pipetted 
into the transfer line and separated from subsequent samples by 500μl of a push buffer 
containing HPLC grade water containing 0.1% Sodium Azide (NaN3). The transfer time 
for each sample was approximately 180s to allow time for the sample to adjust to the 
probe temperature. Spectra were acquired utilising a standard one-dimensional pulse 
sequence, the first increment of which is the NOESY pulse sequence which suppresses 
the large 
1
H-NMR signal of the solvent water. For each sample 64 free induction decays 
were collected into 32768 time domain data points with a spectral width of 3140.7Hz, 
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an acquisition time of 5.22s and a total recycle time of 6.22s. The FIDs were multiplied 
by a line-broadening function of 1.0Hz to improve the signal–to-noise ratio prior to 
Fourier transformation, phase and baseline correction. The magnetic field was shimmed 
for the first control sample only and then held throughout all of the subsequent sample 
data collections.  
 
2.5.2 Carbon 13 NMR spectroscopy 
2.5.2.1 Heteronuclear Single Quantum Coherence (HSQC) 
1
H-
13
C 2D HSQC NMR spectra were recorded in echo-antiecho mode using the 
gradient selection. The 
1
H and 
13
C spectral widths were 10.5 and 200 ppm respectively 
with the recycle delay of 2 s. A total of 200 scans were collected into 2k data points for 
the acquisition dimension and 128 increments for the second dimension (
13C). The δ-
shifted sine bell window functions were applied for both dimensions before Fourier 
transforming into data with the standard Bruker linear-prediction function applied for 
the second dimension.  
 
2.5.2.2 Heteronuclear Multiple Bond Coherence (HMBC) 
1
H-
13
C 2D HSQC NMR spectra were performed using a standard pulse sequence from 
the library supplied by the vendor. 900 t1 increments with 128 transients and 4096 
complex data points were recorded with a spectral width of 6613 Hz in f2 and 30183 Hz 
in f1, resulting in a total acquisition time of about 57 h and 36 min. The delay for the 
proton carbon long-range coupling was optimised for 10 Hz. For processing, a (π/2) 
squared sine bell window function in both dimensions was applied. Data comprising 
4096 data points were processed in f2 and 2048 in f1, respectively. 
 
2.5.3 Authentic standard compound spike in for NMR peak assignment 
The identities of unknown NMR spectral features were confirmed for metabolite 
assignment by successive addition of 1μl of 100mM authentic standard compound and 
1D 
1
H NMR spectra acquisition on a Bruker 400MHz spectrometer maintaining 
consistency in the acquisition parameters for the purposes of comparison. Standard 
compound was added in a step-wise manner to attempt to increase the resonances of the 
unknown metabolite(s). Increasing intensity of the resonance and similarity in splitting 
pattern at the frequency of the unassigned unknown resonance of interest was taken as 
positive confirmation. 
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2.5.4 Structural assignments 
Both 
1
H and
 13
C NMR assignments were made using both online NMR database 
searches (particularly human metabolome database Hmdb, Genome Alberta), NMR 
prediction software (ACD labs) and previously assigned metabolites, taken within the 
group and where available assignments were made using published assignments at 
neutral pH 
147, 148
. Any ambiguity in assignment was surmounted by statistical total 
correlation spectroscopy (STOCSY), 2D homo- and hetero- nuclear NMR experiments 
and spiking of authentic (sigma-aldrich) or synthetic standards. 
2.6 Ultra High Performance Liquid Chromatography (UPLC) 
UPLC chromatography is a chromatographic technique utilised in high-throughput 
biological analyses to provide high resolution separation of complex sample mixtures 
for quantitative analysis. UPLC utilises high pressures to force samples through a 
column packed with a sorbent solid medium, usually the separation consists of a mobile 
liquid phase which passes the analyte samples through a stationary phase which 
separates components in the solution based upon polarity. In the context of this 
metabonomics study C18 columns were used in a reversed phase, this is where the 
stationary phase is less polar than the mobile liquid phase whereby increasing the 
polarity of the mobile phase non-polar metabolites are repelled onto the surface of the 
column stationary phase where they remain attracted until the mobile phase becomes 
increasingly less polar over time. The desired result of this effect is that metabolites are 
retained upon the column entirely dependent on their hydrophobicity and this serves to 
serially separate metabolites in urine this serves to greatly increase the resolution of 
subsequent mass spectral analyses. The resolution and peak efficiency of liquid 
chromatograpy is highly reliant on the particle size of the stationary phase which 
necessarily requires high pressures to force the mobile phase through the column. 
However, the flow rate through the column is limited by the considerable back 
pressures in the system when small particle sizes in the stationary phase are used. UPLC 
chromatography utilises sub 2μm stationary phase particle sizes operating at pressures 
of ca. 12,000 psi, this provides increased speed, sensitivity and peak resolution. The 
advantages over larger stationary phases (~3.5μm) in high performance liquid 
chromatography (HPLC) which in a reversed phase is a doubling of peak capacity, a 10-
fold increase in speed and a 3-5 fold increase in sensitivity 
149
. The qualities of UPLC 
are highly desirable in high-throughput metabonomic biofluid studies where large 
sample numbers need to be time-efficiently and accurately quantified particularly when 
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analysing urine which is the most chemically complex biofluid produced by the body 
containing tens of thousands of low molecular weight components, consisting of many 
by products of metabolism, excess metabolites, bacterial co-metabolites, waste 
metabolites and environmental xenobiotics. 
150
 
 
2.7.3 Ultra High Performance Liquid Chromatography Methodology 
Chromatographic separations were performed on a Waters ACQUITY
TM 
UPLC BEH  
2.1x 100 mm 1.7 µm C18 column (Waters Corp, Milford, USA) using an ACQUITY
 TM 
Ultra Performance Liquid Chromatography system (Waters). UV spectra were acquired 
with a Waters PDA UV detector. The column was maintained at 40 °C and eluted with a 
reversed phase gradient (See Table 2.2) of 100- 5% A (0–10.1 mins) with 0–95% (0–
10.1 mins) B where A =  H2O (UPLC grade, SigmaAldrich, UK) with 0.1% formic acid 
and B = acetonitrile (UPLC grade, VWR, UK) with 0.1% formic acid. The gradient 
duration was 12 min at a flow rate of 0.5 ml min
–1
. A 10 µL injection of each sample 
was made onto the column. 
 
Table 2.1  Reversed phase gradient conditions for UPLC of Human Urine samples. 
A=H2O (0.1% formic acid), B=acetonitrile (0.1% formic acid). 
 
 
 
 
  
 
 
  
Time (mins) %A %B 
0 100 0 
1 100 0 
3 85 15 
6 50 50 
9 5 95 
10 5 95 
10.1 100 0 
12 100 0 
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2.7 Mass Spectrometry (MS)  
The basic principal of mass spectrometry is the separation of compounds based on their 
mass to charge ratio or m/z. Mass spectrometers can provide accurate masses, structural 
information and dependent on the resolution of the spectrometer exact mass which can 
be used for the identification of unknown compounds within a biological matrix. 
Samples are ionised producing either a positive (+ve) or negative (-ve) ion which are 
directed electrostatically in a vacuum through a mass analyser based on m/z and are 
subsequently detected in the ion detector.  
 
2.7.1 Application of Mass Spectrometry to Biological Samples 
Metabolites in biological samples such as urine can be ionised using a variety of 
different sources, however within this study the most suitable was electrospray 
ionisation (ESI), as ESI provides superior mass range (>50 m/z, however this is often 
close to the noise threshold) and sensitivity (in the fentimolar range, dependent on 
metabolite). ESI ionises metabolites within a biofluid by creating a fine spray of highly 
charged droplets of the sample and solvent in a strong applied voltage across the 
ionisation cone (cone voltage). The applied voltage separates the charges within the 
gaseous ionised droplets on the liquid surface, when ionic repulsive forces and surface 
tension of the droplet are equal the droplets change into a cone shape known as a Taylor 
cone 
151
.  Following this ionisation process the electrosprayed sample droplets are 
electrostatically attracted into the mass analyser. The significant advantage of ESI for 
biological sample analysis lies in the ease of use with liquid chromatography (LC) and 
compatibility with MS/MS tandem mass analysers. However, ESI suffers from a 
reduction in sensitivity due to ion suppression in complex mixtures (such as urine) and 
the presence of salts, a particular problem in urine, although this can be surmounted by 
careful sample preparation and the gradient selection. Reproducibility can also be 
affected by carry over between samples with high-through put analysis for 
metabonomic applications.  
 
The choice of mass analyser is another important consideration when applying mass 
spectrometry to biological samples. For the purposes of high throughput LC-MS 
metabonomic analysis and MS/MS fragmentation analysis, an orthogonal acceleration 
time of flight mass analyser was found to be most suitable for this application. 
Quadrupole mass analysers are robust, reliable and have a good dynamic range. 
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Quadrupoles separate ions based on their m/z ratio by passing the ions through an 
oscillating electric field. The linear quadrupole consists of four rods across which a 
voltage is applied by electrodes at either end of the four rods, through which the ions 
produced by ESI pass. The ions are confined between the rods by a 2D radio frequency 
field and by varying the voltage across the quadrupole rods brings the full range of ions 
based on their m/z to the detector.  
 
Time of flight (TOF) mass analysers are higher resolution than quadrupole mass 
analysers and are also commonly used for many biological applications and in biofluid 
analyses. TOF mass analysers produce ions with the same kinetic energy. The ions are 
then separated based on the inverse relationship between the velocity of each ion to the 
square root of its mass and the time of flight of each ion will be proportional to its m/z 
ratio. The UPLC-MS data acquired and the MS/MS fragmentation of both urine and 
authentic standards utilised an orthogonal acceleration time of flight mass spectrometer. 
ESI is coupled to the TOF mass analyser by orthogonal extraction whereby the ions 
introduced are accelerated along an axis perpendicular to the initial direction of motion. 
This orthogonal acceleration provides a very high resolution. Prior to orthogonal 
acceleration the ESI produced ions are focused into a narrower beam by first passing 
through electrostatic lenses in high vacuum to minimise divergence. This is followed by 
collision with residual gas in multipole mass guides. The combination of collisional 
cooling and orthogonal acceleration allows a significant increase in resolution without a 
detrimental reduction in mass sensitivity 
152
. 
 
When the separated ions in the mass analyser reach a detector, a small current signal is 
generated. This determines the associated m/z ratio of the ion reaching the detector. The 
mass analyser in a TOF mass spectrometer consists of a microchannel plate detector. 
The electrical signal generated is recorded by a time to digital converter (TDC). These 
register the arrival of single ions at discrete time bins which are able to discriminate 
between noise and ion arrivals. The Gaussian-shaped electrical pulses generated are 
converted into common-shape pulses. The TDC detector can count down to picoseconds 
resolution. However it suffers from a reduction in dynamic range, therefore TDC 
detectors are utilised in a multiple system where each single ion-hit event is placed in a 
time bin and the large number of single ion detection events in each time bin is summed 
up in a histogram providing a value for each peak.   
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2.7.2 Sample preparation for mass spectrometry analysis 
For human urine UPLC-MS analysis a 50μl aliquot of the urine samples was 
centrifuged at 13,000rpm for 5mins in order to remove particulates. However, human 
urine in healthy individuals should contain no proteins or other macromolecules unlike 
rats which are known to be proteinuric.  Centrifuged urine samples were then mixed 
with 50μl UPLC grade H2O containing 0.1% formic acid and subsequently transferred 
to 96-well plates with cap mats in a random order with UPLC-grade H2O blanks in 
position 1 and 96 of each plate with additional blanks every 7
th
 sample. Prepared 96-
well plates were maintained at 0°C prior to transference to the autosampler for UPLC-
MS analysis. 
 
2.7.3 Mass Spectrometry Methodology 
Mass spectrometry was performed on a LCT Premier
TM
 (Waters MS Technologies, 
Manchester, UK) orthogonal acceleration time of flight (oa-ToF) mass spectrometer 
which was operated in both positive and negative ion electrospray modes. The 
desolvation gas was set to 900 L h
–1
 for positive mode and 500 L h
–1
 for negative mode 
at a temperature of 350 °C, the cone gas set to 0 L h
–1
 and the source temperature set to 
120 °C. The capillary voltage and the cone voltage were set to 3200 V (positive mode)/ 
2500 V (negative mode) and 30 V, respectively. Data from the LCT-Premier
TM 
was 
collected in continuum rather than centroid mode for increased resolution. All analyses 
were acquired using the lock spray to ensure accuracy and reproducibility; leucine-
enkephalin was used as the lock mass (m/z 556.2771) at a concentration of 250 pg/ul 
and flow rate 50 µl min
–1
. Parameters are summarised in (Table 2.1). 
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Table 2.2 Summarising LCT Premier
TM
 parameters for both positive and negative ion 
modes. 
 
 
  
 
 
 
 
 
 
  
Parameters Positive 
mode 
Negative 
mode 
Capillary voltage 3200 2500 
Sample cone voltage 30 30 
Desolvation temperature 
(˚C) 
350 350 
Source Temperature (˚C) 120 120 
Desolvation set at litres hr
-1
 900 500 
MCP 2100 2100 
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Chapter Three:  Chemometric Methods 
3.1 
1
H-NMR Spectral Pre-Processing 
3.1.1 Data Reduction and Pre-Processing 
Full resolution 
1
H NMR spectroscopic data  (δ10.0-0.24) were zero filled by a factor of 
2 and all FIDs for the acquired spectra were multiplied by an exponential weighting 
function to a line broadening of 0.3 Hz before fourier transformation. Data processing 
was initially performed using NMRProc (in house software) which corrected the NMR 
spectra for phase shift, peak alignment and baseline distortion, referenced to TSP at 0.0δ 
and bucketed into reduced 0.001ppm spectral buckets by polynomial curve fit (using a 
Matlab Version 7.0 program developed in house).  The raw spectra were then imported 
into Matlab for multivariate data analysis using MetaSpectra software. Spectra were 
then Spline cubic interpolated from 32k to 42k data points and the region corresponding 
to water (4.9-4.5ppm) was removed prior to peak alignment. Spectra were then 
normalised to total spectral area and alternatively to the probabilistic quotient for 
improved biomarker recovery. Matlab imported NMR data was also exported to 
SIMCA-P
+
 for comparative analysis 
 
3.1.2 Recursive Segment-Wise Peak Alignment 
Chemical shift variation in 
1
H-NMR signals of biofluids reduces biomarker information 
recovery following multivariate statistical techniques 
153
. Most peak alignment methods 
fail to maintain minor peak shift variations, however recursive segment-wise peak 
alignment (RSPA) reduces the peak shift variability across all peaks and 
1
H NMR 
spectra by top down segmentation of reference and test spectra. Sequential sub-division 
of larger segments improves local spectral alignments across all spectra in a dataset. 
RSPA improves alignment accuracy by aligning NMR spin coupled multiplets as a 
whole instead of separate singlet peaks by local recursion. 
 
3.1.3 Probabilistic Quotient Normalisation 
Normalisation accounts for different sample dilutions by scaling 
1
H NMR spectra to the 
same overall concentration; this produces more robust multivariate models. A major 
problem in human biofluid samples is reduction of inter-individual differences and 
maximising the contribution of subtle dietary changes. Integral normalisation is the 
preferred method of data normalisation and works well for more highly controlled 
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studies such as in genetically and environmentally homogenous animal studies. Large 
increases in metabolites confound integral normalisation particularly which can produce 
poor chemometric models and incorrectly scaled spectra.  Probabilistic quotient 
normalisation calculates a most probable dilution factor by factoring in the distribution 
of quotients of the amplitudes of test spectrum when compared to a reference spectrum. 
Spectra normalised to probabilistic quotient have been found to be more successfully 
pre-processed for multivariate modelling than both integral and vector length 
normalisation methods 
154
. 
 
3.2 Pattern Recognition 
3.2.1 Principal Components Analysis (PCA) 
PCA is an orthogonal linear projection which calculates eigenvectors with the data set, 
the first principal component (or eigenvector with the largest eigenvalue) within a data 
set is a coordinate onto with all data points are projected down corresponding to the 
maximum source of variation within the X matrix. PCA is used with the context of 
Metabonomic investigation as an initial dimensionality reduction of the data and is the 
initial linear transformation providing the subspace with greatest variation. 
 
The principal components are a set of scores that highlight clustering, trends or outliers 
in the sample direction in the data matrix, which gives a quick visual analysis of the 
data in the form of a 2D scores plot, where each point on the plot represents an 
individual sample. The ‗loadings‘ plot focuses on the variation in the variable direction 
and gives an indication of the influence of the variables on the scores. Each coordinate 
on the loadings plot represents one NMR spectral region. Non-systematic variations that 
cannot be explained by the model gives the residual or unexplained variation matrix.  
 
PCA analyses were used primarily before any other data treatment to overview and 
explain clustering of sample and trends within the multivariate data and to identify any 
outlier samples. PCA is an ‗unsupervised‘ chemometric method which uses no 
information other than the spectral data (X matrix) without any knowledge of variables 
in the Y data matrix such as class membership (i.e. dietary intervention). 
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3.2.2 R
2
 and Q
2 
values 
It is important to distinguish in any multivariate model the difference between a models 
fit to the data and its ability to predict class membership. Typically in statistics the 
wellness of fit is provided by the parameter R
2
, this Figure represents the amount of 
variation within the X matrix that is explained by the model. Unfortunately with a 
sufficient number of components within a model the R
2
 can anomalously appear close 
to 1 the optimum value. The Q
2 
on the other hand measures the predictive ability of the 
model and how well the X matrix can be predicted, this is measured using either the 
existing data set or an independent validation set. 
 
The strength of the Q
2
 value is that if many intrinsic variables are introduced into the 
data set, lack of correlation of these with patterns in the dataset deteriorates its 
predictive power. The number of components in a model is selected based on the 
combination of both the R
2
 and Q
2
 parameters. The Q
2
 is calculated using cross 
validation within the model, a component‘s significance is determined compared to the 
rest of the components in the model. A test set and training set are generated and using 
an iterative process removed samples are predicted against the remaining samples in a 
model until every sample has been removed and tested against the remainder. 
 
3.2.3 Partial Least Squares Analysis (PLS) 
The PLS method provides a model of the maximum separation between defined class 
samples in the data; it differs from PCA in that variables in the Y data matrix (class, 
dietary intervention) are known and used to optimise the model. After calculation and 
validation of the PLS model it can be used for prediction of the class membership of 
unknown samples. The sources of variation in the X and Y matrix may disturb the PLS 
model causing the imprecise prediction of new samples and can affect the robustness of 
the model. 
 
3.2.4 Orthogonal Projection on Latent Structures Discriminant Analysis (O-
PLS-DA) 
A more favourable method has been developed which avoids the two-step process of 
OSC followed by PLS called O-PLS-DA 
155
. This statistical method incorporates the 
orthogonal variation partitioning in the algorithm. This method produces a far more 
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robust model that models any ‗structured noise‘ separate from the data variation 
common to both the X and Y data matrices. 
 
The O-PLS-DA model is based on unit variance scaled data and back-transformed by 
multiplying the O-PLS coefficients by their standard deviations. The O-PLS coefficients 
relate to the relative influence of the each coordinate of the loadings and its relative 
influence on the class discrimination. The O-PLS-DA provides an excellent model in 
which the loadings are plotted in a similar fashion to an NMR spectrum for ease of 
interpretation. On the same plot the O-PLS coefficients are colour coded, the range of 
which are set to the maximum and minimum of the unit variance scaled model weight. 
The colour of the coefficient in the back-transformed loadings plot represents the 
correlation of the X variables with Y and gives an indication of the influence of an 
individual metabolite in class discrimination. 
 
3.2.5 STOCSY Statistical Total Correlation Spectroscopy 
STOCSY offers a powerful chemometric method for identification of highly correlated 
peak intensities in this case within a set of 
1
H-NMR spectra. STOCSY also confers an 
advantage over the comparable NMR experiment of Total Correlation Spectroscopy, 
which is unable to correlate resonances between protons in a molecule of interest, which 
are magnetically independent of one another, for example where resonances are a 
singlet. STOCSY operates by generating a pseudo-2D NMR spectrum that shows 
correlation among intensity variables across an entire sample of the various peaks in a 
set of spectra. As a rule of thumb, the method necessitates a minimum of 25 spectra in 
any one sample to class to be statistically significant 
156
. Intermolecular correlations due 
to biological covariance or negative correlation can provide information on a metabolite 
of interest, with regards to homology of molecular structure or common metabolic 
pathway inter-dependency or subject to a common regulatory mechanism. 
 
O-PLS-DA combined with STOCSY provides an excellent combination of techniques 
for metabonomic analysis. O-PLS-DA first identifies class discriminating spectral 
peaks; this information combined with STOCSY analysis helps to discern the 
statistically significant correlations within the sample class. 
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3.3 Statistical analysis of mass spectral data 
3.3.1 MarkerLynx PCA analysis 
UPLC-MS data in both negative and positive modes was aligned within mass and 
retention time windows and then normalised using the Waters MarkerLynx 4.1 
software. This generated a matrix of m/z and retention time pairs with associated peak 
areas. This data was then processed using an unsupervised statistical approach, principal 
components analysis (PCA) initially with pareto scaling. Chromatograms were reduced 
to the (0-6mins) regions to include the more polar urinary compounds of urine in the 
analysis and to reduce data size and the required computing power. The scores plot 
produced gives an overview of potential class separation in the raw data and the 
loadings plot allows extraction of potential biomarker candidates which are statistically 
significant and within defined confidence limits. This also allows easier visualisation of 
the raw UPLC-MS data and detection of any outlying samples.  
 
The Waters MassLynx 4.1 software was also used to extract chromatograms of interest 
based on the expected m/z of candidate biomarkers using a targeted approach. 
Chromatographic peaks exclusive to sample classes were considered as putative 
biomarkers. 
 
3.3.2 XCMS
1
 spectral feature identification 
XCMS
1 
incorporates nonlinear retention time alignment, matched filtration, peak 
detection, and peak matching; this software operates without the need to use internal 
standards.  The method identifies hundreds of endogenous metabolites for use as 
‗internal standards‘, calculating a nonlinear retention time correction profile for each 
sample. This retention time correction allows the relative metabolite ion intensities to be 
directly compared to identify changes in specific metabolites such as potential 
biomarkers within the mass spectral dataset. The step by step XCMS
1
 data processing 
method begins with filtering and identification of peaks within the raw mass spectral 
data, extraction of ion chromatograms, application of the model peak matched filter and 
then identification and integration of the peak areas. This is followed by matching the 
peaks across samples by segmentation of global peak lists by mass, identification of 
retention times with high peak density and the creation of groups in these dense regions. 
Simultaneously the retention times are corrected identifying groups for use as standards, 
calculation of retention time deviations and finally alignment of peaks using non-linear 
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warping. The missing peak data is subsequently filled identifying groups missing 
samples, calculation of the mass/time peak regions and integration of intensity from the 
raw data. These results are then statistically analysed revealing a visualisation of the 
statistically important peaks in the form of an extracted ion chromatogram and box and 
corresponding box and whisker plot. 
 
3.3.3 Application of XCMS
1
 for Tentative Biomarker Identification. 
A significant challenge of interpretation of UPLC-Mass Spectral data is its sheer size 
which makes manual analysis of raw data almost impossible.  The use of chemometric 
techniques particularly in the form of software packages from research groups, such as 
XCMS
1
 
157
 are useful for the discovery of biomarkers. 
 
Data-mining programs such as XCMS
1
 use special algorithms that filter and bin raw 
mass spectral data then extract chromatographic features identified by m/z ratio and 
retention time. The features are then aligned, normalized and a peak table created which 
can be subjected to further statistical analysis. XCMS
1 
uses a peak picking algorithm 
that identifies chromatographic features that represent the differences between sample 
classes and produces a list of Extracted Ion Chromatograms (EICs) and box and whisker 
plots and sorted in ascending order of confidence based on p-value and other statistical 
measures. Tentative biomarkers of cruciferous vegetable consumption were selected 
based on their class exclusivity within the mass spectral data and by interpretation of the 
EIC, box and whisker plot, p-value and presence within the raw data. The purpose of 
this process is to identify ions of interest on which the investigations can focus attention 
as a possible source of biomarker information. 
 
Initial biomarker identification is based on knowledge of potential exogenous and 
endogenous candidate metabolites, database mining, (i.e. Human Metabolome 
Database, Hmdb, Genome Alberta www.hmdb.ca) fragmentation analysis and accurate 
mass atomic formulae identification or a combination of these. Final confirmation is 
achieved using authentic standard.  
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Chapter four: The Effects of the Naturally Occurring Food-
Derived Genotoxic Carcinogen Methyl Eugenol on Rat 
Metabolic Phenotype  
4.1 Background 
Methyl Eugenol (ME) is a member of the alkenylbenzene derivatives family and a 
natural component of many plants, fruits and spices. It is most abundantly found within 
the herb basil which is widely consumed in the Mediterranean. It is widely used in the 
food additives and cosmetics industries as a flavour enhancer and fragrance component 
respectively (ICEM 2005). The ubiquity of ME‘s use and its similarity in structure to 
known carcinogens estragole and safrole has generated considerable interest in its 
potential carcinogenicity and is the subject of great environmental toxicological interest. 
ME has been identified as a genotoxin and hepatocarcinogen and been shown to form 
DNA adducts at high doses in rats and as such may be a potential human carcinogen. A 
previous 2 year NTP (national toxicology programme) study demonstrated significant 
gastric and hepatic carcinogenicity of ME (NTP 2000). However, the study may have 
overestimated the carcinogenic potential of ME by using a dosage far in excess of 
normal human levels of exposure and administration by orogastric gavage rather than 
using a food matrix method. 
 
This study utilised urine samples for metabonomic analysis from a 28 day feeding study 
with F344 strain rats at relatively low ME doses of 1, 5, 50 and 50 (administered by 
gavage) mg/kg bw/day with appropriate controls to assess effects of a low ME feeding 
regimen on the global rat metabolic phenotype. This dietary regimen was designed to 
reflect more realistic levels of human ME exposure (~1mg/kg bw/day) and by 
encouraging a more natural dietary administration.  
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4.2 Aims and Objectives 
 To determine the effect of ME dietary exposure at exposure levels (1-50mg/kg 
bw/day) relevant to human dietary exposure (~1mg/kg bw/day) on the rat urinary 
metabolic phenotype. 
 To examine dose related responses (1, 5 and 50mg/kg bw/day) of the rat metabolic 
phenotype in a 28 day repeat dose oral ME study. 
 Identify potential urinary biomarkers of ME exposure and any metabolic pathways 
modified. 
 To investigate gender-specific differences on ME metabolism. 
 To assess any effect of route of administration by either orogastric gavage or dietary 
matrix on the rat metabolic phenotype. 
 
4.3 Introduction 
4.3.1. Methyl Eugenol-Chemical Properties  
ME is also found in many commonly consumed fruits, vegetables and spices eg. basil, 
bananas and nutmeg and is also present as an environmental contaminant. ME is 
extensively used as a flavouring agent in many processed foods such as soft drinks, 
chewing gum and ice creams where it imparts a cooling and slightly bitter flavour, 
which is remiscent of the flavour of basil. It is also used as a fragrance in perfumes, 
laundry detergents and soaps, and as an insect attractant and rodent anaesthetic 
158
.  
 
ME was identified as a toxicological concern and investigated in a 2 year NTP 
toxicology study due to its structural similarity to safrole, isosafrole and estragole which 
are known carcinogens. The study confirmed that ME is a rodent carcinogen inducing 
tumours of the fore stomach and liver (NTP 2000). 
 
ME is an alkenylbenzene derivative, which consists of a benzene ring with a 1-allyl side 
chain and methoxy groups at meta- and para- ring positions. It is a hydrophobic 
compound and is highly insoluble in water but is miscible in organic solvents such as 
chloroform and DMSO.  In common with the known carcinogens estragole and safrole, 
ME contains the allyl side chain with a terminal carbon – carbon double bond (Fig. 4.1). 
It is this side chain that is thought to be responsible for their genotoxicity  
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Fig. 4.1 Molecular structures of ME, estragole and safrole. 
 
4.3.2 Toxicological evaluation of Methyl Eugenol 
Median lethal oral doses of ME are reported to be 810 to 1560 mg/kg bw in rats (NTP 
2000), therefore ME is considered to possess low toxicity as such doses are far beyond 
doses relevant to normal dietary exposure in humans (estimated to be ~1mg/kg bw/day). 
The primary issue of concern relates to carcinogenicity rather than acute toxicity.  
 
In vitro genetic toxicology assays show little to no activity with ME, however positive 
results were obtained using unscheduled DNA synthesis (UDS) assays 
58
. Negative 
results were observed for ME, estragole and safrole in the Ames Salmonella reversion 
test and the E.coli WP2 uvrA reversion assay 
159
. However, ME has been shown to 
demonstrate intrachromosomal and interchromosomal recombination events in 
Saccharomyces cerevisiae 
160
. 
 
ME presents negative results in most in vitro genotoxicity models but in in vivo models 
ME appears to have a more pronounced effect. In the Big Blue transgenic female rat and 
male mouse ME significantly increases mutation frequency of the lacl gene when dosed 
with high doses (300-1000mg/kg bw/day) for a period of 90 days by gavage 
161
. 
 
It is believed that ME produces a genotoxic effect in both in vivo and in vitro 
experimental models in a similar fashion to that of safrole and estragole by DNA adduct 
formation. Safrole and estragole are known to form 3 different adducts at the exocyclic 
position N
2
 of guanine and also at the N
6
 of adenine 
162
. ME is also known to form 
adducts with hepatic proteins in vivo in F344 rats and in vitro hepatocyte cell 
O
O
O O
O
methyl eugenol estragole safrole
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cultures
163
.  ME has been shown to form DNA adducts in the livers of treated rats 
164
. 
This was observed in a dose-dependent manner using ELISA, however the biological 
significance of the ME-protein adducts is unclear as ME has little cytotoxicity or 
apoptotic effect and the proteins affected are therefore unlikely to be involved in cancer-
related processes such as cell cycle, cell growth or apoptotic mechanisms. 
 
The toxicity and carcinogenic potential of ME has been examined in a 2 year NTP 
bioassay (NTP 2000). This study examined high doses of ME (37mg-300mg/kg 
bw/day) via an orogastric gavage delivery system. This dosage regimen produced 
extensive gastric and hepatic genotoxicity, hyperplasia, neoplasia and tumourigenesis 
for all of the doses examined. The dosing regimen was selected according to accepted 
bioassay guidelines and to ensure toxicity. In general human exposure is estimated to be 
much lower (~1mg/kg bw/day) than the doses used in the bioassay and according to 
64
 
the lowest dose examined is 370 times higher than the estimated dose for ―specialised‖ 
or super eaters of ME. Human exposure occurs mainly through naturally occurring ME 
within the matrix of many fruits and vegetables and through exposure to food and 
cosmetic additives and collectively would likely never achieve acutely carcinogenic 
levels in the normal human diet. In the NTP study animals were also dosed by gavage 
which would have undoubtedly increased the rate of ME absorption and potentially its 
site-specific genotoxicity in the liver following rapid clearance of this lipophilic 
compound from the stomach. Non-neoplastic treatment-related changes seen in the liver 
such as inflammation and hyperplasia and extensive damage of the stomach would also 
certainly have exacerbated hepatic and gastric tumourigenesis by altering ME 
absorption and metabolism 
165
. 
 
Here I have utilised a more conservative dosing regimen than the NTP study with a 
lower range of ME doses between 1-50mg/kg bw/day over a 28day repeat dose period 
in an attempt to achieve more realistic human levels of exposure in order to evaluate the 
true potential risk of ME and to probe further potential toxic mechanisms. 
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4.3.2 ME Metabolism 
It was initially hypothesised that the high structural similarity of the alkenylbenzene 
derivatives ME, estragole, safrole and isosafrole would imply shared metabolic, 
pharmacokinetic and toxicological properties 
64
.  
 
Following oral administration of ME by gavage, absorption is rapid; with peak serum 
concentration within 5mins and ~95% of the dose recovered in urine after 24 hours. 
Therefore urinary excretion represents the predominant route of elimination of ME from 
the rat with some evidence of conversion to CO2 and no unchanged ME is found within 
rat urine  
166
.  
 
Metabolism of ME is primarily hepatic and occurs by three main routes and these are 
believed to be common amongst the alkenylbenzene derivatives (Fig.4.2). Two of these 
pathways of metabolism are not thought to produce procarcinogenic metabolites. At low 
doses the primary route of ME metabolism is via O-demethylation with m- or p- 
hydroxylations of the benzene ring. This is followed by excretion by sulphation or 
glucuronic acid conjugation. Further reduction of the allyl side chain of demethylated 
ME to quinine methide followed by glutathione conjugation is also known to occur 
along the same pathway 
167
.  
 
It is known that only at higher doses of ME are the other two routes of metabolism the 
epoxidation and 1‘-hydroxylation pathways significant 168. It is anticipated that with the 
lower doses used within this study (1-50mg/kg bw/day) that the main urinary 
metabolites of ME would be the sulphate or glucuronic acid conjugate of eugenol or 5-
allyl-2-methoxy phenol. As such these metabolites represent potential candidates for 
metabonomic biomarkers of ME exposure within rat urine.  
 
Eugenol is less genotoxic than ME but is more cytotoxic. It is rapidly eliminated by 
glucuronidation and sulphonation at the para-hydroxy group, and has also been shown 
to conjugate with glutathione by formation of the highly reactive quinine methide 
169
. 
 
At higher doses ME is reported to be metabolised by two further routes of metabolism 
within the rat liver 
170
.  
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The second route of metabolism of ME is by epoxidation of the allyl side chain forming 
the ME-2‘,3‘-epoxide which is eliminated by conjugation with glutathione (Fig. 4.2).  
The third route of ME biotransformation is by 1‘-hydroxylation by a member of the 
phase I cytochrome P450 superfamily, which has been shown to be the primary 
intoxication pathway (Fig. 4.2 pathway 3). The 1‘-hydroxymethyl ME is sulphated by a 
sulphotransferase at the hydroxyl group and the sulphated 1‘-hydroxymethyl ME forms 
a reactive intermediate carbonium ion. It is this reactive intermediate that is thought to 
be responsible for the genotoxic and cytotoxic effects of methyl eugenol by reacting 
with DNA/RNA and protein 
64
. 
 
This current study examines whether the exposure of rats to ME at doses that are more 
representative of human exposure alters the urinary metabotype.  
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Fig. 4.2 Metabolic scheme of ME in rodent liver. The primary route of ME excretion at 
low dosage is by O-demethylation and suphation or glucuronic acid conjugation of 
either eugenol or 5-allyl-2-methoxy phenol (pathway 1). Metabolic scheme adapted 
from 
64
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4.3.3 Histopathological, Biochemical and Molecular Biological Findings 
Toxicological properties of ME using a low dosage regimen were assessed by Dr J. 
Ellis, Dept. Of Biomolecular Medicine (BMM), Imperial College (IC) 
165
. Body weight 
gain, liver weight and blood/urine biochemistry were all recorded to identify overt 
evidence of toxicity, however little evidence of this was observed. Proliferative, 
atrophic and inflammatory effects of ME on the liver and gastric mucosa were assessed 
with immunoblot assay/proliferating cell nuclear antigen (PCNA) enzyme-linked 
immunoabsorbent assay (ELISA) and a competitive binding radio immunoassay (RIA) 
for gastrin.  
 
ME dosage between 1-50mg/kg bw/day via dietary dosage and the 50mg/kg bw/day via 
gavage over 28 days did not produce any overt signs of toxicity, with no treatment 
related effects on body or liver weight 
165
. Histopathological findings showed no macro- 
or microscopic lesions in any organs. The blood and urine biochemical analysis did not 
identify any toxicological effects of ME with this dosing regimen. ELISA and 
competitive binding RIA failed to identify any proliferative effect in the liver or 
inflammatory or atrophic effect on the gastric mucosa. Thus no gross toxicological 
aberrations were observed using a dosing regimen more in line with realistic human 
exposure levels 
165
. 
 
Analysis of the expression levels of hepatic cytochrome P450 enzymes (1A2, 2E1 and 
2C6) found no significant alteration in the dose range 1-50mg ME /kg bw/day of this 28 
day study dietary matrix or gavage 
165
. However it is known that at higher dose ranges 
(100-300mg/kg bw/day) by intra peritoneal injection CYP1A2 protein expression is 
increased 
171. This is thought to be one of the major enzymes involved in 1‘-
hydroxylation intoxication pathway of ME in the rat and human liver. The 28 day 
dietary regimen therefore did not markedly induce any hepatic detoxification enzymes, 
suggesting that the effect of ME was subtle. 
 
The molecular biology findings did however identify a dose-dependent quantifiable 
effect on DNA adduct formation utilising a 
32
P-postlabelling assay in both the liver and 
stomach. This genotoxic effect was  evident at doses of 5mg/kg bw/day and greater in 
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the liver and at 50mg/kg bw/day in the stomach at a detection limit of 1 DNA adduct in 
10
7
 bases 
165
. The higher level of DNA-ME adducts in the liver than in the gastrum was 
expected as the liver is a more biologically active organ and CYP450 enzymes and a 
sulphotransferase are required for the intoxication pathway 
171
 and these are found in 
greater concentration in the liver. It was found the dietary dosing regimen produced 
more pronounced effects at the high dose (50mg/kg bw/day) in the stomach than did the 
gavage treatment. The constant dosing via feeding of ME was thought to provide a 
continual exposure as against a one-shot gavage dosage in which the highly lipophilic 
nature of ME would mean rapid clearance from the stomach and a saturation of the 
intoxication pathway in the liver. 
 
Gene fishing-polymerase chain reaction (GF-PCR) analysis identified differentially 
expressed genes in the livers of rats dosed with the high dosage feeding regimen 
(50mg/kg bw/day). This molecular biology technique uses primers to amplify and 
quantify differentially expressed genes 
165
. There was also an increased expression of 
specific genes within the male rats compared to females, and suggests gender difference 
in the response to ME. Unfortunately the gene expression findings were not confirmed 
by protein expression analysis. Systemic change at the genomic, transcriptomic or 
proteomic level can in theory cause potentially significant perturbation of the metabolic 
phenotype. 
 
In summary the genotoxicity and molecular biological findings associated with the ME 
treatment provided impetus for further complimentary investigation by metabonomic 
analytical techniques. The histopathological and biochemical findings did not 
demonstrate any gross toxicological effects in the dosage range (1-50mg/kg bw/day) 
and thus strong perturbations of homeostatic control in the experimental animals was 
unlikely. However, the subtle genotoxic effects seen in DNA adduct formation in the 
liver and stomach and differential gene expression in the liver, particularly in male 
animals, is potentially detectable using the highly sensitive analytical platforms of 
metabonomic analyses.    
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4.4 Methods 
4.4.1 Animal husbandry and twenty-eight day study outline 
One hundred and ten Fischer 344/NH/sd strain rats were supplied by Harlan UK ltd 
(Oxford) (55 male and 55 female) were acclimatised for 6 days prior to commencement 
of the ME dosing regimen and were approximately 6 weeks old at the start of the 
experiment. The animals were randomly allocated to control or the 1mg, 5mg or 
50mg/kg bw/ day dosage groups and the control or 50mg/kg bw/day gavage groups 
(table 4.1). Animals were housed with 5 per cage of the same sex in a single air-
conditioned room. The study was performed by Safepharm in a Barrier-Maintained 
Rodent Facility. 
 
ME microencapsulated into a maltodextrin matrix was supplied by FEMA (Flavour and 
Extracts Manufacturers Association). Food was prepared by mixing with the 
microencapsulated ME and stored at 4ºC. Analysis of the microencapsulated matrix 
revealed a load of 3.76% ME oil. 
 
All animals dosed with ME or vehicle controls were treated once a day for each of the 
28 days of the study until the necropsy date on the 29
th
 day.  
Table 4.1 28 day ME F344 Rat Study animal numbers, treatment groups and dosage 
regimen 
 
*Vehicle-maltodextrin matrix (no ME) mixed with food. 
 
 
 
Treatment Group Dose Route ME Dosage No. of animals
mg/kg bw/day male female
Dietary untreated control Dietary 0 5 5
Dietary vehicle control* Dietary 0 5 5
Dietary 1mg/kg bw Dietary 1 10 10
Dietary 5mg/kg bw Dietary 5 10 10
Dietary 50mg/kg bw Dietary 50 10 10
Gavage vehicle control Gavage 0 5 5
Gavage 50mg/kg bw Gavage 50 10 10
Treatment Group Dose Route ME Dosage No. of animals
mg/kg bw/day male female
Dietary untreated control Dietary 0 5 5
Dietary vehicle control Dietary 0 5 5
Dietary 1mg/kg bw Dietary 1 10 10
Dietary 5mg/kg bw Dietary 5 10 10
Dietary 50mg/kg bw Dietary 50 10 10
Gavage vehicle control Gavage 0 5 5
Gavage 50 mg/kg Gavage 50 10 10
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4.4.2 Urine sample collection 
All animal work was carried out by SafePharm laboratories (Derby,UK). Urine samples 
were taken from all animals in each control and dose group on the day indicated (table. 
4.2). Urine samples were collected in metabolism cages overnight from all dose groups 
and control animals on a weekly basis with water but restricted food access. Four 
hundred and fifty urine samples were snap frozen and sent to the department of 
Biomolecular Medicine, Imperial College London on dry ice at a temperature of -20ºC. 
Upon receipt the urine samples were maintained at -80ºC.  
 
Table 4.2 28 day ME F344 Rat Study showing urine sample collection time-points and 
numbers. 
 
*Vehicle-maltodextrin matrix (no ME) mixed with food. 
 
 
 
 
 
 
 
 
 
 
 
 
Treatment Group Urine collection time point
day 7 (no. of samples) day 14 (no. of samples) day 21 (no. of samples) day 28 (no. of samples)
male female male female male female male female
Dietary untreated control 5 5 5 5 5 5 5 5
Dietary vehicle control* 5 5 5 5 5 5 5 5
Dietary 1mg/kg bw 10 10 10 10 10 10 10 10
Dietary 5mg/kg bw 10 10 10 10 10 10 10 10
Dietary 50mg/kg bw 10 10 10 10 10 10 10 10
Gavage vehicle control 5 5 5 5 5 5 5 5
Gavage 50mg/kg bw 10 10 10 10 10 10 10 10
Total: 440
Treatment Group Dose Route ME Dosage No. of animals
mg/kg bw/day male female
Dietary untreated control Dietary 0 5 5
Dietary vehicle control Dietary 0 5 5
Dietary 1mg/kg bw Dietary 1 10 10
Dietary 5mg/kg bw Dietary 5 10 10
Dietary 50mg/kg bw Dietary 50 10 10
Gavage vehicle control Gavage 0 5 5
Gavage 50 mg/kg Gavage 50 10 10
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4.4.3 Urine preparation and 
1
H-NMR spectroscopic analysis  
Rat urine samples were prepared for 
1
H-NMR analysis. Aliquots of 200 μL of 
phosphate buffer solution (0.2 M Na2HPO4/0.2 M NaH2PO4, pH 7.4) were added to 
400 μL of rat urine. The resulting solutions were left to stand for 15 min before 
centrifuging at 10,000 g for 15 min, to separate solids. Aliquots of 500 μL of the 
resulting supernatants were added to a 96-well plate containing 50 μL of a solution of 
0.1% (w/v) sodium 3-trimethylsilyl-[2,2,3,3-
2
H4]-1-propionate (TSP) chemical shift 
reference (δ = 0)/1% (w/v) sodium azide (bactericide) in deuterium oxide (2H2O) for a 
field frequency lock. 
Ninety-six well plates were placed into a Gilson sample handling system for automated 
injection of urine samples into the spectrometer. Single-pulse 
1
H NMR spectra of urine 
samples were measured at 600.13 MHz on a Bruker DRX 600-MHz spectrometer at 
300 K using a standard excitation sculpting pulse programme to remove the water peak 
172
. Spectra were acquired using 64 free-induction decays (FIDs) into 64 K data points, 
with a spectral width of 9615.4 Hz, an acquisition time (t1) of 3.41 s, a mixing time (tm) 
of 100 ms, and a total pulse recycle delay of 6.41 s. Prior to applying Fourier transform 
(FT), the FIDs were multiplied by an exponential function corresponding to a line 
broadening of 0.3 Hz. 
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4.5 Results  
A representative 
1
H-NMR urine spectrum for a Fischer 344/NH/sd strain rat is shown in 
(Fig. 4.3). Typically, control urine spectra were dominated by resonances from normal 
urinary constituents including glucose, taurine, creatinine, hippurate, citrate, 2-
oxoglutarate, succinate and trimethylamine-N-oxide. A complex region of the spectrum 
revealed resonances deriving from amino acids, and organic acids. Creatine, acetate, 
acetoacetate, dimethylglycine, N-acetyl glycoprotein fragments and m-
hydroxyphenylpropionate (m-HPPA) were also identified in the urine spectra. Although 
it was expected that in the high dosage (50mg/kg bw/day) animals urinary metabolites 
of ME may have potentially been identified, namely the sulphate or glucuronide of 
eugenol or 5-allyl-2-methoxy phenol, visual comparison of control and the 50mg/kg 
bw/day dose animals failed to identify significant difference between groups in the 
phenolic region of the spectra. 
 
 
Fig. 4.3 Representative 600 MHz 
1
H NMR spectra of urine from a female Fischer 
344/NH/sd strain rat.  
TMAO: trimethylamine-N-oxide; m-HPPA: meta-hydroxyphenylpropionic acid; PAG: 
phenylacetylglycine. 
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4.5.1 Principal Components Analysis (PCA) all samples 
An unsupervised overview of the 
1
H-NMR spectra of all samples from all time-points 
and dose groups revealed homogeneity in the data set with no obvious grouping of data 
based on sample class, with variation in all components dominated by inter-subject 
variations (Fig.4.4). The model demonstrated a high cross validation parameter Q
2
:0.43 
but relatively low R
2
:0.56 by the second principal component and only reaching a 
cumulative value of 0.7 by the 7
th
 principal component with a very gradual rise toward 
1. The R
2
 value suggests that total variation in the data set is described by many 
principal components, however the fit of data to the model is satisfactory for urinary 
data. It can be inferred that the variance due to dose group and dosage regimen is 
underlying inter-subject variations. 
 
 
Fig. 4.4 PCA scores plot showing t[1]/t[2] principal components revealing an overview 
of the 
1
H NMR spectra of rat urine samples from all dosage groups and dosage 
regimens showing no clustering of samples based on class. (Q
2
:0.43 R
2
:0.56). 
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4.5.1.1 Pairwise PCA and Partial Least Squares Discriminant Analysis (PLS-DA) 
PCA calculated on the entire dataset revealed gender based clustering in the first two 
principal components, however there was evidence of overlap of male and female 
samples in the scores plot. This suggests that there are underlying sources of variation 
related to inter-subject variation in the dataset. To augment separation PLS-DA 
modelling improved gender based separation but the influence of inter-subject 
variations could still be seen (Fig. 4.5).  The female rat urine samples showed evidence 
of tighter clustering and therefore greater homogeneity.  
 
Analysis of the PLS-DA loadings plot revealed variables corresponding to urinary 
metabolites identified as 2‘-deoxycytidine and glycerophosphocholine (GPC) 
discriminatory of male samples and loadings corresponding to TMAO and axial C18 
protons of bile acids discriminatory of female samples.  
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Fig. 4.5 Scores maps showing (A) t[1]/t[2] PCA scores (Q
2
: 0.43 R
2
: 0.56) and (B) 
t[1]/t[2] PLS-DA scores (Q
2
: 0.28 R
2
: 0.32) from the 
1
H-NMR spectra of all rat urine 
samples showing clustering of samples based upon gender. Unit variance scaled. 
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4.5.1.2 Orthogonal-Partial Least Squares Discriminant Analysis (O-PLS-DA) 
gender related metabolic differences 
Analysis of all samples in all dose groups and time-points provided evidence of sexual 
dimorphism within the data set. Examination of the O-PLS-DA loadings plot identified 
statistically significant biomarkers related to gender. Modelling of gender related 
differences was particularly robust for biological matrices reflected in high R
2Ŷ: 0.87 
(explanation of total variance) and Q
2Ŷ: 0.8 (cross validated predictive ability) values. 
Metabolites diagnostic of male rats were increased excretion of GPC and a 
deoxyribonucleoside, 2‘-deoxycytidine identity was confirmed by STOCSY analysis 
and comparison to database reference spectra. Metabolites diagnostic of female rats 
were TMAO, the chlorogenic acid metabolite 3-hydroxyphenylpropionic acid and the 
axial C18 methyl protons of bile acids (Fig. 4.6). 
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Fig. 4.6 O-PLS-DA loadings plot showing urinary metabolic differences between male 
and female F344 strain rats all samples.  
Clear differences are seen between the metabolic phenotypes of male and female rats 
with upward pointing metabolites diagnostic of females and downwards pointing 
metabolites diagnostic of males. (Q
2Ŷ: 0.73; R2Ŷ: 0.96).  
Statistical significance of the O-PLS-DA coefficients is indicated by the colour with 
red: strong correlation and blue: weak correlation. 
 
  
 62 
 
4.5.2 The effect of high dosage methyl eugenol dietary intervention 
In order to ascertain any effect of ME exposure on the rat urinary metabolic phenotype 
following the 28 day dietary regimen, chemometric methods were used to compare the 
high 50mg/kg bw/day dosage group with the vehicle control diet group at all timepoints.  
 
4.5.2.1 Pairwise PCA and PLS-DA high ME dietary exposure vs. vehicle controls 
 
Fig. 4.7 PCA scores plot showing t[1]/t[2] principal components of urinary 
1
H-NMR 
spectral data from the vehicle control diet and 50mg/kg bw/day ME dosage regimen 
samples in all time-points.  
Clustering can be seen based on gender rather than dosage group indicating that the 
metabolic effects of ME, if any, are subtle.  Unit variance scaled (Q
2
: 0.39 R
2
: 0.46). 
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Pairwise PCA performed on unit variance scaled data of the vehicle control diet and 
50mg/kg bw/day dosage group samples at all time-points showed that variation in the 
first two principal components (PC1–PC2) was gender-based predominantly along the 
second principal component (Fig.4.7). Clustering could also be seen based on time point 
along the first and second principal component. However there was no evidence of 
clustering of samples based on dietary class. Analysis of the loadings plot identified 
specific loadings attributable to TMAO and GPC which discriminated female from male 
rats respectively along the first principal component. Loadings attributable to dietary 
time-point were widely scattered and therefore it was difficult to identify urinary 
metabolite changes responsible for the grouping seen in the scores plot along the second 
principal component.  
 
In order to prevent incorporation of variation in the model due to the known sexual 
dimorphism in experimental animals, statistical modelling was performed on each sex 
separately 
173
. In order to remove variation related to gender and time-point bias, PCA 
was recalculated on a smaller subset of the dataset. Male day 28 samples of the vehicle 
control diet and 50mg/kg bw/day ME diet groups were first analysed by PCA which 
revealed some evidence of clustering based upon ME dietary exposure along the first 
principal component (Fig 4.8). 
 
This separation was enhanced using PLS-DA modelling which achieved improved 
separation between the 50mg/kg bw/day ME dietary exposure regimen and the vehicle 
control diet in male F344 strain rats in the first two PLS-DA components (Fig 4.8). 
Analysis of the PLS-DA loadings plot revealed variables corresponding to unidentified 
urinary metabolites between δ3.8-3.9 responsible for discrimination between the control 
and ME dose groups.   
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Fig. 4.8 Scores maps showing (A) t[1]/t[2] PCA scores (Q
2
:0.36 R
2
:0.73)  and (B) 
t[1]/t[2] PLS-DA scores (Q
2
:0.79 R
2
:0.94 ) from the 
1
H-NMR spectra of vehicle control 
diet and 50mg/kg bw/day ME dosage groups day 28 rat urine samples showing 
clustering of samples based on ME exposure. Unit variance scaled. 
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4.5.2.2 O-PLS-DA male rats day 28 high ME vs. Day 28 vehicle controls 
An O-PLS-DA model was constructed to maximise the separation identified by PCA 
and to more readily identify the spectral features identified in the loadings of the PLS-
DA analysis. The cross validated scores and loadings coefficient plot of the supervised 
model is shown in (Fig. 4.9).  
 
 
Fig. 4.9 O-PLS-DA loadings plot showing male day 28 vehicle control diet vs. 50mg/kg 
bw/day dietary dose group.  (Q
2Ŷ: 0.21 and an R2Ŷ:0.67). Normalised to total area, Unit 
Variance scaled. 
 
 
A number of peaks were identified as diagnostic of ME exposure in rats; however the 
splitting patterns were necessarily identified by comparison with the raw spectral traces. 
The model suffered from a relatively low Q
2Ŷ value: 0.21. The low excretory 
concentration of the metabolites identified may be a potential reason for the poor model 
strength.  
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O-PLS-DA analysis revealed a triplet peak (δ3.86), three singlet peaks (δ3.80, δ2.06, 
δ2.04) and a multiplet (δ1.78) in the day 28 50mg/kg bw/day dose samples in both male 
and female rats (Fig. 4.9). Based upon chemical shift of the singlet peak (δ3.80) and 
correlation of this peak with creatine revealed by STOCSY analysis this peak was 
identified as guanidoacetate (Fig. 4.10). Analysis of the raw spectra revealed that these 
peaks were at a very low excretory concentration level this would also limit the use of 
sensitive 2D-NMR experiments to aid structural identification. This suggests that the 
metabolites associated with ME exposure are being excreted at a very low concentration 
or that effect of ME dietary on the urinary metabotype is subtle. Analysis of the raw 
1
H-
NMR spectra revealed that these peaks were also found to be present in the day 7, 14 
and 21 urine samples but not in the lower concentration dosage groups 1 or 5mg/kg 
bw/day samples. This is possibly due to a lower urinary concentration of the 
metabolite(s) at lower ME exposure levels. The O-PLS-DA loadings plot also showed 
an increased urinary concentration of creatinine in the 50mg/kg bw/day dose group 
animals.  
 
Fig. 4.10 STOCSY analysis of singlet peak δ3.80 reveals correlation with creatine. This 
singlet peak was identified as guanidoacetate. 
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STOCSY analysis of the triplet peak at δ3.86 revealed a clear correlation with the other 
unknown peaks identified by the O-PLS-DA analysis but also strong correlation with a 
singlet at δ2.30 and two doublets at δ7.06 and δ7.23. This was identified as p-cresol 
glucuronide (Fig. 4.11). However this biological covariance could be attributable to 
spectral overlap of the sugar protons of glucuronic acid in this area of the spectrum with 
the triplet peak (δ3.86) and does not necessarily provide further evidence of structure or 
biological origin for this spectral feature. The spectral features the two singlet peaks 
(δ2.06, δ2.04) and the multiplet (δ1.78) were tentatively identified as N- and O- 
acetylglycoprotein fragments by STOCSY analysis and comparison to reference spectra. 
However, low urinary concentration of these spectral features prevented absolute 
structural identification. 
  
 68 
 
 
Fig. 4.11 STOCSY analysis of unknown triplet peak δ3.86 reveals strong correlation 
with the other unknown peaks identified by the O-PLS-DA analysis and also with p-
cresol glucuronide. 
 
Further analysis of the 1mg/kg bw/day and 5mg/kg bw/day dietary exposure dose 
groups did not identify any discrimination between control and dose groups in either of 
the sexes. Chemometric models suffered from a poor fit (R
2Ŷ) and predictive strength 
(Q
2Ŷ) this was due to a predominance of underlying sources of variation. Attempts to 
chromatographically separate these spectral features were made using a concentrated 
urine sample from a 50mg/kg bw/day dietary dosage group rat in a SPE. SPE proved 
unsuccessful as the peaks of interest eluted in the highly polar fraction with many 
overlapping spectral features in higher abundance. 
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4.5.3 Time-course effects of methyl eugenol dietary intervention 
In an attempt to improve model strength and to determine whether metabolic changes 
could be observed throughout the course of the 28 day dietary regimen related to ME 
exposure, 
1
H-NMR spectra of urines of days 7, 14, 21 and 28 were compared by 
multivariate analytical methods. By comparison of the same experimental animals, 
variance due to inter-subject variability was limited and the animals acted as their own 
controls eg. Comparison of day 7 with day 28. Cumulative effects of ME were assessed 
by various chemometric modelling techniques. 
 
4.5.3.1 Pairwise timecourse PCA and PLS-DA high ME dietary exposure dose 
group 
PCA was performed to model the time-course cumulative effect of ME exposure in the 
high (50mg/kg bw/day) dosage group and to identify any age-related effects of ME 
exposure. 
 
To remove variation related to sexual dimorphisms, genders were modelled separately. 
Day 28 and day 7 urine samples from the 50mg/kg bw/day dietary intervention group 
were initially subjected to PCA analysis. Consideration of animals over time course of 
the study removed variation due to inter-subject variations and was found to improve 
model strengths.  In both the PCA and PLS-DA scores plots clear separation could be 
seen between the day 7 and day 28 urine samples (Fig. 4.12). Loadings attributable to 
either the day 7 or day 28 time-points were widely scattered and therefore it was 
difficult to extract urinary metabolite changes responsible for the grouping seen in the 
scores plot along the second principal component.  
 
PCA analysis of all time-points days 7, 14, 21 and 28 of male rats in the 50mg/kg 
bw/day dose group revealed evidence of a time-point dependent clustering of samples. 
This separation was further augmented using PLS-DA modelling of the data subset 
(Fig. 4.13). Most variation in the PLS-DA model was found to be non-systematic inter-
subject variations, however in the second and third PLS components clustering can be 
seen discriminating samples over the time course of the dietary intervention. PCA and 
PLS-DA analyses were repeated using the dietary matrix control animals to attempt to 
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identify any separation based upon ME dietary exposure. The PCA scores plot of the 
male dietary matrix control samples demonstrated limited evidence of clustering based 
upon time-point however it offered satisfactory cross validation and fit of data (Q
2
:0.36 
; R
2
:0.52) (Fig.4.14). The PLS-DA scores plot satisfactorily separated the dietary matrix 
control urine samples based upon time-point, however evidence of inter-subject 
variations still existed where samples appeared to cluster more strongly and demonstrate 
class membership with a different time-point.  These models suffered from weaker Q
2
 
and R
2
 values. This could possibly have been brought about by a greater degree of inter-
subject variation or the elucidation of a true dose response pattern in the 50mg/kg 
bw/day ME dietary intervention. It could also be due to the lower sample number in the 
dietary matrix control group (n=19) compared to the 50mg/kg bw/day ME dietary 
intervention (n=32) animals which could potentially bias the data. It could also indicate 
a dose response of the animals in the 50mg/kg bw/day dietary intervention group based 
upon ME dietary exposure, however analysis of the loadings revealed a similar 
ambiguity of 
1
H-NMR spectral features responsible for the time-point based clustering 
observed in both the dietary matrix control and 50mg/kg bw/day ME animals. These 
results suggested that the time-point based separation seen in the 50mg/kg bw/day ME 
dietary intervention samples were most likely based upon age of the animals rather than 
a specific effect of the 50mg/kg bw/day ME administered. 
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Fig. 4.12 Scores maps showing (A) t[1]/t[2] PCA scores (Q
2
: 0.4 R
2
: 0.59) and (B) 
t[1]/t[2] PLS-DA scores (Q
2
: 0.62 R
2
: 0.89) from the 
1
H-NMR spectra of the 50mg/kg 
bw/day ME dosage group of male rat urine samples showing clustering of samples 
based on the day 7 and day 28 timepoints. Unit Variance scaled. 
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Fig. 4.13 Scores maps showing (A) t[1]/t[2] PCA scores (Q
2
: 0.37 R
2
: 0.46) and (B) 
t[2]/t[3] PLS-DA scores (Q
2
: 0.21 R
2
: 0.51) from the 
1
H-NMR spectra of the 50mg/kg 
bw/day ME dosage group of male rat urine samples showing clustering of samples 
based upon time-point. Unit Variance scaled. 
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Fig. 4.14 Scores maps showing (A) t[1]/t[2] PCA scores (Q
2
: 0.36 R
2
: 0.53) and (B) 
t[1]/t[2] PLS-DA scores (Q
2
: 0.16 R
2
: 0.51) from the 
1
H-NMR spectra of the dietary 
matrix control group of male rat urine samples some clustering of samples based upon 
time-point can be seen but there is also evidence of inter-subject variations. Unit 
Variance scaled. 
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4.5.3.2 Pairwise timecourse O-PLS-DA high ME dietary exposure dose group 
Pair-wise time-course analysis of day 7 to day 14, day 14 to day 21 and day 21 to day 
28 produced robust O-PLS-DA models with excellent cumulative R
2Ŷ and Q2Ŷ values 
that demonstrated clear discrimination based upon time-point. The result suggests the 
modelling of the maturation of the rats metabolism and alterations identified are 
therefore likely attributable to the age of the rat. At the time of the commencement of 
the dietary regimen rats were 6 weeks old and considered juvenile rats. The statistically 
significant metabolite changes observed in the O-PLS-DA loadings plots were 
attributable to transition of the experimental animals into adulthood. To identify 
metabolites attributable to ME comparison of the control vehicle diet group O-PLS-DA 
loadings to the high ME dose group O-PLS-DA loadings, found that metabolites 
contributing to discrimination between time-points did not contain any signals unique to 
ME exposure. 
   
Comparison of the 7 day urine to the 28 day urine of the 50mg/kg bw/day dosage group 
produced the statistically strongest modelling of age related metabolic changes. A 
number of statistically significant changes in metabolic phenotype between the 7 week 
old (day 7) rats and the 10 week old (day 28) rats were seen. The model was particularly 
robust at discriminating the age difference between the rats with a Q
2Ŷ: 0.86 and an 
R
2Ŷ:0.98 by the second O-PLS-DA component. 
 
Ten week old (day 28) animals were shown to excrete increased concentrations of 
creatinine, taurine, an unknown triplet (δ3.16), hippurate, PAG and p-cresol 
glucuronide. There were also various unidentified 
1
H-NMR features discriminatory of 
the 10 weeks old animals. STOCSY analysis unknown triplet (δ3.16) showed strong 
correlation with taurine, a peak at δ3.96. The strong correlation of this unknown with 
taurine suggested the unknown may have been a taurine derived metabolite however 
potential taurine metabolites were discounted by comparisons with database references 
spectra (Fig.4.15-17). 
 
The 7 week old rats were shown to excrete increased concentrations of 2-
ketoisocaproate and the dicarboxylates; succinate, adipate and lactate and also 
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resonances corresponding to N- and O-acetylglycoprotein fragments. Identifications 
were made utilising STOCSY analysis, literature sources and database mining 
138, 147
.  
 
 
 
- 
Fig. 4.15 Aliphatic region of O-PLS-DA loadings plot demonstrating urinary metabolic 
differences between day 7 (7 weeks old) and day 28 (10 weeks old) male F344 strain 
rats of the 50mg/kg bw/day dose group.  
Differences in metabolic phenotype can be seen between juvenile (7 week old) and 
adult (10 week old) rats. A similar pattern of metabolic differences can be seen in the 
control dose group with no changes indicated based on ME exposure. (Q
2Ŷ: 0.86 and an 
R
2Ŷ:0.98). 
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Fig. 4.16 Aromatic region of O-PLS-DA loadings plot showing urinary metabolic 
differences between day 7 (7 weeks old) and day 28 (10 weeks old) male F344 strain 
rats of the 50mg/kg bw/day dose group. 
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Fig. 4.17 STOCSY analysis showing correlation of the unknown triplet peak (δ3.16) 
with taurine and another unknown peak (δ3.96). 
 
     
 
 
3.13.23.33.43.53.63.73.83.94
0
0.05
0.1
0.15
0.2
0.25
0.3
0.35
d,ppm
Co
v
ar
ia
nc
e(
X,d
=
3.
16
32
)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
d =3.1632
3.16d
3.96d
taurine
 78 
 
4.5.4 Gender related effects on methyl eugenol metabolism 
Sexual dimorphism and age-related effects have been shown to dominate variations 
between animals in chemometric models of this dietary intervention urinary dataset. In 
order to ascertain whether there was an under-lying gender-specific effect on the 
metabolism of ME, comparison was made between the 50mg/kg bw/day ME urine of 
male rats to the 50mg/kg bw/day ME urine of female rats. To limit variation due to age 
and maximise cumulative effects of the high ME dosage groups, comparison was made 
between the 28 day samples. It has been shown that male rats have a greater degree of 
differential hepatic gene expression to female rats due to ME exposure, also males are 
thought to be more susceptible to the genotoxic effects of ME 
165
.  
 
4.5.4.1 Pairwise PCA and PLS-DA 
A subset of the 50mg/kg bw/day ME dietary intervention dataset was initially analysed 
using PCA to determine the source of greatest variation in the 
1
H-NMR X matrix. It was 
found that a one PC model was sufficient to determine variation in the 28day subset 
(Q
2
: 0.46; R
2
: 0.81). Clustering in the scores plot along the first PC was not related to 
gender as female and male samples (♀: 9; ♂: 7) fell equally above the 0 standard 
deviation line, however the data points were between the +/- 2.50 standard deviations 
confidence interval and this did not indicate outlying samples within the subset 
(Fig.4.18). This finding was further augmented using supervised PLS-DA which 
suggested a gender biasing of the variation in the urinary 
1
H-NMR data. Analysis of the 
loadings plot showed separation attributable to various signals however TMAO and 
GPC could be identified as separating female and male rats respectively.   
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Fig. 4.18 Scores maps showing (A) t[1]/sample no. PCA scores (Q
2
: 0.46 R
2
: 0.81) and 
(B) t[1]/t[2] PLS-DA scores (Q
2
: 0.37 R
2
: 0.73) from the 
1
H-NMR spectra of the 
50mg/kg bw/day ME dietary intervention animals contrasting gender in order to 
determine any gender specific effects of ME exposure in the F344 rat strain. Clustering 
of samples based upon gender can be seen in the PLS-DA scores. Unit Variance scaled. 
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4.5.4.2 Pairwise O-PLS-DA 
Calculation of the O-PLS-DA model of the day 28 50mg/kg bw/day ME dietary 
intervention samples revealed robust statistical discrimination between male and female 
animals. This model utilised one aligned component to give particularly strong 
modelling of the variation in Y (Q
2Ŷ: 0.93; R2Ŷ: 0.98). This model succeeded in 
confirming the sexual dimorphism seen in the F344 rat strain previously identified by 
the comparison of all male and female samples but with a more robust cross validation 
and explanation of variance (Fig.4.19). Key metabolic differences in females included 
evidence of bile acid metabolites, N-acetylglutamate, alpha-ketoglutarate and TMAO, 
and in male rats evidence of increased GPC and 2‘-deoxycytidine excretion. This 
finding was largely consistent with the previously known metabonomic sexual 
dimorphism in experimental animals 
173
 but was not suggestive of any gender related 
metabolic change related to ME exposure. 
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Fig. 4.19 O-PLS-DA loadings coefficients plot showing evidence of metabolic sexual 
dimorphism in the F344 rat strain. Robust modelling of the data was achieved 
suggesting the majority of urinary metabolic variation is gender specific in the first 
aligned O-PLS component (Q
2Ŷ: 0.93; R2Ŷ: 0.98). 
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4.5.5 Effect of methyl eugenol administration method on urinary metabolic 
phenotype 
Comparison of the orogastric gavage administration method to the dietary matrix 
intervention were made to examine any effect on the metabolism of ME or any 
homeostatic effect on the metabolic phenotype due to gavage administration. Oral 
gavage is known to cause rapid absorption of ME from the stomach and a rapid 
accumulation in the liver, it also can potentially damage the GI tract and cause 
confounding metabolic changes due to an acute stress response in experimental animals. 
Chemometric modelling of the 50mg/kg bw/ day gavage treatment against the dietary 
matrix and gavage controls against vehicle dietary controls were made to establish any 
effect of ME exposure on the urinary metabolic phenotype in F344 strain rats.  
 
4.5.5.1 Pairwise PCA and PLS-DA high ME exposure dietary matrix vs. orogastric 
gavage 
In order to model the effect of orogastric gavage treatment on ME dietary exposure a 
PCA model was calculated comparing the 50mg/kg bw/day dietary matrix group to the 
50mg/kg bw/day gavage treatment group rats at all time-points. To remove variation 
related to sexual dimorphism only male samples were included in the model. Variation 
in the first four principal components was dominated by inter-subject variation; 
however cross-validation of the model showed an ability to correctly predict 52% of 
samples with 44% of the predictions being within the 99% confidence interval. No clear 
clustering was seen attributable to gavage treatment. PLS-DA modelling succeeded in 
identifying variation attributable to gavage treatment and dietary matrix intervention in 
the second and third PLS-DA components (Fig. 4.20).  
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Fig. 4.20 Scores maps showing (A) t[1]/t[2] PCA scores (Q
2
: 0.44 R
2
: 0.52) and (B) 
t[2]/t[3] PLS-DA scores (Q
2
: 0.43 R
2
: 0.56) from the 
1
H-NMR spectra of the 50mg/kg 
bw/day gavage treatment and 50mg/kg bw/day ME dosage group of male rat urine 
samples showing clustering of samples based upon treatment method in the PLS-DA 
model only. Unit Variance scaled. 
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4.5.5.2 O-PLS-DA high ME exposure dietary matrix vs. orogastric gavage 
Evidence of an acute stress-related response was observed in male F344 strain rats 
following repeated orally gavaged high dose ME animals when compared to the high 
dose ME dietary matrix animals. O-PLS-DA revealed statistically significant increases 
in hippurate, methylmalonate, lactate, succinate, methylamine, scyllo-inositol and an 
unknown singlet peak at δ4.03 in the high ME dose (50mg/kg bw/day) gavage animals. 
The high ME dietary matrix (50mg/kg bw/day) animals showed increased urinary 
excretion of creatinine, taurine, phenylacetylglycine, p-hydroxyphenylacetate and m-
hydroxymandelate (Fig. 4.21). 
  
The unknown at δ4.03 which was found to discriminate the gavage treatment from the 
dietary dosing regimen was found to show correlations with creatine, dimethylamine, 
succinate and N-acetylglyprotein by STOCSY analysis.  
 
Calculation of an O-PLS-DA model of the gavage control group samples against the 
vehicle control samples revealed a similar pattern of metabolic changes and no evidence 
of a ME specific effect. 
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Fig. 4.21 O-PLS-DA loadings coefficient plot showing (A) aliphatic region 
demonstrating urinary metabolic differences between 50mg/kg bw/day ME dietary 
matrix (downwards pointing peaks) and 50mg/kg bw/day ME gavage treatment 
(upwards pointing) male F344 strain rats. (B) aromatic region of the spectrum. 
Metabolic differences can be seen attributable to the orogastric gavage treatment. (Q
2Ŷ: 
0.66 and an R
2Ŷ:0.96). 
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4.6 Discussion 
ME has been identified as a multiple site carcinogen when using high dosages in both 
the rat and mouse (NTP, 2000). It is of concern to environmental toxicology due to its 
ubiquity in many commonly consumed foodstuffs and its use as a food and cosmetics 
additive. Genotoxic DNA/RNA adduct formation has been seen in both in vitro and in 
vivo animal models 
167
. Mutagenicity, however, has been shown to be largely negative 
in standard in vitro cell cultures of both human and rat/mouse tissues and positive in in 
vivo rat and mouse models 
159, 163
. The high dosages administered by gavage within the 
2 year NTP bioassay (37-300mg/kg bw/day) most likely overestimated the 
carcinogenicity of ME and its potential effects in humans (NTP, 2000). This is 
exemplified by the fact that the serum concentration of ME in human populations due to 
dietary exposure is several orders of magnitude lower in humans than  the lowest doses 
utilised in the NTP bioassay 
167
. 
 
Assessment of carcinogenicity is further confounded by the dose dependent metabolism 
of ME where O-demethylation is most likely to be the primary route of metabolism and 
elimination from the body in humans where the estimated dietary exposure is (~10-
100µg/kg bw/day) 
174
. It is only at higher dosage levels where the genotoxic metabolite 
1‘-hydroxymethyl ME is formed which is metabolised to the reactive carbocation 64. 
This study utilised a more realistic 28 day dosage regimen in accordance with the 
known levels of human exposure to resolve the issues highlighted by the 2 year NTP 
bioassay. It also utilised a more realistic dosing strategy, comparing administration 
using a dietary matrix with the commonly used but potentially confounding oral gavage 
method. 
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4.6.1 The effect of high dosage methyl eugenol dietary intervention 
It was anticipated with the lower doses used within this study (1-50mg/kg bw/day) the 
most abundant metabolites of ME in the urine would be the sulphate or glucuronic acid 
conjugate of eugenol or 5-allyl-2-methoxy phenol formed by O-demethylation of ME, 
based on the known metabolism of ME in the rat 
167
. 
 
As such these metabolites represent candidates for metabonomic biomarkers of ME 
exposure within rat urine, although with human dietary relevant doses of ME the 
identification of these metabolites by 
1
H-NMR spectroscopy proved problematic due to 
low urinary concentration and spectral overlap of constitutive urinary metabolites in 
higher concentration. Metabolites tentatively identified as discriminatory of ME 
exposure were guanidoacetate and acetylglycoproteins fragments, however absolute 
identification was confounded by intensity of the spectral features close to the threshold 
of noise. The STOCSY correlation of the singlet peak δ3.80 to creatine was highly 
indicative of the assignment of the methylene protons of guanidoacetate. 
Guanidoacetate is an essential component of the de novo synthesis of creatine in the 
body. Guanidoacetate is synthesised in the kidneys from the amino acids arginine by the 
enzyme arginine:glycine amidinotransferase where it also serves the function as a 
osmolyte. In the rat liver hepatocytes the enzyme guanidoacetate methyltransferase 
converts guanidoacetate into creatine by methylation 
175
. 
 
The identification of guanidoacetate in the urine of the 50mg/kg bw/day dose group 
animals suggests an effect of ME dietary exposure on the energy metabolism and a 
potential blockage of creatine synthesis and would be consistent with the known hepatic 
genotoxicity of ME (NTP 2000). However the low urinary concentration and tentative 
assignment of this peak is inconclusive. 
 
Acetylglycoprotein fragments in the urine are indicative of an inflammatory response, 
acute phase acetylglycoproteins are released by hepatocytes as an anti-inflammatory 
response to cytokine release following tissue damage, cellular disruption or infections. 
Acetylglycoprotein fragments are also known to be excreted during normal growth 
processes and are not necessarily pathologically indicative 
176
. 
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The presence of signals attributable to acetylglycoprotein fragments in the experimental 
animals exposed to ME, although tentative may possibly indicate an inflammatory 
response in the rat liver.  
 
However discrimination was obtained between the high ME dietary exposure dosage 
group and the vehicle control group animals, yet confirmation of the identity of the 
metabolites is problematic as the regions of the spectrum in which the potential 
biomarker of ME exposure appeared, revealed a very low urinary concentration. This 
would make the identification of this unknown difficult by 2D-NMR experiments such 
as J-resolved, COSY, TOCSY and carbon 13 isotope experiments such as HSQC and 
HMBC where minimum urinary concentrations are necessary for successful metabolite 
identification 
177
.  
 
Experimental 
1
H-NMR spectra of eugenol were found to be available in the literature 
178
. The splitting pattern of eugenol was found to be inappropriate to account for the 
discriminatory spectral peaks identified by O-PLS-DA. The experimental  
1
H-NMR of 
eugenol from the spectral database for organic compounds (SDBS) showed aromatic 
proton peaks at δ6.6 and δ6.75; an aromatic alcoholic proton peak at δ5.0; allyl protons 
between δ4.9 to δ6.3 and methoxy protons at δ3.8 and benzylic protons at δ3.2. The 
unknown triplet peak at δ3.8 could potentially represent the methoxy protons of 
eugenol, however other peaks of eugenol which would present at higher intensity in the 
spectrum are notably absent. It is also important to note that the sulphation or 
glucuronidation of eugenol would cause a shift of the peaks upfield in the spectrum 
identified by O-PLS-DA and also result in a more complicated proton NMR spectrum. 
It can also be reasonably anticipated that due to the great structural similarity of 5-allyl-
2-methoxy phenol to eugenol that the splitting pattern and peak positions of the 
1
H-
NMR spectrum would be similar.  
 
The STOCSY correlation of the peak at δ3.80 with p-cresol glucuronide suggested that 
the unknown metabolite may be associated with a similar metabolic pathway to p-cresol 
glucuronide or demonstrate biological covariance. However it is more likely that 
spectral overlap may have occurred in this region with the proton signals of glucuronic 
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acid causing the STOCSY correlations observed with p-cresol glucuronide. It is also 
possible the peak at δ3.80 could also be a glucuronide conjugate of a ME metabolite or 
perhaps a similar microbially-derived metabolite associated with ME exposure. 
However, there were no statistically significant features in the aromatic region of the 
1
H-NMR spectra associated with ME exposure.  
 
The low urinary concentration of the spectral features associated with the 50mg/kg 
bw/day ME dietary exposure group animals confounded absolute metabolite 
identification. It is conceivable that if the spectral features are urinary metabolites of 
ME detoxication these would be expected to be in relatively low concentration in the 
urine with a 50mg/kg bw/day dosage regimen and the use of higher ME dosages may 
improve the 
1
H-NMR signal from these spectral features. The low urinary concentration 
of the spectral features associated with ME exposure could also be related to a subtle 
perturbation of endogenous homeostasis which also may be more readily observed 
utilising a higher concentration ME dosage regimen. The use of high-throughput UPLC-
MS analysis of the rat urine samples combined with a targeted mass spectral analysis 
could be used to characterise the urinary metabolites of ME. Further UPLC-MS  
analysis was unfortunately beyond the financial scope of this study. 
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4.6.2 Gender related effects on methyl eugenol metabolism 
No urinary biomarkers of ME were identified in this study and therefore sex-related 
differences related to ME exposure could not be fully investigated. However sex-related 
differences in endogenous urinary metabolites were identified between male and female 
F344 strain rats.  
 
As proof of principal metabonomic investigation succeeded in identifying sexual 
dimorphism in the 
1
H-NMR urinary metabolic profiles of the F344 rats in this study. 
Many of these metabolites have previously been identified within our group in Han 
Wistar strain rats 
173
.  
 
The higher concentration of TMAO found in female rats is potentially due to the 
influence of the oestrus cycle. TMAO is known to form from oxidation of 
trimethylamine by flavin-containing monooxgenases 
179
, a degradation product of 
choline which is derived from catabolism of phospholipids or from the diet 
180
. 
Testosterone is known to inhibit expression of flavin-containing monooxygenases 
which would account for the higher excretion of TMAO in the female and a higher 
concentration of GPC in the male rat urine samples 
181
. Rats are known to excrete 
aromatic chlorogenic acid metabolites which are processed by and dependent on the 
composition of the gut microbiota 
182
. The excretion of the chlorogenic acid metabolite 
3-hydroxyphenylpropionic acid is known to occur in both male and female rats 
183
. 
However male rats predominantly have a higher sulphation rate for this metabolite 
which inactivates its inhibitory effect on platelet aggregation. Decreased platelet 
aggregation seen in female rats is possibly due to this gender-specific metabolic 
difference 
184
. It is also known that urinary concentrations of N-acetylglycoproteins 
fluctuate dependent on the stage of the oestrus cycle and this could explain its increased 
concentration in female rat urine 
185
. Female rats were also shown to be characterised by 
increased excretion of alpha-ketoglutarate, an important keto acid formed from the 
deamination of glutamine and an important intermediate in the krebs cycle and also an 
important element in the removal of excess nitrogen in the body. Also evidence was 
seen of the C18 axial methyl protons of bile acids in the female F344 strain rat urine 
173
. 
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In male rats an interesting discriminatory metabolite was identified in the aromatic 
region of the 
1
H-NMR spectra attributable to the deoxyribonucleoside, 2‘-
deoxycytidine. Deoxycytidine is formed by the attachment of the pyrimidine cytosine to 
a deoxyribose by a β-glycosidic linkage. Metabonomic studies have previously 
identified this deoxyribonucleoside in urine in F344 strain male rats treated with the 
model hepatotoxin galactosamine. 2‘-deoxycytidine was found to be depleted in 
galactosamine treated rats and therefore present in higher concentrations in untreated 
control F344 strain male rats 
186
. 
 
The region in the aliphatic region of the spectrum was attributed to the –CH protons of 
deoxyribose. STOCSY analysis also confirmed statistical covariance of the peaks in the 
aromatic region and these peaks in the aliphatic region. It is thought that male F344 
strain rats are susceptible to the genotoxic effects of ME and are subject to increased 
differential hepatic gene expression 
165
. Potentially the increased urinary concentration 
of a deoxyribonucleoside such as deoxycytidine could be representative of the increased 
ME genotoxicity in male F344 strain rats. It is known that rats excrete higher 
concentrations of deoxycytidine in response to DNA damage caused by X-irradiation 
187
 
and in animals bearing ascites sarcoma 
188
 and as such it represents a potential urinary 
biomarker of oxidative DNA damage and a potentially important metabolic difference 
of male experimental F344 strain rats. However, it is more likely that this 
deoxyribonucleoside represents a normal constitutive urinary metabolite associated with 
male F344 strain rats and represents a gender-related differential deoxyribonucleoside 
turnover in these experimental animals. 
 
Male F344 strain rats were also shown to be characterised by an increased excretion of 
GPC. GPC is a ubiquitous choline derived metabolite which acts along with 
phosphocholine as the major source of choline storage in the cytosol, it is also a major 
organic osmolyte in renal medullary cells. GPC functions to counteracts the effect of 
urea on proteins and other macromolecules in the renal medullar, renal cells are exposed 
to greatly fluctuating extracellular solute concentrations and respond to hypertonic 
stress by accumulating GPC and other osmolytes such as betaine and myo-inositol. The 
presence of GPC in rat urine attributable to male rats is unexpected as GPC would 
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normally be utilised as a storage source of choline and retained within the renal 
medullary cells. 
 
The findings of this study reaffirm previously demonstrated gender specific urinary 
metabolic change already elucidated by the metabonomic approach. However the 
identification of unknown discriminatory metabolites such as the unknown aromatic 
spectral features associated with male F344 strain rats is still of great interest to 
understanding the relationship between experimental animal sex, urinary metabotype 
and differential drug metabolism/toxicology.  
 
 4.6.3 Time-course effects of methyl eugenol dietary intervention 
Chemometric evaluation of 
1
H-NMR data by PCA, PLS-DA and O-PLS-DA provided 
robust models demonstrating evidence of age-related differences in metabolic 
phenotype between the 7 day, 14 day, 21 day and 28 day time-points. The F344 rats 
were 6 weeks old and considered juveniles at commencement of the dietary intervention 
study. Time course pair wise examination of animals in each of the separate dosage 
groups provided strong evidence of changes in metabolic phenotype due to age 
differences. This was shown not to be related to an influence of ME in the higher 
50mg/kg bw dosage group as a very similar fingerprint of metabolic changes was 
observed in the control animals dosage group.    
 
Evaluation of age-related differences in the urinary metabolic composition of rats has 
been previously reported and is in agreement with the findings of this study 
189, 190
. Ten 
week old animals were shown to excrete increased concentrations of creatinine, taurine, 
hippurate, PAG and p-cresol glucuronide and also an unidentified triplet peak at δ3.16 
which when submitted to STOCSY analysis correlated strongly with taurine.  
 
Increased creatinine urinary concentration with age is associated with increased muscle 
mass and concentration is directly correlated with body mass 
191
. 
 
The increased concentration of metabolites strongly associated with the gut microbiota 
in the 10 week old (day 28) rats such as hippurate, PAG and p-cresol glucuronide 
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indicates that the gut microbiota is still in the process of establishment and stabilisation 
in the 6 week old (day 7) rats as they continue to adapt to an adult diet 
97, 192
.  
 
The increased excretion of the amino acids taurine in the 10 week old adult rats is 
almost certainly attributable to increased muscle mass and also more specific maturation 
of organs in the rat 
189
. Increased taurine excretion is related to decreased liver function 
and is known to be protective against reactive oxygen species 
193
. 
 
The increased urinary excretion of amino acids and creatinine is also associated with 
changes in renal function in older rats 
194
. 
There was also an unidentified metabolite discriminatory of the 10 week old (day 28) 
animals a triplet peak at δ3.16 which was shown to correlate strongly with taurine when 
subjected to STOCSY analysis. Statistical correlations were also observed with the peak 
at δ3.98. Potential analogues and metabolites of taurine such as hypotaurine, amidino-
taurine and taurine carbamate were discounted as candidate biomarkers as the expected 
peaks were not identified in the spectra.  
 
The 7 week old rats were shown to excrete increased concentrations of 2-
ketoisocaproate and the dicarboxylates; succinate, adipate and lactate and also 
resonances corresponding to N- and O-acetylglycoprotein fragments. Metabonomic 
investigation has shown decreased concentrations of metabolic end-points of the 
mitochondrial respiratory chain, dicarboxylates and Kreb‘s cycle intermediates in the 
urine of older rats with increased concentrations in younger animals 
189, 190
. This is 
consistent with the increased energy requirements of growth and development in 
adolescence and a diminishing mitochondrial function in older animals. It is known that 
the ability to metabolise ME decreases with age in rats 
166
. The excretion of 
acetylglycoprotein fragments in adolescent animals is also known to be associated with 
growth processes and has been shown to be discriminatory of adolescence in a long-
term study of aging in dogs 
195
. 
 
The complexity of characterizing the response to dietary intervention superimposed on 
the background of dynamic biological processes such as aging presents a substantial 
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challenge and confounding biological information associated with aging needs to be 
taken into consideration when analysing metabonomic datasets. 
 
4.6.4 Effect of methyl eugenol administration method on urinary metabolic 
phenotype 
A similar pattern of metabolic change was seen by chemometric comparisons of the 
vehicle control diet dosage group to the control gavage dosage group as in comparison 
of the high dosage gavage to the high dosage dietary intervention. This suggests there 
were no observable effects of acute ME exposure by gavage treatment in the 
experimental animals and metabolic phenotypic change was due to stress-related 
responses only. 
  
It was found the dietary dosing regimen produced more pronounced genotoxic effects at 
the acute high dose (50mg/kg bw/day) in the stomach with increased DNA adduct 
formation than the gavage treatment 
165
. The constant feeding of ME was thought to 
provide a continual exposure, whereas the one-shot gavage dosage and the highly 
lipophilic nature of ME would mean rapid clearance from the stomach and a saturation 
of the intoxication pathway in the liver with this latter route of administration. 
 
The oral gavage is a commonly used method of drug administration in toxicology and 
can potentially introduce confounding effects in experimental models due to acute 
stress.  Oral gastric gavaging involves physical stressors of handling and restraining 
experimental animals, insertion of a rigid needle from the mouth to stomach and can 
lead to respiratory interference and stomach distension. This method can also cause 
oesophageal/tracheal perforations, aspiration pneumonia, haemothorax and increased 
morbidity 
196
 
 
Repeated daily oral gavage can also lead to tissue damage of the pharyngea with 
development of granulation tissue. This granulomatous inflammation has been linked to 
higher mortality in the F344 strain rat in a carcinogenicity study 
197
, although this was 
found to be strain specific 
198
.  It has important implications for the observed 
metabonomic effect in this study as it can lead to oral intake aversion, acute stress and a 
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reduction in body weight and other confounding histopathological findings unrelated to 
ME exposure.  
 
Furthermore acute stress can cause induction of the corticotrophin-releasing hormone 
system potentially causing a catabolic impact in the experimental animals 
199
. There 
exists a need for less invasive measurement of the acute stress response in experimental 
models as the principal measurement of stress is by analysis of plasma concentrations of 
corticosterone, the main glucocorticoid produced by stress, which is in itself an invasive 
method. Measurement of faecal corticosterone concentrations is also insufficient as the 
oral gavage event itself is brief 
200
. Metabonomic analysis offers a potential method of 
gauging drug administration stress accurately and non-invasively in urine of 
experimental animals. Metabonomic analysis of blood plasma of rats has already been 
shown to be effective in gauging the extent and the amelioration by diet of the severity 
of the stress response 
201
. 
 
The biochemical changes due to repeated oral gavage treatment are potentially related to 
a disturbance in energy metabolism, amino acid metabolism and gut microbial changes 
related to stress. The accumulation of short-chain organic acids in the urines of oral 
gavage dosed rats is suggestive of a disruption of energy metabolism and components of 
the respiratory chain and krebs cycle in the mitochondria. Increased urinary 
concentration of succinate, lactate and methylmalonate indicate impairment of 
mitochondrial function the detrimental effects of which result from accumulation of 
acyl-coA groups, which reduce the availability of coenzyme A for important metabolic 
enzymes 
202, 203
. These findings provide evidence of oral gavage induced organic 
aciduria. Succinate is an important component of the citric acid cycle which donates 
electrons to the electron transfer chain and methylmalonate urinary excretion is known 
to increase in rats with vitamin B12 deficiency 
204
. 
 
The higher urinary concentration of an osmolyte scyllo-inositol in the urine of the 
gavage treated rats was not anticipated and could potentially be an introduced 
contaminant, however the gavage vehicle consisted simply of maltodextrin and distilled 
water and was thoroughly tested for its stability over a period of 14 days. A single 
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singlet peak for scyllo-inositol at δ3.35 is also shared by methanol, however the 
presence of significant quantities of methanol in the gavage treated urine samples seems 
unlikely. Scyllo-inositol is a stereo isomer of inositol and is a naturally occurring plant 
sugar alcohol. In Alzheimers disease research scyllo-inositol has been shown to block 
the formation of β-amyloid plaques in mice brain and reduce memory deficits 
associated with this condition 
205
. The presence of scyllo-inositol in these urine samples 
is not readily explainable.  
 
The increased excretion of methylamine in the gavage treated animals is likely to be 
derived from the degradation of dietary choline by the gut microbiota 
206
. Concurrent 
changes in excretion of aromatic metabolites such as hippurate, phenylacetylglycine, 
hydroxyphenylacetate and m-hydroxymandelate are suggestive of fluctuations in the 
activities or populations of members of the gut microbiota. Changes in gut microbial 
metabolites are known to occur in rats subjected to acute and chronic stress and 
fluctuations in these metabolites are perhaps related to the stress response or gastric 
dysbiosis induced by the gavage treatment method 
207
.  
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4.6.5 Conclusion 
The findings of this study confirm that at doses relevant to human levels ME has no 
detectable acute toxicity in the rat urinary metabolic profile. As proof of principle the 
metabonomic approach has successfully identified metabolic differences related to 
gender, age and a stress-response related to the use of the orogastric gavage. The 
evidence of genotoxicity in the dose range 1-50mg ME/kg bw/day confirmed by DNA-
ME adduct formation and differential gene expression by Dr. J Ellis BMM, IC 
165
 
produced no pronounced perturbation of homeostasis in the F344 strain rat, however 
low urinary concentration NMR spectral features were implicated as attributable to ME 
exposure but absolute identification was confounded by signals close to the threshold of 
noise. Tentative assignments were made of guanidoacetate and acetylglycoprotein 
fragments to the spectral features associated with ME exposure. These were biologically 
plausible and were indicative of a potential disruption of energy metabolism and 
inflammatory response. It can also be reasonably surmised that the peaks attributable to 
ME exposure could derive from the O-demethylation of ME and its subsequent 
excretion as either the sulphate or glucuronic acid conjugate of either eugenol or 5-allyl-
2-methoxy phenol. 
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Chapter Five: Changing Dietary Fat Composition and 
Carbohydrate Glycaemic Index in Subjects at Risk of 
Developing the Metabolic Syndrome – Mapping Metabolic 
Change Through Metabonomics 
5.1 Background 
The RISCK study (an acronym derived from the participating institutions; Reading 
University, Imperial College London, Surrey University, MRC Human Nutrition 
Research Cambridge and Kings College London) was designed to examine a significant 
issue in public health; the effects of different amounts and types of dietary fat and 
carbohydrate on metabolic syndrome, which is diagnosed by a set of criteria associated 
with an increased risk of morbidity; coronary heart disease (CHD), type 2 diabetes and 
other chronic diseases and increased mortality. This cohort study aimed to address the 
health impact of changes in dietary fat and carbohydrate amount and composition, to 
inform public health policy. Understanding metabolic syndrome and associated risks 
will aid management and therapy and help alleviate the growing social and financial 
burden associated with heart disease and type 2 diabetes. Within the context of this 
study metabonomic techniques were applied to a 130 participant subset of the study, 
which was performed to attempt to identify global metabolic changes associated with 
dietary change in humans. 
 
5.2 Aims and Objectives 
 The overarching aim of the study was to identify metabolic changes in both 
urine and faecal water samples attributable to dietary modulation of the type and 
amount of fat and carbohydrate, utilising 
1
H-NMR spectroscopy combined with 
multivariate statistical analyses. 
 To monitor metabolic responses caused by dietary change in human biofluids 
attributable to gut microbial metabolism  
 To investigate co-variation of 1H-NMR spectroscopic data of both urine and 
faecal water with faecal bacterial population numbers and 
clinical/anthropometric measures in obese volunteers at risk of or suffering from 
MS.  
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5.3 Introduction  
5.3.1 Metabolic syndrome 
The increasing incidence of obesity, the pleiotrophic diagnostic criteria of metabolic 
syndrome (MS) and the associated health risks is an area of serious public health 
concern and study. Obesity is highly prevalent with estimations of half of the female 
population and around a third of the male population considered obese in the UK (Food 
Standards Agency data www.food.gov.uk). MS is strongly correlated with obesity and 
many of the diagnostic criteria of these conditions are shared, it is estimated of obese 
individuals in the UK ~25% are symptomatic of MS 
7, 208
. Higher incidence of MS has 
also been noted in ethnic subgroups such as Asians and African-Caribbeans 
209
.  
 
MS is a cornucopia of characteristics, which confer increased risk of coronary heart 
disease (CHD), diabetes, cancer incidence and increased morbidity and mortality. The 
diagnostic criteria characteristic of MS include hypertension, dyslipidaemia (elevated 
plasma triacylglyceride (TAG) levels, low High Density Lipoprotein (HDL)-cholesterol 
levels), central adiposity and insulin resistance. MS is thought to confer greater risk to 
the development of diabetes and CHD than any of the individual diagnostic components 
of the syndrome 
7
. Dyslipidaemia is a strong risk factor for CHD and is defined by a 
resistance of insulin to lipid metabolism 
210, 211
. Insulin resistance is known to be 
causative of adiposity and a primary cause of many of the metabolic perturbations 
linked with MS (European Group for Study of Insulin Resistance, 2002).  
 
Diet is known to be strongly associated with the aetiology and severity of CHD. Highly 
processed, westernised diets containing a high proportion of saturated fats and refined 
simple carbohydrates with low intakes of fruits, vegetables and fibre have been 
demonstrated to be linked to increased risk of CHD 
212
, while conversely reductions in 
calorific intake and increased consumption of fruit and vegetables have been shown to 
be preventative of CHD 
18, 19
. The complexity and quantity of dietary carbohydrates in 
the human diet is known to affect the risk factors and development of MS and CHD. 
Increased consumption of complex carbohydrates with a low GI  (classification to 
quantify the relative blood glucose response to carbohydrate-containing foods) can 
reduce the severity of insulin insensitivity by dietary modulation 
10
. 
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The proportions and type of dietary fatty acids are known to affect many of the 
diagnostic risk factors associated with MS which include blood pressure, blood serum 
lipid profiles, insulin desensitisation and function of the endothelial system 
212
. In 
particular, the most favourable alteration of dietary fatty acid intake is substitution of 
SFA especially from animal sources with monounsaturated fatty acids (MUFA) and a 
subsequent reduction in calorific intake. This has been shown to alter in blood serum 
lipid profiles in human hyperlipidaemic study participants; increasing HDL-cholesterol 
levels and reducing TAG 
213
.  
 
It is important to note that MS does not have the status of a disease and is a syndrome 
because there are many factors that can be considered diagnostic of MS. This means 
that the classification of MS is open to a degree of subjectivity and is not absolute. 
Practically, this can cause problems when considering study participants as a 
homogeneous set, as would be the case in a more defined disease state such as type II 
diabetes or CVD. 
 
5.3.2 Role of the Gut microbiota in Fatty Acid and Carbohydrate Metabolism 
It is important to consider the influence of the human gut microbiota in metabolic 
processes in metabonomic analyses. The gut microbiota is recognised to be essential to 
proper lipid and carbohydrate metabolism in humans. It is known that populations of the 
microbiota are responsible for deconjugation of bile acids and the production of 
secondary bile acids, the synthesis of short chain fatty acids such as acetate, propionate 
and butyrate and the absorption of cholesterol 
137, 214
.  
 
Dietary intake levels of different food components are known to affect the composition 
and metabolic rates of specific gut microbial populations 
215
. It has been shown that 
diets containing high levels of soluble and insoluble fibres encourage the growth of 
fermentative gut microbiota populations in the GI tract such as Lactobacillus and 
Bifidobacteria which are known to be beneficial to health 
126, 139, 141
. Investigations with 
prebiotics (fermentable carbohydrates which encourage growth of beneficial bacteria in 
the gastro-intestinal tract) in both animal and human studies, have shown subsequent 
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changes in gut microbial metabolism can affect blood serum fatty acid composition. 
Supplementation with inulin or oligofructose has been shown to reduce the blood serum 
fatty acids in hypercholesterolaemic and hyperlipidaemic study participants 
216
.  
 
Several studies, including that by Martin, Wang et al. 2008 have demonstrated the 
critical role of the gut microbiota in germ free mice where a human gut microbiota 
population had been introduced. This study demonstrated strong influence of the gut 
microbiota in the recycling of bile acids between the liver and gut and in fatty acid 
metabolic processes and blood serum lipid profiles, particularly in the synthesis of very 
low density lipoprotein (VLDL)-TAG. Treatment of this humanised colonic microbe 
mouse model with either the probiotic bacteria Lactobacillus paracasei or Lactobacillus 
rhamnosus was shown to produce reduced  serum VLDL and low density lipoprotein 
concentration, evidence of a stimulation of glycolysis and increased lipid concentrations 
in the liver 
138
.  
 
Few studies have elucidated the effect of high fat composition diets on the human gut 
microbiota. It is thought the increased fat intake typical of western diets would increase 
the concentrations of both fat and bile acids metabolised by the gut microbiota. Gut 
microbial populations are known to convert mammalian primary bile acids (synthesised 
in the liver) into microbially derived secondary bile acids and are also responsible for 
the synthesis of diacylglycerols, which can directly affect the population levels of 
specific gut microbial species 
217, 218
. Several studies have demonstrated the effect of 
high fat dietary interventions on the most abundant species of the gut microbiota in 
mice particularly reductions in Bifidobacterium spp., Bacteroides spp. and 
E.rectale/C.coccides populations 
219
. A high fat diet in mice, has also been shown to 
produce inflammation in the gut, alter insulin sensitivity and increase blood serum 
concentrations of lipopolysaccharides. Conversely, introduction of the prebiotic 
oligofructose into the diet of these high fat diet mice led to reduction in the alterations 
of gut microbial populations with an increase in the levels of Bifidobacterium spp. and a 
reduction of intestinal inflammation 
220
. The important role of the gut microbiota in the 
metabolism of both fatty acids and carbohydrates is suggestive of a strong role in 
obesity, the development of MS and the subsequent onset of type II diabetes and CVD. 
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5.3.3 Application of Metabonomics to Human Studies 
It is known that the analysis of data from human subjects is confounded due to high 
genetic and environmental diversity of populations. The metabolic profiles of human 
participants are also affected by pleiotrophic physiological factors unrelated to diet such 
as hormonal status, diurnal cycles and additionally, variations in the gut microbial 
population of an individual. These factors have been shown to exert a powerful effect 
on the metabolic phenotype. In animal studies where a higher degree of genetic and 
environmental certainty is possible, such variation is significantly reduced. Convolution 
of the data in human studies is reduced primarily by limiting inter-subject variability, 
ensuring dietary compliance and by use of mathematical filtering tools for removing 
and interpreting ―irrelevant‖ data in complex multivariate datasets.  
 
Techniques such as metabonomics can determine accurately the subtle metabolic effects 
related to dietary and lifestyle changes. Spectral pre-treatment such as OSC (orthogonal 
signal correction) has been used to remove disrupting variation in human studies related 
to non relevant sources of variation to reveal the relevant features in 
1
H-NMR spectra 
associated with the subtle effects of nutritional intervention. This has notably been used 
to characterise the metabotype in vegetarian, and high and low meat consumption diets 
221
. OSC has also been used successfully in facilitating the diagnosis of coronary heart 
disease 
222, 223
, the interaction of stress and dietary intervention 
201
, in soy isoflavone 
112
, 
chamomile 
110, 224
 and in alcohol dietary interventions 
111
. 
 
OSC ensures that systematic variation in the spectroscopic data unrelated to the 
biological response of interest is removed so that separation between different sample 
classes caused by more subtle sources of variation may be observed. When OSC is 
incorporated into supervised pattern recognition algorithms such as PLS-DA (Partial 
Least Squares-Discriminant Analysis), it is a powerful tool for identifying potential 
biomarkers and for understanding the metabolic effects of dietary change. 
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5.3.4 Reduction of Inter-subject Variability in Nutritional Intervention Studies 
Long-term effects of different dietary components and dietary population 
epidemiological studies have investigated the beneficial/detrimental effects of certain 
diets and food components. However, there is little understanding of the underlying 
mechanisms of nutritional protection against disease. 
 
Evaluation of dietary intake is crucial to nutritional studies to assure dietary compliance. 
Prosaic methods of dietary assessment include quantitative food diaries, dietary recall, 
or simple blood biochemistry measures. These methods are simplistic and in some cases 
flawed and are open to subjectivity and falsification by study participants. Thus, these 
methods can cause false positives/negatives within a dataset and can misinform datasets 
when the aim of a study is to examine subtle short-term dietary interventions and 
underlying mechanistic information.  
 
Dietary recall and compliance is difficult to assess by the researcher and relies upon 
subject trust, therefore biochemical confirmation of dietary compliance is a major goal 
of nutritional studies. A recent metabonomic study has successfully identified proline 
betaine as a putative biomarker of citrus fruit consumption with further validation in 
citrus fruit consumers within the 
1
H-NMR urinary dataset of the INTERMAP 
epidemiological study  
96
. Likewise, in Chapter 6 of this thesis, S-methyl-L-cysteine 
sulphoxide and its N-acetylated mammalian derived metabolite were shown to be stable 
urinary biomarkers of cruciferous vegetable intake. Identifying anomalous outliers in 
chemometric models, which would otherwise bias the data and removing them from the 
model, can reduce the influence of non-compliance. For example, this has been 
observed previously in studies where an outlier in the data was due to the presence of 
trimethylamine-N-oxide (TMAO) 
225
. TMAO is used to increase osmotic concentration 
and thus depress the freezing point of body fluids, in cold-water fish. The finding of 
TMAO indicated that the subject in question had consumed fish and thereby did not 
adhere to the dietary restrictions. Similarly it is also possible to identify subjects who 
have not adhered to alcohol and prescription/over-the-counter drug restrictions, due to 
the characteristic 
1
H-NMR splitting patterns of ethanol and presence of drug metabolites 
in the urine 
111, 226
. 
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The importance of limiting inter-subject variability to produce meaningful, statistically 
relevant results is of paramount importance in metabonomics. The ability to reduce 
variation within study populations is extremely important, for example differences in 
age, gender, race, smoking status, alcohol consumption, prescription drug use and 
consumption of biologically active dietary components, such as constituents of many 
fruit and vegetables, can all affect the statistical strength and predictive power of a 
model of human data.  
 
Assessing the effects of subtle perturbations of metabolic phenotype in nutritional 
intervention studies is potentially confounded by many environmental, genetic and 
commensal gut microbial variations in human populations. These considerations are of 
great importance in design of experiment in human nutritional intervention studies and 
in interpretation of the statistical significance of results. 
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5.4 Methods 
5.4.1 Study Design and Protocol 
Urine and faecal water samples were obtained for a subset of 130 volunteers taking part 
in the RISCK study at the University of Reading. Men and women (age range: 30–70 
y), who were recruited from the general population, attended a clinic at the participating 
centers in a fasting state for measurement of height, weight, waist, seated blood pressure 
(BP), liver function test, glucose and lipid concentrations, and haematology. RISCK 
was a Food Standards Agency funded project involving 5 UK research institutions 
227
. 
Free-living volunteers (650) were recruited to a randomised,  controlled, single blind, 
parallel design dietary intervention study involving the manipulation of total dietary fat 
(~38% vs. ~28%) and its composition (i.e. saturated fatty acids SFA  vs. 
monounsaturated fatty acids MUFA) and total dietary carbohydrate (~45% vs. ~55%) 
and its composition  (i.e. high vs. low GI) for a six month period.  
Exclusion criteria for this study were as follows:  
 medical history of ischaemic heart disease;  
 >30% 10-y risk of CVD;  
 diabetes mellitus;  
 cancer;  
 pancreatitis;  
 cholestatic liver disease;  
 renal disease;  
 use of lipid-lowering drugs;  
 systemic corticosteroids;  
 androgens;  
 phenytoin; 
 erythromycin or drugs for regulating haemostasis (excluding aspirin);  
 exposure to any investigational agent ≤30 d before the study;  
 presence of gastrointestinal disorder or use of a drug that is likely to alter 
gastrointestinal motility or nutrient absorption;  
 a history of substance misuse or alcoholism;  
 a current pregnancy, planned pregnancy, or given birth in the past 12 mo;  
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 an allergy or intolerance to intervention foods;  
 an unwillingness to follow the protocol or to give informed consent;  
 a weight change of >3 kg in the 2 months before the study;  
 intake of >1 g eicosapentaenoic and docosahexaenoic acids/d;  
 smoking >20 cigarettes/d. 
 
The 130 volunteers were randomly assigned to one of five different dietary intervention 
groups, four experimental diets (Diets B-E) and a control diet (Diet A). All 
experimental groups were age matched (average age = 54 ± 9.5 years). (Table 5.1) 
 
Table 5.1 Table showing RISCK study dietary interventions performed in human 
participants. (SFA: saturated fatty acid; MUFA: monounsaturated fatty acid; PUFA: 
polyunsaturated fatty acid; CHO: carbohydrate; GI: glycaemic index.)  
 
 
 
  
% energy from fat % types of fatty acids % energy from CHO GI points reduction 
Dietary Intervention SFA % MUFA % PUFA %
A 38 18 12 6 45 -
B 38 10 20 6 45 -
C 38 10 20 6 45 11
D 28 10 11 6 55 -
E 28 10 11 6 55 13
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All the diets were isoenergetic and the protein intake remained constant. The n-6:n-3 
PUFA ratio in the study foods was kept constant at 5:1. The volunteers were provided 
with spreads and oils for cooking and other foods with modified fat composition, in 
order to facilitate the dietary change. To reduce the overall GI of the diets, appropriate 
complex carbohydrate substitutes for simple carbohydrate-rich foods were also 
provided. Dietary calculations were based on estimates of habitual intake derived from 
the latest National Diet and Nutrition Survey (NDNS) and National Food Survey 
228
.  
Dietary manipulation was achieved by replacing all major fats and carbohydrates in 
volunteers‘ baseline diets with products specifically chosen or formulated to provide the 
required fat/carbohydrate intake and composition in each of the intervention diets 
(spreads, oils, dairy products, cakes, biscuits, breakfast cereals, pasta, rice, bread, 
potatoes).  
 
All volunteers underwent a 4-week run-in period following the control diet (Diet A). 
Subsequently, the volunteers were randomly allocated to one of the five dietary 
interventions for a period of 24 weeks, urine and faecal water sample collections were 
performed at 0 and 24 weeks (Fig. 5.1). One hundred and fourteen volunteers provided 
urine and faecal water samples at the baseline, of which eighty-eight provided samples 
at the end of the 24 weeks dietary intervention.  
 
 
Fig. 5.1 Schematic showing study outline of the RISCK study dietary intervention 
 
 
O week 24 week
4 week control
Diet A run-in
period
Baseline
urine and faecal 
water  sample collection
Treatment
urine and faecal 
water  sample collection
24 week dietary intervention
Diets A, B, C, D and E
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5.4.2 Diagnostic recruitment criteria 
One hundred and thirty volunteers were recruited at the Hugh Sinclair Unit of Human 
Nutrition, Department of Food Biosciences at the University of Reading on the basis of 
their increased risk for developing the MS and its associated cardiovascular risk factors. 
The volunteers were recruited in two cohorts of 65 volunteers. The recruited volunteers 
were male and female, non-smoking and aged between 30-65 years. In order to be 
included in the study, the volunteers were screened for their risk of developing MS. The 
entry criteria for the volunteers were insulin resistance, dyslipidaemia, hypertension, 
obesity and central adiposity. Screening of the volunteers consisted of single 
measurements of fasting blood glucose and insulin, fasting serum lipids (e.g. HDL-
cholesterol, LDL-cholesterol, TAG), seated diastolic and systolic blood pressure, waist 
circumference, weight and height.  The recruitment of the volunteers was based on a 
scoring system which ensured that volunteers expressed a minimum of two features of 
the metabolic syndrome (score  4) (Fig. 5.2). Scores were weighted according to their 
relevance to the development of the metabolic syndrome, and/or technical reliability of 
the measurement with respect to biological and analytical variation. 
 
 
Fig. 5.2 Schematic showing the RISCK study diagnostic recruitment criteria. Intial 
targeted subject recruitment was based on an inclusion criteria. 
TARGETTED SUBJECT RECRUITMENT 
1. Impaired fasting glucose  2. Polycystic ovary syndrome 3. Asians
4. Atherogenic lipoprotein phenotype 5. Gestational diabetes 
6. Family history of type II diabetes 
SCREENING CRITERIA
Insulin resistance
Fasting glucose >6.1 (3)
Fasting insulin >40pmol/l (3)
Dyslipidaemia
HDL-C <1m <1.3f (2)
TAG >1.3mmol/l (1)
Hypertension
>140(1)/>90(1)
Treated or untreated
Central adiposity
Waist circumference
>94cm (1) >102cm(2) males
>80cm(1) >88cm(2) females
or Obesity
BMI 25-30 (1) >30 (2)
SCORE 4-10 (max) TO BE RECRUITED 
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5.4.3 Faecal Water Sample Preparation 
Faeces for all five dietary interventions were collected for both a baseline (0 week) and 
a treatment (24 week) time point and frozen at -40˚C. Faeces (1g) were mixed with 5ml 
of PBS agitated for 10mins and then centrifuged for 30mins at 10,000 g. The 
supernatant was finally filtered using Whatman filter paper to remove cells and cell 
debris. The completed samples were received from our collaborators at the Hugh 
Sinclair Unit of Human Nutrition, Department of Food Biosciences at the University of 
Reading, where faecal samples were also prepared for bacterial enumeration by 
fluorescent in situ hybridisation (FISH) and faecal short chain fatty acids (SCFA) 
analysis 
 
Samples for 
1
H-NMR spectroscopic analysis were prepared by adding between 200-
400μl of faecal water (dependent on volume available) to UPLC standard water 
containing 50% D2O (which acts as a field frequency lock) and 0.01% TSP (sodium 3- 
(trimethylsilyl) propionate-2,2,3,3-d4 for chemical shift reference) to a final volume of 
600μl. The samples were centrifuged at 10,000 g for 10mins to remove any precipitates 
and 580μl aliquot of the supernatant transferred to a 5mm outer diameter NMR tube 
(Goss Scientific Instruments, Great Baddow, Essex, UK) for analysis. 
 
5.4.3 Faecal Water 
1
H-NMR Spectroscopy acquisition 
One hundred and fourteen volunteers provided faecal samples at the baseline 0 week 
time point, with a total of 88 participants providing faecal samples at the end of the 24 
weeks dietary intervention. The analysis was performed on samples from volunteers 
who completed one of the five dietary intervention regimens and provided faecal 
samples at both time points. 
 
Faecal water samples were analysed using a Bruker DRX 600 NMR spectrometer 
(Bruker Analytische GmbH, Rheinstetten, Germany) operating at 600.13 MHz for 
1
H 
equipped with 5mm triple resonance probe with inverse detection. The pulse program 
used was RD-90
o
-t1-90
o
-tm-90
o
-acquire free induction decay (FID). The RD represents a 
relaxation delay of 1.5s; t1 refers to an interval of 4μ seconds. The water signal was then  
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re-irradiated during tm for 150ms the mixing and relaxation delay. FIDs (64) were 
collected for each sample into 32k data points with a spectral width of 8000Hz. The 
FIDs were then multiplied by an exponential weighting function with a line broadening 
of 0.3Hz prior to Fourier transformation. Acquired NMR spectra were phase and 
baseline corrected using a MATLAB script (Dr. Tim Ebbels, Imperial College) and 
referenced to TSP at δ0.0.  
 
5.4.4 Urine 
1
H-NMR Spectroscopy acquisition 
The same participants provided urine samples at weeks 0 and 24 of the dietary 
intervention study. The analysis was performed on samples from volunteers who 
completed one of the five dietary intervention regimens and provided urine samples at 
both time points. All urine analyses were performed at 600.13MHz on a Bruker DRX 
600 Spectrometer (Bruker Analytische GmbH, Rheinstetten, Germany) coupled to a 
sample-handling system Gilson (Middleton, WI, USA) XL233 interfaced to the 
XWinNMR data system for control and timing. 
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5.4.5 Clinical markers and food diary analyses of study participants 
Clinical assays to assess efficacy of the dietary interventions were performed by 
collaborators at the Hugh Sinclair Unit of Nutrition at the University of Reading. These 
were expected to correlate with and inform the further metabonomic analysis carried out 
in this study. Four day food diaries at the baseline and treatment timepoints as well as 
an interim analysis at 12 weeks were also analysed by the Nutrition Epidemiology 
Group at Human Nutrition Research, Department of Nutrition and Health Research, 
Cambridge to monitor the macronutrient content of participants dietary regimens to 
ensure isoenergetic interventions and the correct proportions of PUFAs, MUFAs and 
SFAs in each dietary intervention.  All study participants were assessed for the 
following clinical markers of interest at the end of the run-in period (0 week baseline) 
and after 24 weeks of dietary intervention (treatment) for all five diets:- 
 
1. Insulin sensitivity measures of glucose and insulin by intravenous glucose 
tolerance tests (IVGTT). 
2. Fasting lipid profile; total blood serum levels of low density lipoprotein (LDL), 
high density lipoprotein (HDL) cholesterol, triglycerides and non-esterified fatty 
acids (NEFA). 
3. Anthropometric measures including, weight, waist circumference and body fat 
percentage. 
4. Seated blood pressure measurements. 
5. Haemostatic factors; PAI-1, factor VIIc and fibrinogen. 
6. C-reactive protein (CRP) as an indication of inflammatory response. 
7. Plasma leptin. 
8. Urinary microalbumin:creatinine ratio.  
9. Plasma fatty acid composition. 
 
These clinical measures were performed as markers of risk of cardiovascular disease 
(CVD) to determine if the dietary interventions carried out resulted in any significant 
changes. These data are not included in this study but results pertaining to the effects of 
the dietary regimens are referred to in order to facilitate interpretation of the 
metabonomic analysis.  
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5.5 Results 
A representative 
1
H-NMR spectrum of a faecal water sample from a RISCK study 
participant is given in (Fig. 5.3). Also provided is a table of typical constituents of 
faecal water which includes the short chain fatty acids; acetate, propionate, butyrate, 
valerate and isovalerate, amino acids such as alanine, lysine, glutamine, tyrosine and 
threonine, also urocanate, β-glucose and the pyrimidine uracil (Table 5.1). 
 
 
Fig. 5.3 Typical 600 MHz 
1
H-NMR spectra of Faecal Water obtained from a RISCK 
study participant.  
Assignments were made based on literature and 
1
H-NMR peak assignment databases 
available publically and within the section of Biomolecular Medicine. 
 
 
 
 
 
 
 3  2 45 6 7 8 910  1
uracil
urocanate
fumaratetyrosine
urocanate
uracil
formate
butyrate
propionate
threonine
alanine
lysine
acetate
proprionate/
glutamine
glutamate
glutamine/
alanine
glycine
 1 1.5 2 2.5 6 6.5 7 7.5 8 8.5
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Table 5.2 
1
H-NMR chemical shifts (δ) and multiplicity resonances observed from 
faecal water 
 
 
1
H-NMR Shift (δ) Molecule Multiplicity
0.9 Butyrate (CH3) Triplet
1.06 Propionate (CH3) Triplet
1.33 Threonine (CH3) Doublet
1.48 Alanine (CH3) Multiplet
1.56 Butyrate (CH2) Doublet
1.73 Lysine (βCH2) Multiplet
1.91 Lysine (γCH2) Quartet
2.11 Glutamate (αCH2) Multiplet
1.92 Acetate (CH3) Singlet
2.16 Glutamine (αCH2) Triplet
2.19 Propionate (CH2) Quartet
2.36 Glutamate (βCH2) Doublet of triplets
2.41 Succinate (CH3) Singlet
3.03 Lysine (αCH2) Triplet
3.06 Tyrosine (CH2) Doublet
3.2 Tyrosine (CH2) Doublet
3.57 Glycine (CH3) Singlet
3.59 Threonine (αCH) Doublet
3.76 Lysine (CH) Triplet
3.77 Glutamine/glutamate (-CH) Triplet
3.79 Alanine (CH) Quartet
3.94 Tyrosine (CH) Doublet
4.26 Threonine (βCH) Multiplet
5.23 β-glucose (CH) Doublet
5.81 Uracil (αCH) Doublet
6.4 Urocanate (βCH) Doublet
6.53 Fumarate (CH) Singlet
6.91 Tyrosine (phenolic CH) Doublet
7.2 Tyrosine (phenolic CH) Doublet
7.31 Urocanate (αCH) Doublet
7.41 Urocanate (imidazole CH) Singlet
7.54 Uracil (βCH) Doublet
7.89 Urocanate (imidazole CH) Singlet
8.46 Formate (CH) Singlet
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5.5.1 PCA analysis of urine and faecal water 
Initial unsupervised chemometric analysis of the NMR data was performed to obtain an 
overview of variance in the 
1
H-NMR data X matrix. All subjects post treatment samples 
were included within the model to obtain an overview of the sources of variation in the 
data set and for the purposes of detecting outlying samples. It was also performed to 
identify any evidence of clustering associated with dietary intervention in the urinary 
and faecal water X matrices. PCA models of both the urinary and faecal water 
1
H-NMR 
spectra produced very poor predictive abilities and modelling of variance as reflected in 
the Q
2
 (0.01) and R
2
 (0.12) values indicating a high degree of variation within the data. 
Analyses of the scores plots revealed no evidence of grouping of samples based upon 
dietary intervention (Fig. 5.4). It is unusual to observe clustering of samples in an 
unsupervised analysis based on dietary changes in human studies in the PCA scores plot 
due to a predominance of variance unrelated to dietary intervention. This suggests the 
greatest source of variation based on PCA is due to inter-subject variations between the 
study participants rather than the effects of dietary change in the X matrix.  Four strong 
outlying (outside of the hotellings ellipse) samples were identified in the urine dataset 
and 3 strong outliers in the faecal water dataset and were subsequently removed from all 
subsequent modelling of the datasets. Analysis of the raw 
1
H-NMR spectra revealed 
poor spectral acquisition and evidence of poor water suppression in these samples.  
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Fig. 5.4 Human urine PCA scores scatter plot of 
1
H-NMR spectra from all subjects post 
dietary intervention (24 weeks).  
The plot does not identify any separation or grouping of subjects based on dietary 
intervention, variation is accounted for largely by intersubject variability.  
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5.5.2 PCA, PLS-DA and O-PLS-DA pair-wise comparisons of control and post 
dietary intervention urine and faecal water samples   
Pair-wise comparisons of baseline (0 week) to treatment (24 week) urine and faecal 
water samples were performed initially using PCA (Fig. 5.5) followed by supervised 
PLS-DA (Fig. 5.6). This was in order to obtain evidence of any statistically significant 
effect of the 24 week dietary interventions (A-E) on either the urinary or faecal water 
metabolic phenotype altering with respect to the composition and proportions of energy 
from fats and the GI of carbohydrates.  
 
Initial PCA analysis of diets A-E demonstrated low cross validation values (Q
2
) and 
relatively low explanation of variance (R
2
). As a result the scores plots could not be 
considered an accurate representation of the sources of variance in the X matrix, 
clustering based upon dietary intervention could not seen within the scores, however it 
was anticipated that subtle metabolic variations related to dietary intervention would not 
be observed in the unsupervised PCA.  
 
Supervised PLS-DA analysis of diets A-E was not suggestive of class discrimination 
between the baseline and treatment samples due to poor modelling strengths (Fig. 5.6) 
Therefore, evidence of clustering within the PLS-DA scores plots could not be 
considered a true representation of class membership. Diet B represented the most 
statistically significant PLS-DA model of the effects of dietary intervention. Analysis of 
the spectral loadings of diet B (where alterations to total energy derived from PUFAs 
(~20%) and SFAs (~10%) were made), identified alanine, creatinine, glycine and 
TMAO as discriminatory of the baseline samples. The modelling strength of this dietary 
intervention based upon Q
2 
(0.17) and R
2 
(0.63) indicates a degree of over-fitting of the 
data and spectral assignments of candidate biomarkers may be misleading (Fig.5.6). 
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Fig. 5.5 Scores maps showing t[1]/t[2] PCA scores from the 
1
H-NMR spectra baseline 
vs. treatment urine samples of diets A (Q
2
:0.017; R
2
:0.26), B (Q
2
:0.043; R
2
:0.28), C 
(Q
2
:0.092 ; R
2
:0.25), D (Q
2
:0.015; R
2
:0.23) and E (Q
2
:0.01; R
2
:0.24). Models showed 
poor explanation of variance in the X matrix. Unit variance scaled. 
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Fig. 5.6 Scores maps showing t[1]/t[2] PLS-DA scores from the 
1
H-NMR spectra 
baseline vs. treatment urine samples of diets A (Q
2
:-0.027; R
2
:0.63), B (Q
2
:0.17; 
R
2
:0.63), C (Q
2
:0.034; R
2
:0.68), D (Q
2
:-0.12; R
2
:0.79) and E (Q
2
:-0.056; R
2
:0.701). 
Models showed poor discrimination of class indicating sources of variance in the 
dataset unrelated to dietary intervention. Unit variance scaled. 
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Pair-wise comparisons of 
1
H-NMR spectra of the baseline (0 week) and treatment (24 
week) time points for each dietary intervention (A-E) (see section 5.4.1) using O-PLS-
DA were performed. Initially, baseline and treatment samples were compared with each 
other using ―Unit Variance‖ (1/standard deviation) scaling, pre-processed data were 
bucketed into 0.001ppm buckets and normalised to total spectral area to control for 
variable dilution of samples. 
  
The O-PLS-DA models were constructed using the 
1
H-NMR spectral data as X 
variables and the dietary group as the Y variables. The number of orthogonal 
components calculated for each model varied based on the values of the cross-validation 
parameter (Q
2Ŷ) and the proportion of explained variance of the model parameter 
(R
2Ŷ).  
 
During the 4 week run-in period all subjects followed Diet A; a diet typical of the UK 
where approximately ~38% of energy is obtained from fat with a high (~18%) 
proportion from saturated fats and 45% of energy from largely simple carbohydrates 
with a high GI. Comparison of the 0 week to 24 week time points for the group 
following the control Diet A should therefore not detect any statistically significant 
differences in the O-PLS-DA models. This null hypothesis was proved correct by a 
negative predictive ability of the models in the first O-PLS component (Q
2Ŷ: -0.26) and 
with poor explanation of sample class to variation within the (X) matrix (R
2Ŷ: 0.29). 
However, O-PLS-DA loadings plots of pair-wise comparisons within Diets B, C, D and 
E also suffered from poor model strength for both urine and faecal water, loadings 
indicative of discrimination between the baseline and treatment samples for diets A, C, 
D and E were found to be in very low concentration and close to the threshold of noise 
in the urine and faecal water samples. It was therefore not possible to construct 
statistically robust models and identify metabolites in such low concentration in the 
urine and faecal water samples. 
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The O-PLS coefficients indicated by the applied colour code with red being the highest 
correlation with diet, in subjects following Diet B suggested increased excretion of 
alanine, creatinine, glycine and TMAO as discriminatory of the baseline samples. 
However poor model strength prevented absolute identification of these metabolites as 
diagnostic of diet B (Q
2Ŷ: 0.18; R2Ŷ: 0.59). However, this represented the most robust 
modelling of the dietary interventions (Fig. 5.7). The subtle effect of changing dietary 
fat composition, proportions of energy from fat and glycaemic indexes of carbohydrates 
in human subjects produced no observable effects within the 
1
H-NMR spectra of either 
urine or faecal water. These results suggested inter-subject variation in metabotype 
dominated the modelling with greater variation between subjects than due to following 
the dietary interventions assigned. 
 
In an attempt to improve the O-PLS-DA models, alternative data pre-processing steps 
were utilised; peak alignment, normalisation and scaling. A superior data pre-processing 
step RSPA or Recursive Segment-wise Peak Alignment was utilised to improve peak 
alignment within the 
1
H-NMR spectra 
153
. This was followed by changing the 
normalisation step method to probabilistic quotient normalisation. However 
improvement of 
1
H-NMR pre-processing, followed by re-calculation of the O-PLS-DA 
also failed to improve model strengths sufficiently for robust modelling of metabolic 
phenotypic change attributable to the dietary interventions the results of which are 
summarised in (Table 5.3). 
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Fig. 5. 7 O-PLS-DA coefficient loadings plot showing dietary intervention B baseline 
(0 week) vs. Treatment (24 week) of urinary 
1
H-NMR spectra normalised to total area.  
The red colour scaling of alanine, creatinine, glycine and TMAO indicates a reduction 
in excretion in the treatment group with an increased concentration in the baseline 
1
H-
NMR spectra. 
However due to the poor predictive strength of the model reflected in the low values of 
the Q
2Ŷ (0.18) and R2Ŷ (0.59) statistical parameters these metabolites cannot be 
considered absolutely diagnostic but indicative of dietary change. 
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Table 5.3 Summary of baseline vs. treatment O-PLS-DA models of urine and faecal 
water comparing effects of pre-processing on Q
2Ŷ and R2Ŷ values.  
RSPA: recursive segment-wise peak alignment; TA: total area; PQ: probabilistic 
quotient; UV: unit variance; MC: mean centred. 
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The inter-subject variations in global metabolic phenotype were not surpassed by 
dietary intervention. Disappointingly, the O-PLS-DA model for diet E failed to 
discriminate between the 0 week and 24 week time-points in spite of attempts to 
improve data pre-processing. However the model fitting of diet E was slightly superior 
to many of the other diets with a one predictive component model in the urine and a one 
orthogonal component model in the faecal water samples (Table 5.3). Associated 
1
H-
NMR variables in the O-PLS-DA loadings plot appeared to be widely dispersed, close 
to the threshold of noise and subsequently difficult to identify.  Diet E represented the 
greatest change in SFA%, proportion of energy from fat, and reduction in carbohydrate 
GI from the control diet A and it was anticipated that the greatest change in metabolic 
phenotype would be observed in study participants following this dietary intervention. 
The negative Q
2Ŷ of many of the models regardless of alteration of pre-processing and 
data treatment methods is indicative of poor cross validation of the model and a poor 
predictive ability to distinguish sample classes.  Sources of variance in the urinary and 
faecal water datasets were therefore found to be unrelated to dietary intervention. 
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5.5.3 O-PLS-DA comparisons of inter-dietary variation 
Step-wise comparisons of treatment (24 week) urine and faecal water samples using O-
PLS-DA were performed to identify global metabolic changes between the different 
dietary regimens. 24 week time-point samples were compared between diets A, B, C, D 
and E in order to address aims of the study. The following experimental iterations of 
interest were generated and for which O-PLS-DA were performed:- 
 
1. Diet A vs. B (HIGH SFA vs. HIGH MUFA) 
2. Diet A vs. C (HIGH SFA vs. LOW GI, HIGH MUFA) 
3. Diet A vs. D (HIGH SFA vs. LOW FAT) 
4. Diet A vs. E (HIGH SFA vs. LOW GI, LOW FAT) 
5. Diet B vs. D (HIGH MUFA vs. LOW FAT) 
6. Diet D vs. E (HIGH GI vs. LOW GI) 
7. Diet C vs. E (HIGH MUFA vs. LOW FAT) 
8. Diet B vs. C (HIGH GI vs. LOW GI) 
9. Diet D vs. C (LOW FAT vs. HIGH MUFA, LOW GI) 
 
Unfortunately, analysis of the O-PLS-DA loadings plots for all of the experimental 
iterations revealed no evidence of metabolic variation due to dietary intervention in 
either the urinary or faecal water spectral data (Table 5.4). Models demonstrated poor 
predictive power and low O-PLS-DA coefficient values. Superficial changes in the 
loadings plots were seen in acetate, creatinine and creatine in urinary 
1
H-NMR spectra. 
However these were statistically insignificant and could not be considered diagnostic of 
dietary class due to a very low and often negative value for Q
2Ŷ. In most cases it was 
found that only one orthogonal O-PLS component was necessary as the calculation of 
successive orthogonal components lead to a reduction in the Q
2Ŷ parameter and an 
introduction of noise into the O-PLS-DA models (Table 5.4). 
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Table 5.4 Table showing O-PLS-DA model strengths of experimental iterations of 
interest in urine and faecal water. 
The number of O-PLS components included for each model was based on the value of 
Q
2Ŷ and R2Ŷ to avoid over-fitting the data. 
As can be seen each model suffered from poor predictive value with a negative/low Q
2Ŷ 
cross-validation parameter. 
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Further attempts to improve data pre-processing using RSPA and probabilistic quotient 
normalization followed by recalculation of the O-PLS-DA models also failed to 
improve detection of significant correlations between diet classes. The dietary 
interventions set out within this study involved changes in macronutrient component of 
the diet, the effects of which were not seen to be reflected in the urinary or faecal water 
metabolic phenotypes. 
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5.5.4 Bacterial Regression analyses to dietary intervention 
1
H-NMR spectra 
Changes between the baseline (0 week) and treatment (24 week) in the total gut 
microbial numbers enumerated by fluorescence in situ hybridisation (FISH) by our 
collaborators at the University of Reading were regressed to the 
1
H-NMR spectra of 
both urine and faecal water. The changes in total bacterial population numbers as well 
as of 7 major groups of bacteria of the human gut microbiota were assessed, namely E 
rectale/C.coccoides, Bacteriodes spp., Bifidobacterium spp, Lactobacillus/Enterococcus 
spp., Atopobium gp., F. Prasnutzii and C. Histolyticum gp.  
 
This was performed in order to identify metabolic indices statistically associated with 
changes in gut microbial profiles due to the dietary interventions A-E and to determine 
if gut microbial alterations would concurrently produce any change in urinary or faecal 
water metabolic phenotype. It was anticipated that any correlation between bacterial 
population changes and global metabolic phenotype would result in identification of 
statistically significant metabolites within the 
1
H-NMR data characteristic of a particular 
bacterial population. 
 
The difference in the bacterial population data from the baseline and treatment groups 
(T-B) was calculated for each of the study subjects (88) for which FISH data was 
obtained to produce a Y-matrix of bacterial population changes where the dummy 
matrix was substituted for bacterial population changes (Table  5.3).  
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Table 5.5 Table showing change in bacterial population numbers (Log10 bacterial 
cells/g faeces) between baseline and treatment time-points and paired t-test values. 
Numbers highlighted in red represent statistically significant changes in bacterial 
populations attributable to diet according to p-statistics. (Bacterial population numbers 
enumerated by FISH analysis; provided by our collaborators at the University of 
Reading). 
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Y-matrices for total bacterial population change and for each of the 7 major gut 
bacterial groups were used to calculate regression models for the dietary intervention 
(A-E) regressing to the urinary and faecal water 
1
H-NMR treatment (week 24) data. The 
1
H-NMR spectra were optimally pre-processed using RSPA and probabilistic quotient 
normalisation to improve signal to noise ratio and enhance statistical discrimination.  
 
Regression analyses failed to produce good model strengths and low predictive ability 
for any of the regression models of diets A, B, C, D, or E calculated against the FISH 
enumerations of bacterial populations. Typically samples outside of normal F-
distributions above the F-critical line in each regression model were not found to be 
driving the separation or causative of the poor model statistics (Fig.  5.7). Removal of 
these outlying samples did not improve model strengths and often resulted in further 
samples appearing above the F-critical line following recalculation of the model. Our 
collaborators found statistically significant changes in some bacterial populations 
numbers attributable to the dietary intervention by t-test however these were not 
reflected in the multivariate statistical analyses of the urine and faecal water 
1
H-NMR 
spectral datasets (Table. 5.5).  
 
In terms of the bacterial population number to 
1
H-NMR spectral data regression models 
the upwards and downwards direction of metabolites in the regression models indicates 
positive and negative correlation of metabolites with bacterial population numbers 
respectively (Fig.  5.8). As can be seen in the regression models generated here, initial 
observation showed evidence of strongly correlated metabolites, with red coloured 
regression coefficients in the loadings plot. However, even red coloured features in the 
loadings plots were considered not to be statistically significant and to have low 
discriminatory value to the changes seen in members of the gut microbiota. Low and 
often negative values for the Q
2Ŷ parameter for each O-PLS-DA model demonstrates 
low predictive values and cross validation and any interpretation of red coloured O-
PLS-DA loadings coefficients could be misleading.  
 
Analysis of the raw 
1
H-NMR spectra of urine and faecal water for metabolites 
potentially discriminatory of bacterial population change revealed that in many cases 
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the metabolite in question was only present in increased concentration for one 
individual. Succinate in faecal water of Diet D study participants revealed that this peak 
was only in substantially elevated concentration in only one study participant (Fig. 5.8). 
This perhaps explains the low discriminatory value of the regression models and that 
most variation in the urine and faecal water are unrelated to bacterial population change 
(Y) and are more likely based upon unique host-microbe associations for each study 
participant. 
 
The poor model strengths of the bacterial regression analysis suggested the subtle 
changes in bacterial population numbers identified by FISH due to dietary intervention 
did not assert a statistically significant influence on the urinary or faecal water 
1
H-NMR 
metabolic profiles. Furthermore the regression analyses did not identify an influence of 
specific individual bacterial populations upon the global metabolic phenotype. 
Relatively small but statistically significant changes in bacterial species attributable to 
dietary intervention would not necessarily effect global metabolic change reflected in 
the urine and faecal water of study participants and sources of variation unrelated to 
bacterial population changes were shown to predominate.  
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Fig. 5.8 Model overview plots of dietary interventions A, B, C, D and E, showing 
bacterial regression analyses of total bacterial population changes (calculated by 
subtraction of treatment from baseline bacterial counts) to 
1
H-NMR data of human 
urine.  
The models demonstrate poor cross validation and predictive value reflected in the low 
and negative values of the Q
2Ŷ statistical parameter. This suggests a poor correlation of 
bacterial population changes to urinary metabolic phenotype due to dietary intervention. 
The calculation of 6 model components gradually improved the model strength. 
However, this was at the potential cost of overfitting the regression analyses.
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Fig. 5.9 Example O-PLS-DA loadings plot of bacterial regression analysis of faecal 
water. Total bacterial population change of E. rectale/C. coccoides gp .within the Diet 
D intervention regressed to the 
1
H-NMR spectra of faecal water.  
The direction of features in the loadings plot represent upwards positive correlation of 
metabolites and downwards negative correlation of metabolites with bacterial 
population change.  
Prima facie evidence suggests strong correlations with gut microbial change. However 
correlation strength is weak, which is reflected in the low values of the O-PLS-DA 
coefficients of 0.025. Analysis of the raw 
1
H-NMR spectra revealed the increased 
concentration of succinate was attributable to one study participant.  
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5.5.5 Regression analyses of significant bacterial population changes to all 
1
H-
NMR spectra 
In an attempt to improve elucidation of discriminatory metabolites related to bacterial 
population numbers, regression analyses were performed using all treatment (24 week) 
1
H-NMR spectra of both urine and faecal water irrespective of dietary class. All 
treatment 
1
H-NMR spectra were regressed to statistically significant changes in 
bacterial population numbers (T-B) as assessed by p-statistics by our collaborators at 
Reading University (Table. 5.5). This approach also failed to produce any evidence of 
metabolite associations with the bacterial population number changes observed (Table 
5.6). This indicated the changes in major bacterial populations due to dietary 
intervention could not in this case be related to alteration of metabolic phenotype. 
Similarly poor values of the Q
2Ŷ parameter in relation to the R2Ŷ parameter was 
evidential of poor correlation of changes in bacterial population numbers from baseline 
to treatment values in relation to metabolic phenotype in both urine and faecal water 
samples. This indicated sources of variance in the dataset which were unrelated to 
bacterial population changes resulting from dietary interventions. 
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Table 5.6 Regression analyses of all treatment (24 week) urine and faecal water 
1
H-
NMR spectra to statistically significant bacterial population changes (assessed by p-
statistics).  
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5.5.6 Regression analyses of significant bacterial population changes to all 
1
H-
NMR spectra of urine and faecal water 
A number of statistically significant blood, faecal, urinary and anthropometric clinical 
markers were found to be related to dietary intervention by our collaborators at the 
University of Reading (Table 5.7). The changes observed between the baseline and 
treatment samples in these clinical markers were regressed to the urinary and faecal 
water 
1
H-NMR spectral data in order to identify any correlations with urinary or faecal 
water metabolites. Regression analyses to the observed changes in faecal short chain 
fatty acids (SCFA) acetate, propionate, isobutyrate and butyrate failed to produce 
correlations to any metabolites within either the urinary or faecal water 
1
H-NMR 
spectra. In an attempt to reconcile the concentrations of these SCFAs measured by our 
collaborators with the corresponding signals of these SCFAs in the faecal water 
1
H-
NMR spectra, TSP normalised raw spectra were regressed to measured concentrations 
in the treatment (24 weeks) samples. These regression analyses produced strong 
correlations of the measured concentrations of these SCFAs to their respective 
1
H-NMR 
spectral peaks in the faecal water (Fig. 5.8). This result suggested that in principle 
regression analyses could be made to clinical markers successfully however the 
biological significance of changes in concentrations and measurements of the clinical 
markers between the baseline and treatment sample time-points could not be correlated 
to any metabolic changes in the 
1
H-NMR spectral profiles (table 5.8). 
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Fig. 5.10 Regression analysis of faecal acetate treatment samples concentration values 
to TSP normalised faecal water 
1
H-NMR spectra. Strong correlations can be seen 
between acetate concentrations measured by capture compound mass spectrometry 
(CCMS) by our collaborators at the University of Reading and faecal water 
1
H-NMR 
signals corresponding to both acetate and butyrate (Q
2
:0.41; R
2
:0.77). 
Interestingly, despite poor modelling strength in the soluble intercellular adhesion 
molecule (ICAM) regression analysis (Q
2
:0.01; R
2
:0.19) an indicative association was 
seen with acetaminophen metabolites in the urine. It is biologically plausible as ICAM 
is a blood biochemical measure of inflammation and acetaminophen is a very common 
anti-inflammatory drug. There also appeared to be an indication of an inverse 
correlation between total cholesterol measured in blood with hippurate in the urine, 
suggestive of a shift in gut microbial metabolism related to cholesterol levels (Q
2
:-0.32; 
R
2
:0.59). However the significance of these findings is extremely low and possibly 
related to a subset or individual within the study participants. These findings are most 
probably misleading due to low modelling strengths and predictive ability of the 
regression analyse in spite of a suggestion of biological plausibility.  
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Table 5.7 Table showing statistically significant clinical markers (according to p-
statistics) related to dietary intervention between baseline and treatment time-points. 
(Clinical measures provided by our collaborators at the University of Reading). 
 
 
 
 
 
 
 
 
 
 
 
  
Clinical marker Av. Treatment - Av. Baseline Paired t-test (p -value)
Faecal acetate (m mol/l) 5.4029 0.0105
Faecal proponiate (m mol/l) 1.2933 0.0045
Faecal isobutyrate (m mol/l) 0.1876 0.0478
Faecal butyrate (m mol/l) 1.7394 0.0093
Waist measurement (cms) 2.0364 0.0008
Body fat % -1.1524 0.0103
Total cholesterol (m mol/l) -0.2722 0.0494
LDL cholesterol (m mol/l) -0.3182 0.0115
NEFA* (m mol/l) 78.8130 0.0130
Av. blood glucose (m mol/l) -0.1905 0.0149
Av. blood insulin (p mol/l) -11.0919 0.0284
ICAM** (u /ml) 35.1111 0.0452
*non-esterified fatty acids
**Soluble Inter-cellular adhesion molecule
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Table 5.8 Table showing regression analyses of statistically significant clinical markers 
(according to p-statistics) to all treatment (week 24) urine and faecal water 
1
H-NMR 
spectra. Models were characterised by poor strength reflected in low Q
2Ŷ and high R2Ŷ 
values. Indicative biologically plausible metabolite associations were observed but 
could not be considered diagnostic. 
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5.6 Discussion 
 
In this study dietary interventions in human participants considered at risk of 
developing MS were carried out over a 24 week period. These dietary interventions 
differed in the type and quantity of fat and carbohydrates. Manipulation of the diet 
included either a replacement of SFA with MUFA in a high fat-diet or a substitution of 
energy from fat for energy from carbohydrate in a low fat diet. Moreover, a 
simultaneous variation of the type of carbohydrates within each intervention group was 
performed to alter the GI, comprising low GI- and high GI- diets. Unfortunately, no 
effects were seen in the urinary or faecal water metabolic phenotypes attributable to 
dietary intervention by the chemometric methods utilised within this metabonomic 
study. The changing of proportions of fatty acids and energy from fats and carbohydrate 
GI would be unlikely to cause any acute homeostatic perturbation detectable within the 
urine, particularly over a study period of 24 weeks. However, alteration of excretory 
concentration of endogenous metabolites associated with changes in fatty acid 
metabolism, energy metabolism and gluconeogenesis may have reasonably been 
anticipated to be detectable in urine or faecal water samples. The alteration of normal 
constituents of the diet, fatty acids and GI of carbohydrates, may have required a longer 
term adjustment to the dietary interventions to produce observable effects in the urinary 
or faecal water metabolic phenotypes of study participants. Alteration of the gut 
microbiota as a consequence of the diet may potentially have been reflected in bacterial 
co-metabolites in the urine, but these were also not detected.  
1
H-NMR spectroscopic 
analysis of blood serum may have been useful for identification of changes in lipid 
profiles and glycoprotein levels. However this was not possible to assess within this 
study 
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5.6.1 Correlation of clinical marker changes by regression analysis 
Original findings examining CVD risk factors and gut microbial ecology were 
performed by our collaborators at the University of Reading and are summarised here. 
 
The dietary intervention was found to be successful as analysis of 4-day food diaries 
supported dietary compliance within the study cohort. Even though diets were designed 
to be isoenergetic, a significantly lower total energy intake was observed compared to 
baseline within diets D and E by paired t-test of the food diary analysis (1920.1 ± 569.5 
vs 1644.7 ± 479.2 and 2212.5 ± 425.9 vs 1853.7 ± 313.7 kcal, mean ± SD, p = 0.015 
and p = 0.002 respectively for diet D and diet E) with a resultant reduction in body 
weight and BMI.   Blood plasma analysis found a reduction of total cholesterol and 
triacylglyceride TAG following the consumption of the high MUFA diets and a 
decrease in LDL-cholesterol after diets C, D and E. There was also no observed increase 
in HDL-cholesterol compared to baseline in any of the dietary intervention groups. 
Elevated levels of LDL cholesterol, lower levels of HDL cholesterol and raised TAG is 
known as the ‗atherogenic lipoprotein phenotype-ALP‘ a risk factor for CHD 229. A 
decrease in non-essential fatty acids NEFA was observed in diet E compared to both the 
control diet A and diet D. Lower fasting NEFA levels are associated with improved 
insulin sensitivity and post-prandial lipaemia and raised levels with increased insulin 
resistance. 
230, 231
. Furthermore, no significant change was seen in vascular or 
haemostatic risk factors or anthropometric measures except for reduced body fat 
percentage in diets D and E, which was almost certainly due to reduced energy intake. 
Attempts were made to regress the changes seen in serum levels of cholesterol and 
particularly the elevation of LDL-cholesterol to the 
1
H-NMR urinary and faecal water 
datasets but no statistically significant correlations were observed although an indicative 
inverse correlation with hippurate levels in the urine could be seen. The poor modelling 
of this regression analysis makes any potential biological significance of this association 
highly misleading despite biological plausibility 
 
The findings demonstrated a healthy alteration of diet reflected in the CVD risk factors 
examined. This was not supported by the metabonomic findings due to poor modelling 
ability of both the urinary and faecal water 
1
H-NMR spectral data. Nevertheless, 
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superficial evidence of metabonomic changes in urine were observed particularly in 
Diet B and changes in Diets A, C, D and E, which were found to be attributable to 
metabolites in very low concentration in the 
1
H-NMR spectra, however the poor 
modelling strengths associated with these tentatively discriminatory spectral features, 
meant any biological interpretation would be misleading. In spite of rigorous attempts to 
improve data analysis by use of alternative pre-processing, normalisation and peak-
alignment algorithms, models of the 
1
H-NMR spectral datasets were confounded by low 
statistical significance. It can be concluded that the alterations of dietary fats consumed, 
GI of carbohydrates, and the proportions of energy obtained from these produced a 
subtle effect on both the urinary and faecal water metabolic profile. The analysis of 
which was dominated by inter-subject variation and it was not anticipated that changes 
in the CVD risk factors observed would not necessarily produce statistically significant 
effects in the urinary or faecal water metabolic phenotypes of study participants. 
 
An important consideration in the construction and interpretation of multivariate 
statistical models is the avoidance of over-fitting of the data and maintaining a good 
relationship between the Q
2
 predictive ability and R
2
 explained variation model 
parameters. Unfortunately within many chemometric models in this study the Q
2
 was 
found to be negative and the R
2
 close to 1, in the case of supervised chemometric 
models this suggests very low dietary class predictive ability and a predominance of 
variation unrelated to the experimental diets. Inadequate statistical modelling suggested 
that the individual research questions being posed within the dataset could not be 
answered and that sources of variation unrelated to dietary intervention were entirely 
responsible for the variation in the X matrices of both the urinary and faecal water 
spectral data. 
 
Effects of dietary changes have previously been identified in human urine using 
metabonomic methods 
112, 221, 232
. Metabonomic studies have proven successful when 
homeostasis is disrupted such as by disease or the introduction of toxins or xenobiotic 
compounds from food sources, which are more readily detectable by 
1
H-NMR 
spectroscopy 
193, 233, 234
. The findings suggest that there was no statistically significant 
effect upon the urinary or faecal water metabolic phenotype due to the dietary 
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interventions, however a longer term study and a reduction of inter-subject variability 
may have allowed more reliable identification of metabolic changes attributable to the 
diets.  
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5.6.2 Gut Microbial Population findings 
Fluorescence In Situ Hybridisation (FISH) analysis using 16S rRNA oligonucleotidic 
probes of faecal samples were performed by our collaborators at the University of 
Reading to assess population changes due to the five dietary interventions A-E, the 
findings of which are summarised with regard to the aims of the metabonomic analyses. 
 
An overall decrease in total bacterial numbers were seen in diets A, B and C and were 
found to be derived from populations not enumerated by FISH analysis, reduction of 
dietary fat in diets D and E did not produce the same effect. However, decreases in total 
colonic microbiota and more specifically in Bacteroides related bacteria are known to 
occur following a high fat diet 
219
. Metabonomic regression analyses specifically with 
bacterial population changes found to be significant by pairwise t-testing with urinary 
and faecal water 
1
H-NMR spectral datasets did not support any correlation of metabolic 
phenotype with diet induced decreases in total bacterial population observed. This is 
perhaps attributable to an inability to elucidate the effects of the bacterial population 
changes observed on the global metabolic phenotypes in urine and faecal water of study 
participants. Sources of variance in the spectral datasets appeared to confound 
elucidation of statistically representative markers of the bacterial population changes. 
The bacterial population changes although significant would not necessarily result in 
sufficiently increased concentrations of urinary or faecal water bacterial co- metabolites 
to overcome inter-individual variations in gut microbial populations. 
 
Diets D and E produced decreases in body fat percentage and fasted insulin levels and 
increases in bifidobacterium, and atopobium populations (known to be carbohydrate 
degraders in the gut). This finding was possibly due to increased substrate availability in 
these diets. Bifidobacteria, are known to be beneficial to human health 
220
 and reduce 
CVD risk factors and development of type 2 diabetes. Diet D also showed significant 
increase in Bacteroides population numbers compared to baseline, reductions of which 
are associated with animal models of obesity and obese humans 
235
. Unsupervised 
chemometric analysis, O-PLS-DA and bacterial regression analyses did not provide any 
evidence for subsequent changes in metabotype, attributable to the beneficial alteration 
of gut microbes observed in diets D and E study participants. 
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Levels of bacterial fermentation products in faecal samples from volunteers revealed 
increases in the SCFAs; acetate, propionate and butyrate. This is in accordance with 
known increases in SCFA levels in faeces in obese individuals, despite lower 
prevalence of polysaccharide degrading bacteria in the gut microbiota 
235
, and this is 
perhaps due to decreased intestinal absorption or modulation of gut microbial activity. 
Evidence of subtle increases in urinary levels of SCFAs was observed in control diet A 
but this trend was not statistically significant.  
 
No differences in bacterial population levels were observed in high vs. low GI diets, 
however fasting NEFA levels were shown to decrease following the low GI high 
carbohydrate dietary intervention (diet E). This study did not include compositional 
analysis of soluble and insoluble sources of fibre within the dietary interventions which 
is known to have a GI altering effect; increases of which are recognised to decrease the 
GI of dietary carbohydrates. The fibre containing dietary constituents may also have had 
an influence on the gut microbial composition. 
 
Regression of the gut microbial findings to the urinary and faecal water 
1
H-NMR 
spectral data was performed in an attempt to identify biomarkers associated with gut 
microbial population changes and to potentially identify gut microbial co-metabolites 
that may be associated with response to dietary intervention. Unfortunately, the 
correlations of these data sets produced poor model strengths for both the urinary and 
faecal water 
1
H-NMR spectral data. The very low statistical significance of the bacterial 
regression analyses suggested that perhaps more dramatic alterations of diet, a longer 
period of dietary adjustment, an increased number of time-point urine and faecal water 
collections and a limitation of variation between the study subjects could have produced 
a greater degree of statistical relevance. 
  
Little is known concerning the impact of both type and quantity of dietary fats on the 
colonic microbiota although it is of great interest. There is also little understanding of 
how diets designed to reduce the risk of CVD and the metabolic syndrome impact on 
the gut microbiota. However, recent studies have shown that the gut microbiota might 
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be a significant extragenomic contribution to obesity in animal models and in humans 
235, 236
. It is of great interest to elucidate the extragenomic contribution of the gut 
microbiota to obesity and its impact on the global metabolic phenotype in humans, but 
this was found to be beyond the scope of this study. For the purposes of further 
metabonomic analysis the use of an additional cohort of this multi-centre study would 
be useful to augment the urinary and faecal water 
1
H-NMR datasets already examined. 
This would allow the selection of a more homogeneous subset, which is age, sex and 
racial background matched and with a similar range of diagnostic recruitment criteria 
for more robust multivariate modelling.   
 
5.6.3 Suitability of the RISCK study for Metabonomics 
Human studies cannot ever be as highly controlled as animal experimental models; 
however limitation of experimental variables can be achieved. The subjects involved 
within this study were selected based on their risk of developing the MS and were not 
necessarily considered to be metabolic syndrome sufferers when participating in the 
study. The study participants therefore represented a heterogeneous group in the context 
of metabonomic analysis and not a discrete disease group. The 130 volunteers recruited 
at the University of Reading were split into two cohorts of 65 volunteers. This number 
of subjects which participated in this study represented a statistically significant dataset 
for the purposes of metabonomic analysis.  
 
The diagnostic recruitment criteria allowed for a minimum expression of two features of 
the metabolic syndrome based on a weighted scoring system. The scores were weighted 
according to relevance to development of the metabolic syndrome and reliability of the 
measurement with respect to biological and analytical variation. However this meant the 
volunteer group represented a heterogeneous subset of the population which could not 
easily be classified into a distinct sample or disease group.  
 
The diagnostic criteria included measures of insulin resistance, dyslipidaemia, 
hypertension, obesity and central adiposity. Screening of the volunteers consisted of 
single measurements of fasting blood glucose and insulin, fasting serum lipids (e.g. 
HDL-cholesterol, LDL-cholesterol, TAG), seated diastolic and systolic blood pressure, 
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waist circumference, weight, height. Although these measurements are excellent for 
determination of risk of CHD and MS, they were not discrete variables for a controlled 
metabonomic study. More importantly the volunteers were both male and female, with 
varying racial group and aged between 30-65 years. These demographic factors are 
known to affect metabonomic analysis and cause variance within chemometric models 
185, 237
. Therefore the study may well have been underpowered. 
 
In order for a model of metabonomic data to demonstrate good statistical separation, 
differences in metabotype need to transcend inter-subject variations within a sample 
group for true metabolic differences to be identified. For example for biological 
matrices such as urine a good O-PLS-DA model should have a Q2Ŷ of around 0.4 if 
metabolite changes are to be accepted as being a statistically relevant pattern associated 
with the perturbations of metabolic phenotype related to dietary intervention. The low 
values of model strengths in this study was highly indicative of a predominance of inter-
subject variations overpowering any effects related to changes in the fatty acid 
composition and GI of carbohydrates in the experimental dietary interventions.  
 
Notable metabonomic differences have been detected in rats between common 
experimental strains and also demonstration of sexual dimorphism in rat urinary 
metabolic profiles 
97, 173
. Therefore it would be expected that even more profound 
differences would also be seen in human studies. Indeed urinary metabolic differences 
were identified between healthy British and Swedish populations of both sexes and in 
the age range 21-65 
225
. Increased trimethylamine oxide (TMAO) excretion was found 
to be characteristic of the Swedish population due to increased fish consumption and 
increasing excretion of taurine was found to be characteristic of study subjects 
following the Atkins diet.  
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5.6.4 Conclusions 
Ideally in initial metabonomic experimental design, human study participants can be 
limited in all controllable extraneous variations particularly sex, race and age-matching 
to limit inter-subject variability. Dietary compliance and limitations on prescription and 
over the counter drugs is also of great importance in focusing dietary intervention 
groups, reductions in outlying samples and the creation of a more homogeneous group 
of study participants. Appropriate variable limitation in this way, can have a favorable 
effect on biomarker elucidation in metabolically heterogeneous free-living human 
populations. However, it is important to note that dietary responses even in human 
studies should transcend experimentally narrowed studies. In spite of rigorous 
chemometric optimisation, the selection criteria for the RISCK study were found to be 
too varied between individual participants for accurate discrimination between the 
dietary interventions carried out. Correlations of faecal water 
1
H-NMR spectra to SCFA 
CCMS concentration evaluation carried out by our collaborators suggested that 
regression analyses were possible in principle in the dataset but the regression analyses 
to changes in the significant clinical markers and bacterial population numbers were not 
possible. 
 
The analysis of a larger sample set utilising one or more additional clinical cohorts of 
the RISCK study may have been sufficient to improve the statistical strength of the 
chemometric models elucidating the effect of the RISCK study dietary interventions. 
Also a larger sample set would also have allowed the selection of a more homogeneous 
group of study participants based upon age, sex, ethnic background and in specific 
diagnostic criteria which would have perhaps been more suitable for metabonomic 
analysis. The 24 week time course of the study may not have allowed sufficient time for 
participants to adjust to the dietary interventions and a longer term study may have been 
necessary to determine changes in metabolic phenotype, however, Diet D and E 
participants did show evidence of weight loss however this was found to be an effect of 
an overall reduction in caloric intake in spite of measures to ensure the diets were 
isoenergetic. The metabonomic analysis may also possibly have benefitted from the 
increased sensitivity of UPLC-MS and provided a broader scope for the elucidation of 
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the effect of the dietary interventions on the human metabotype. Additional urine and 
faecal water samples for each study participant over the 24 week study period may also 
have been useful to augment the 
1
H-NMR datasets and for the purposes of monitoring 
time-course effects of the dietary intervention.  
 
The optimal design of experiment in human studies represents one of the challenges of 
modeling mammalian biocomplexity 
75
. An optimised design of experiment would 
perhaps be necessary to create statistically relevant biomarkers of dietary change that 
could then be validated in large scale epidemiological studies. 
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Chapter Six: The Effects of High Cruciferous Vegetable 
Consumption on Human Metabolic Phenotypes  
6.1 Background 
This study investigated the effects of cruciferous vegetable (CV) consumption on the 
handling of chemical carcinogens formed when red meat is cooked and on the kinetics 
of caffeine. Spectroscopic profiling coupled to chemometric pattern recognition was 
performed to elucidate the effect of CV and meat meal/caffeine dietary intervention on 
the human metabotype. 
 
6.2 Aims and Objectives 
 Determine the effect of a CV dietary intervention in humans, on the urinary 
metabolite profile. 
 From the metabotype, identify urinary biomarkers associated with the CV 
intervention.  
 Determine the effect of meat consumption and caffeine intake on metabotype. 
 Investigate the effect of CVs on the metabolic response to meat and caffeine. 
 Identify metabolic pathways modified by CV intervention. 
 
6.3 Introduction  
6.3.1 Cruciferous Vegetables, phytochemicals and cancer 
Epidemiological studies have consistently demonstrated an inverse association between 
cruciferous vegetable (CV) consumption and risk of cancer 
71
.  
 
The family cruciferae is composed of foods of the species Brassica oleracea (cabbage, 
broccoli, cauliflower, Brussels sprouts, Kale) and >350 other genera (rocket, radish, 
watercress, horseradish, wasabi). Consumption of common CVs are strongly associated 
by epidemiological evidence with a decreased risk of lung, stomach, colon and rectal 
cancer 
17
.  
 
The chemoprotective power of CV against neoplastic disease is attributed to their 
abundant levels of glucosinolates (-thioglycoside-N-hydroxysulfates) in the human diet.   
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For a comprehensive review of CV species and their respective glucosinolates see 
238
. 
Glucosinolates are hydrolysed by thioglucoside enzymes known as myrosinases which 
are released upon damage of the plant material, e.g. by mastication. This produces the 
biologically active isothiocyanates (ITC) and indoles 
239
 (Fig 6.1). If myrosinase has 
been inactivated (e.g., with cooking), consumption of CVs can still result in exposure to 
the hydrolysis products of the glucosolinate released by members of the intestinal 
microbiota; Enterobacter cloacae and Paracolobactrum aerogenoides  which have been 
identified with myrosinase-like activity and which undoubtedly also contribute to ITC 
exposure, albeit at a lower level. For example, the metabolism of the glucosinolate 
Sinigrin has been demonstrated in an in vitro large intestinal model where ~4% of 
Sinigrin was converted to allyl isothiocyanate (AITC) by cultured human gut microbes 
240
. 
 
 
Fig. 6.1 Hydrolysis of glucosinolates by thioglucoside enzymes (myrosinases) to their 
isothiocyanate derivatives. 
 
Within Brassica species different glucosinolates predominate and yield distinct ITCs. 
Although Brussels sprouts and broccoli both contain similar glucosinolates they are 
distinguished by their prevailing glucosinolate species and a complete absence of the 
dominant species in the other Brassica (Table 6.1). In Brussels sprouts Sinigrin 
represents 35% of total glucosinolate content (radical name Propenyl according to 
Chemical Abstracts) and Glucoraphanin (4-methylsulphinylbutyl) in Broccoli accounts 
for 35-60% of the total glucosinolate content 
241
. The glucosinolate content in the CVs 
used in this study was analysed using the methods described in 
242
 at The Institute of 
Food Research (Norwich, UK). 
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Table 6.1 Total glucosinolate content in Brussels sprouts and Broccoli. Table adapted 
from (Murray S. et al. 2001). 
 
*Fresh vegetables were used to prepare the meals consumed in this study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Glucosinolate
Brussels sprouts* Broccoli*
Methylsulphinylpropyl 1.33 0.86
Hydroxybutenyl 1.82 0.1
Methylsulphinylbutyl (sulforaphane) 0 5.02
Propenyl (sinigrin) 4.74 0
Butenyl 0.03 0
Methylthiopropyl 2.46 1.15
Indolyl-3-methyl 2.94 1.65
4-Methoxyindolyl-3-methyl 0.7 0.51
1-Methoxyindolyl-3-methyl 0 0.6
Phenethyl 0 0.07
Total 14.02 9.96
Content (µmol/g dry weight)
aFresh vegetables were used to prepare the meals consumed in the study.
Content (µmol/g dry weight)
9.9614.02Total
0.070Phenethyl
0.601-Methoxyindolyl-3-methyl
0.510.74-Methoxyindolyl-3-methyl
1.652.94Indolyl-3-methyl
1.152.46Methylthiopropyl
00.03Butenyl
04.74Propenyl (Sinigrin)
5.020Methylsulphinylbutyl (Sulforaphane)
0.11.82Hydroxybutenyl
0.861.33Methylsulphinylpropyl
BroccoliaBrussels sproutsa
Glucosinolate
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Mechanistically plant phytochemicals such as the isothiocyanates have been shown to 
inhibit the carcinogenic process by modulation of the cellular antioxidant potential, 
upregulation of phase I and phase II detoxification mechanisms, apoptosis of cancerous 
cells, alteration of estrogen status and binding and elimination of 
procarcinogens/carcinogens in in vivo and in vitro studies 
78, 93
. 
 
In the case of cruciferous vegetables important phytochemicals include the 
glucosinolates and their numerous hydrolysis products, flavonoids, kaempfrol and 
quercetin, and various anthocyanins 
83
.  Broccoli is known to contain relatively high 
levels of the glucosinolate glucoraphanin the parent compound of the isothiocyanate 
sulforaphane 
243
 Sinigrin the most abundant glucosinolate in Brussels sprouts is 
primarily converted to allyl isothiocyanate (Fig. 6.2). 
 
Glucosinolates are thermally stable and hydrolysis products are formed by enzymatic 
hydrolysis by the β-thioglucosidase myrosinases. When myrosinase and glucosinolate 
are released following cell wall disruption the thioglycosidic bond is hydrolysed 
releasing glucose and forming an unstable thiohydroxymate-O-sulphone. 
Rearrangement of the unstable intermediate leads to formation in the vast majority of 
cases to isothiocyanate (ITC), nitrile, thiocyanate, epithionitrile, indolic or goitrin-type 
compounds. The formation of the hydrolysis products is highly dependent on reaction 
conditions particularly pH and at a neutral pH ITCs are normally formed. 
 
Glucobrassicin (Radical Indolyl-3-Methyl) is an indolic glucosinolate and forms a 
significant component of the glucosinolate content in both Broccoli and Brussels 
sprouts. However in the case of the indolic glucosinolates the metabolic endpoints of 
hydrolysis are numerous; the indolic ITCs are unstable and form a corresponding 
alcohol eg. indole-3-carbinol which can condense into dimers (diindolylmethane DIM), 
trimers or tetramers. Plant factors known as nitrile-forming factors are suspected but not 
conclusively identified and are thought to contribute to this metabolic endpoint 
especially in low pH conditions 
244
. Indolic glucosinolate hydrolysis products are also 
known to form ascorbigens by the condensation of ascorbic acid and indole-3-carbinol 
at low pH (4-7) conditions in the stomach; these are believed to possess 
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immunomodulatory properties 
245
. Epithionitrile hydrolysis products from terminally 
unsaturated glucosinolate side chains are thought to form in the presence of the 
epithiospecifer protein and Fe
2+
 ions 
246
 (see Fig 6.3). 
 
There are many endogenous mammalian and plant derived factors influencing the 
formation of glucosinolate hydrolysis products and the levels of each possible metabolic 
endpoint are almost certainly highly variable within the complex human biological 
matrix. For example, it is known that myrosinase can be destroyed by cooking, 
particularly microwave cooking 
247
. 
  
 
Fig.6.2 Schematic of metabolism of sinigrin the most abundant glucosinolate of 
Brussels sprouts, a typical aliphatic glucosinolate. Adapted from 
72
. 
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Fig. 6.3 Schematic of metabolism of indolic glucosinolates showing potential metabolic 
endpoints of hydrolysis. Variations are seen in the position of a methyl group in 
neoglucobrassicin and 4-methoxyglucobrassicin. Adapted from 
72
. 
 
6.3.2 Chemoprotective Mechanism 
The active principal ITCs and indoles are known to influence several steps in the 
carcinogenic process by: - (i) Preventing DNA damage by inhibiting the activity of 
phase 1 enzymes (the cytochrome P450 family and flavin dependent monooxygenases) 
and inducing phase 2 biotransformation enzymes such as quinone reductase and 
glutathione S-transferases (GST); (ii) Reducing the DNA – binding, mutagenicity and 
metabolism of procarcinogens by augmenting the endogenous intracellular antioxidant 
potential by inducing GSH synthesis; (iii) The induction of apoptosis in malignant and 
premaligmant cells and the cell cycle arrest of transformed cells 
248-251
. Sulforaphane 
has recently been shown to have potential tumour suppression activity by inhibiting 
Histone Deacetylase (HDAC) 
252
.  
 
GSH is the most abundant sulfhydryl agent in cells and plays a key role in cellular 
defence against
 
a range of exogenous and endogenous toxins. The relationship between 
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GSH and ITC‘s is well characterised 253, 254. GSH abundance is directly linked to the 
level of uptake of ITC‘s and the formation of ITC-GSH conjugates, the levels of which 
are known to be fundamental to the anticarcinogenic activity of ITC‘s. 
 
Following absorption of the principle active thiol, conjugates of ITC are formed by 
conjugation with glutathione, a reaction catalysed by GST. Benzyl-ITC, PEITC, allyl 
ITC and sulforaphane are the most common glucosinolate hydrolysis products and are 
all substrates for the four major human GSTs- GST A1-1, GST P1-1, GST M1-1 and 
GST M2-2. However the reaction velocities differ by as much as 700-fold so there is 
inherent individual variation in the extent to which ITCs are conjugated 
251
. Therefore, 
human ITC exposure is modulated by the type and amount of CV consumed, how the 
food was prepared, level of mastication and individual differences in GST isozyme 
levels. 
 
ITCs can directly inhibit the P450 family and also induce expression of either or both of 
the phase I and II enzyme systems. The mode of induction by the CV compounds is 
dependent on the distinct structure effects of the ITCs and indole derivatives. 
Commonly consumed CVs and their isolated constituents are known to modulate two 
major phase II enzyme systems: GST and Uridine 5‘ diphospho-glucuronosyltransferase 
(UGT) 
255
 and also to alter steroid hormone metabolism 
82, 256
. For example, watercress 
consumption was found to increase UGT glucuronidation of nicotine and tobacco 
carcinogen metabolites 
257
.  
 
ITCs like sulforaphane and AITC activate genes via the antioxidant/electrophile 
response element (ARE/EpRE). Sulforaphane induces expression by dissociating the 
cytoplasmic-anchoring protein Kelch-like ECH associated protein 1 (KeapI) from a 
transcription factor Nrf2 (NF-E2 p45-related factor 2). Nrf2 translocates to the nucleus 
forming Nrf2/Maf (musculoaponeurotic fibrosarcoma oncogene) heterodimers, which 
then activate transcription of Phase II enzymes through ARE/EpRE 
258
. This forms part 
of the MAP-kinase signalling pathway. Indolic derivatives, on the other hand, largely 
induce phase I enzyme systems via xenobiotic response elements (XRE) in the gene 
promoter. Indoles induce expression of enzymes such as CYP1A, CYP1B, GSTA, 
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NQO1 (NAD(P)H:quinone oxidoreductase) and UGT by activation of AhR (aryl 
hydrocarbon receptor) 
259
. It is thought that the glucosinolate hydrolysis products that 
induce both Phase I (XRE) and Phase II (ARE/EpRE) have a chemoprotective effect by 
increasing the speed of metabolic elimination of carcinogens/procarcinogens.  
 
6.3.3 Carcinogenic heterocyclic amines in cooked meat 
Heterocyclic amines (HA‘s) are common carcinogens formed in cooked meat. Their 
carcinogenicity has been demonstrated in rodent bioassays  
260
.  
Murray et al (2001) found that a high cruciferous vegetable diet had a physiological 
effect on the carcogenicity of the carcinogen PhIP (2-Amino-1-methyl-6-
phenylimidazo[4,5-b]pyridine) by inducing levels of the xenobiotic metabolising 
enzyme CYP1A2 with an associated reduction in the levels of excreted red meat 
heterocyclic aromatic amines. There was also an increase in N
2
-glucuronidation of the 
pro-carcinogenic N-hydroxy-PhIP 
81
. The reduction in amine excretion remained even 
after the withdrawal of the dietary CV and indicated a prolonged physiological response 
to a high cruciferous vegetable diet. 
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6.3.4 ITC Elimination 
The primary route of in vivo metabolism of ITC is by the mercapturic acid pathway, a 
major pathway for elimination of many xenobiotics 
261
. Subsequent stepwise cleavage 
of glutamine and glycine yields L-cysteine-ITC, which is N-acetylated to produce N-
acetyl-L-cysteine ITC conjugates (mercapturic acids); these are excreted in urine (see 
Fig 6.4). 
 
Fig. 6.4. The metabolic elimination of ITC showing the excreted dithiocarbamate 
(Mercapturic acid)-ITC conjugates. 
 
A detailed examination of the fates of isothiocyanate and glucosinolate hydrolysis 
products of dietary crucifers has been performed in humans 
93
. Human metabolism and 
urinary excretion of chemoprotective ITCs and glucosinolate hydrolysis products were 
analysed in this study by paired ion chromatography examination of urine following 
oral administrations of broccoli containing known levels of sulforaphane. This led to 
excretion of dithiocarbamates. The observed urinary profiles related to the glucosinolate 
profiles of the cruciferous vegetables administered. Graded doses of ITCs led to rapid 
excretion of proportionate amounts with 1
st
 order kinetics 
93
. Urine was analysed using 
paired-ion chromatography. Excretory products were quantified using a cyclo-
condensation reaction of isothiocyanates with 1,2-benzenedithiol which yields a product 
with highly favourable properties for spectroscopic quantification. Humans were shown 
to convert substantial amounts of isothiocyanates to dithiocarbamates 
262
. The initial 
glutathione adduct and four sequential metabolic products were excreted in the urine 
(See Fig 6.4.). N-acetylcysteine mercapturic acids were predominant amongst the 
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metabolites. Excretion of sulforaphane excretory products was substantial, amounting to 
<67% of the administered dose 8-24 hours post dose. 
262
. 
 
London et al. (2000) showed that genetic polymorphisms in human GSTs reduced their 
activity causing a longer circulating half-life of ITC and greater chemoprotective effect. 
Urinary biomarkers of CV exposure were assessed by Seow, Shi et al (1998). 
Detectable Dithiocarbamate-ITC levels were shown to be inversely associated with lung 
cancer risk in men with homozygous deletions in GSTM1 and GSTT1 
263
.  
 
Mercapturates are the most commonly studied biomarker of cruciferous vegetable 
consumption. However the excretion of these biomarkers is highly dependent on inter 
individual differences in metabolism, abundance of glucosinolates in the vegetable 
consumed, cooking method, bioavailability, absorption, bacterial metabolism and rate 
and specific metabolic endpoints of myrosinase hydrolysis. A more stable biomarker of 
CV consumption is therefore desirable for assessment of epidemiological data, dietary 
intervention study adherence, dietary assessments in human populations and also new 
knowledge on the mechanisms of the beneficial effects of CVs. 
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6.3.5 Evaluation of previous studies of anti-carcinogenic potential of CVs 
The majority of evidence concerning the anti-carcinogenicity of cruciferous vegetables 
and their glucosinolate hydrolysis products comes from in vivo animal studies and in 
vitro cell cultures in which the ITC or indole has been used in isolation (for a review see 
76
. In animal models and cell systems combinations of ITCs have been shown to confer 
protection against genotoxic agents better than individual ITCs 
264
. However, the focus 
on the individual components ignores the potential for chemical interactions and 
synergistic chemoprotective contributions from other compounds found in the normal 
matrix of cruciferous vegetables. Inter-species differences and the use of doses of the 
hydrolysed glucosinolate and carcinogenic compounds far in excess of the estimated 
levels in a normal human diet hinder extrapolation of the results of animal studies in 
relation to humans. The high levels of ITC‘s used for in vitro studies causes acute 
cellular stress which may induce apoptosis and cell cycle arrest and may not be a 
relevant effect in human subjects.  
 
However, In vivo human studies have confirmed the beneficial effects of CV at high but 
realistic consumption levels 
79, 80, 82, 265-271
 and this is in accordance with the 
epidemiological evidence of the negative correlation between high cruciferous 
vegetable consumption and the incidence of diet-related cancers 
71
.  
 
 
 
 
 
 
 
 
  
 160 
 
6.4 Methods 
6.4.1 Study Protocol 
Twenty healthy male Caucasian subjects were subjected to a three period dietary 
intervention study (see Murray et al. (2001) for details). This study was based at a 
single centre and planned with the advice of a clinical nutritionist. To eliminate 
metabolic variables due to ethnic origin, sex and contraceptive steroids, the subjects 
were male, non-smoking Caucasians that were chosen from the TNOBIBRA Clinical 
Unit volunteer panel. Potential recruits were excluded if they had any history of drug 
abuse, chronic alcohol consumption (>28 units/week, 1 unit = 0.5 pint of beer or 1 glass 
of wine or 1 measure of spirits) or had taken prescribed drugs in a 1 month period prior 
to commencement of the study. All subjects underwent a medical examination including 
serum chemistry measurements before the start of the study. The mean age of the 
subjects was 33 years with an age range of 22–46 years. Mean body weight was 82.0 kg 
(range 68.6–103.2 kg) and all subjects were within 15% of the desirable weight range 
for their height.  
Each of the three periods comprised 14 days duration (Fig 6.5). In periods 1 and 3 a low 
CV diet was consumed for 12 days and dietary restrictions were applied designed to 
avoid exposure to known modifiers of enzyme activity. Excluded dietary components 
were cruciferous vegetables and alliums such as Brussels sprouts, broccoli, calabrese, 
cabbage, cauliflower, swede, turnip, mustard, cress, onions, leeks, parsley, kale, radish, 
horseradish, garlic and spinach. On days 11–14 of all three periods, additional dietary 
restrictions were imposed which included avoidance of cooked and smoked meat and 
fish products, toasted items and drinks containing caffeine, chocolate, coffee, alcohol 
and grapefruit juice. The subjects were recommended to consume vegetarian meals 
based on eggs or cheese. The drugs paracetamol, aspirin and ibuprofen were also 
prohibited during these periods and to monitor compliance, subjects were asked to keep 
a written record of food intake during days 10, 11 and 12 of each period of the study. 
All meals were consumed under supervision in the TNOBIBRA Clinical Unit and 
subjects were provided with packed lunches for consumption outside the unit.  
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Following an overnight fast, subjects reported to the TNOBIBRA Clinical Unit on day 
13 of each period of the study. After providing a urine sample, each subject was given a 
meal of 275 g well-cooked lean minced steak, which was consumed with vegetable 
stock and water. A 10 h urine collection was then commenced. A 2 mg/kg body weight 
dose of caffeine was administered, dissolved in a cup of decaffeinated coffee. The 
subjects were provided with a vegetarian lunch and afternoon snack and were released 
from the unit after completing the 10 h urine collection. All subjects were supplied with 
containers for a 10–24 h urine collection. On day 14, subjects returned to the 
TNOBIBRA Clinical Unit with their urine collections. The subjects were then provided 
with containers for a 24–48 h urine collection that were brought to the unit the 
following day. 
All samples were maintained at -80˚C. 
 
Fig. 6.5 Figure showing the study protocol and the nutritional intervention strategy. 
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6.4.2 
1
H-NMR Spectroscopy and UPLC-MS Methods 
All 
1
H-NMR urine analyses were performed at 600.13MHz on a Bruker DRX 600 
Spectrometer (Bruker Analytische GmbH, Rheinstetten, Germany) coupled to a sample-
handling system Gilson (Middleton, WI, USA) XL233 interfaced to the XWinNMR 
data system using parameters described in chapter 2 section 2.5.1. UPLC-MS urine 
analyses were performed on a Waters LCT premier (Waters MS Technologies, 
Manchester, UK) orthogonal acceleration time of flight mass spectrometer which was 
operated in both positive and negative ion mode. Chromatographic separations were 
performed on a Waters ACQUITY
TM 
UPLC BEH  2.1x 100 mm 1.7 µm C18 column 
(Waters Corp, Milford, USA) using an ACQUITY
 TM 
Ultra Performance Liquid 
Chromatography system (Waters). UPLC-MS was conducted using standard parameters 
detailed in chapter 2 section 2.7. 
 
6.4.3 Application of XCMS for Tentative Biomarker Identification. 
A significant challenge of interpretation of UPLC-Mass Spectral data is its sheer size 
which makes manual analysis of raw data almost impossible.  The use of chemometric 
techniques particularly in the form of software packages, such as XCMS
1
 
157
 are useful 
for the deconvolution of complex data sets. 
 
Data-mining programs such as XCMS
1
 use special algorithms that filter and bin raw 
mass spectral data then extract chromatographic features identified by m/z ratio and 
retention time. The features are then aligned, normalized and a peak table created which 
can be subjected to further statistical analysis. XCMS
1
 uses a peak picking algorithm 
that identifies chromatographic features that represent the differences between sample 
classes and produces a list of Extracted Ion Chromatograms (EICs) and their 
corresponding box and whisker plots which are sorted in ascending order of confidence 
based on p-value and other statistical measures. Tentative biomarkers of CV 
consumption were selected based on their class exclusivity within the mass spectral data 
and by interpretation of the EIC, box and whisker plot, p-value and presence within the 
raw data. The purpose of this process is to identify ions of interest on which the 
investigations can focus as a possible source of biomarker information. 
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Initial biomarker identification is based on knowledge of potential exogenous and 
endogenous candidate metabolites, database mining, (i.e. Human Metabolome 
Database, Hmdb, Genome Alberta) fragmentation analysis and accurate mass atomic 
formulae identification or a combination of these. Final confirmation of structural 
identity is achieved using authentic standards. The process of identification is 
confounded by the limitations of slowly developing metabonomic databases and is an 
ongoing challenge. Using approaches such as this, HPLC-MS analysis has been used to 
identify the neutral loss of 129 m/z mercapturates from acetaminophen in human urine 
272
. 
 
6.4.4 Mercapturic acid urinary extraction  
Mercapturate conjugates from human urine samples were extracted using ethyl acetate 
273
. Urine samples (5 ml) determined to be highest in concentration of the unknown 
signatures of interest by PCA analysis were acidified with 0.25ml 4 M HCl. The 
acidified urine was vortexed for 15 mins with 8 ml of ethyl acetate. The layers were 
then separated by centrifugation (3000 g av, 5 mins). The ethyl acetate layer was then 
collected and evaporated to dryness using a rotary evaporator (Savant SpeedVac 
SPD111V). The extraction procedure was then repeated using an additional 8 ml of 
ethyl acetate. The reduced extraction was reconstituted with 500μl D2O and corrected to 
pH 7.2 with 1M NaOH prior to 400MHz 
1
H-NMR analysis.   
 
6.4.5 Synthesis of sulforaphane mercapturate  
For the synthesis reaction equimolar concentrations of 1mM Sulforaphane and 1mM N-
acetyl cysteine (both purchased from Sigma-Aldrich, UK) were reacted overnight in 
methanol and then evaporated to dryness using a rotary evaporator (Savant SpeedVac 
SPD111V). The reduced synthesis was reconstituted with 500μl D2O and corrected to 
pH 7.2 with 1M NaOH prior to 400MHz 
1
H-NMR analysis.   
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6.4.6 Brussels sprouts and broccoli aqueous extraction 
Eighteen experimental iterations were performed in order to assess different extraction 
procedures 
274
, observe the effect of low and neutral pH on enzymatic activity and 
hydrolysis product formation, simulation of mastication by addition of saliva and the 
effect of temperature, and raw versus microwave cooked vegetables, as conducted 
within the original study 
81
 see (Table 6.2). 
 
One ml of either CH3CN:D2O (50:50 ; Acetonitrile:Deuterium Oxide) or a D2O sodium 
phosphate buffer (0.2M Na2HPO4/ 0.2M NaH2PO4 pH7.4, 1% (w/v) NaN3) was used as 
the aqueous extraction media and combined with approximately 600mg of either 
Brussels sprouts, broccoli or a 50:50 combination. It was homogenised using a Quiagen 
tissue lyser (Retsch, ltd.) for 10 mins at the highest setting. An internal 
1
H-NMR 
reference standard 3-(trimethylsilyl)propionic-2,2,3,3-d4 (TSP) (~0ppm) was added to a 
final concentration of 0.1mM. Sodium azide (NaN3) (1% w/v)  was added as an 
antimicrobial to prevent microbial growth during the plant material fermentation and 
prevent confounding peaks due to bacterial fermentation in the 
1
H-NMR spectra. The 
resulting homogenates were allowed to ferment for 4 hours at either physiological 
temperature (37°C) or room temperature (RT) and neutral pH or low pH (1-3). 
Following fermentation the homogenates were centrifuged at 10,000 g for 10 mins and 
the supernatant was filtered using 25mm Micropore syringe filters and transferred to a 
standard 5mm outer diameter NMR tube. 
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Table 6.2 showing CV aqueous extractions experimental iterations. 
 
 
 
 
 
 
 
 
 
 
 
 
Experiment no. Vegetable Cooking procedure Homogenisation Solvent lyophilisation Temperature pH
1 Broccoli Fresh NaPO4 buffer NaN3 X RT 7.4
2 Broccoli Fresh NaPO4 buffer NaN3 X 37°C 7.4
3 Broccoli Fresh NaPO4 buffer NaN3 X 37°C 7.4
4 Broccoli Fresh CH3CN:D2O Freeze drier RT 7.4
5 Broccoli Microwaved NaPO4 buffer NaN3 X RT 7.4
6 Broccoli Microwaved NaPO4 buffer NaN3 X 37°C 7.4
7 Broccoli Microwaved NaPO4 buffer NaN3 X 37°C 7.4
8 Broccoli Microwaved CH3CN:D2O Freeze drier RT 7.4
9 Brussels' Sprout Fresh NaPO4 buffer NaN3 X RT 7.4
10 Brussels' Sprout Fresh NaPO4 buffer NaN3 X 37°C 7.4
11 Brussels' Sprout Fresh NaPO4 buffer NaN3 X 37°C 7.4
12 Brussels' Sprout Fresh CH3CN:D2O Freeze drier RT 7.4
13 Brussels' Sprout Microwaved NaPO4 buffer NaN3 X RT 7.4
14 Brussels' Sprout Microwaved NaPO4 buffer NaN3 X 37°C 7.4
15 Brussels' Sprout Microwaved NaPO4 buffer NaN3 X 37°C 7.4
16 Brussels' Sprout Microwaved CH3CN:D2O Freeze drier RT 7.4
17 Broccoli/Brussels' Sprout Fresh NaPO4 buffer NaN3 X 37°C 2.3
18 Broccoli/Brussels' Sprout Fresh NaPO4 buffer NaN3 X 37°C 2.3
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6.4.7 Synthesis of S-methyl-L-cysteine sulphoxide and N-acetyl-S-methyl-L-
cysteine-sulphoxide standards. 
Authentic S-methyl-L-cysteine (SMCS) was purchased (Sigma-Aldrich) and utilised for 
the synthesis of both S-methyl-L-cysteine sulphoxide (SMCSO) and N-acetyl-S-methyl-
L-cysteine sulphoxide (NAc-SMCSO). For synthesis of SMCSO, 0.53g of SMCS was 
dissolved in 5 ml H2O by use of magnetic stirring, to give a final concentration of 
100mM. To this solution was added 200µl of H2O2 (according to the protocol of Synge 
RLM et. al.1954). The sulphoxidation reaction was left to occur overnight at room 
temperature. Complete destruction of the starting product was observed by 
1
H-NMR 
and evidence of sulphone formation was also observed. Preparation of NAc-SMCSO 
(S-methyl mercapturic acid sulphoxide) was conducted with slight modification 
according to the protocol of Thomson AER et.al. (1963).  
 
One gram of SMCS was dissolved in 28ml of ice-cold NaOH kept on ice and with 
magnetic stirring 1.75ml of acetyl chloride was added cautiously drop-wise. Then a 
further 14ml of ice-cold NaOH was added followed by another 1.75ml of acetyl 
chloride also added in a drop-wise fashion. After a 5min mixing time and when all of 
the acetyl chloride droplets had disappeared the resultant solution was left at 5ºC 
overnight and then shaken 3 times with 10ml of chloroform. The chloroform extracts 
were then combined and left to evaporate to dryness under nitrogen. The resultant 
gummy residue was redissolved in 2ml of ethanol, 5ml H2O and 10ml warm hexane. 
The mixture was shaken vigorously and the aqueous layer was aspirated and filtered. 
The aqueous filtrate was then evaporated to dryness using a speedvac at 60ºC under 
reduced pressure for 5 hours to remove any residual solvent that may interfere with a 
clear 
1
H-NMR spectral signal. The resulting residue was then redissolved in 2ml 
acetonitrile for solid phase extraction using an acetonitrile:water mobile phase. A 2g C-
18 SPE column was first conditioned twice with 5ml acetonitrile. Following this 1ml of 
the N-Ac-SMCSO solution was carefully loaded onto the column. After an initial 1ml 
H2O elution, serial 1 ml elutions of 5, 10, 20, 40, 60, 80, 100% acetonitrile were 
performed and the eluents collected and lyophilised by freeze-drying. The residues of 
each eluent fraction were redissolved in 90% H2O: 10% D2O containing an internal 
reference standard TSP prior to 
1
H-NMR spectroscopic analysis. 
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6.5 Results 
6.5.1 Effect of a cruciferous vegetable dietary intervention in humans, on the 
urinary metabolic profile. 
Representative 
1
H-NMR urine spectra for one subject (number 12) for both the phase I 
predose and phase II time-points clearly revealed the presence of 4 singlet peaks (δ2.83, 
δ2.81, δ2.78 and δ2.75) which discriminate between the restricted CV (phase I) and 
high CV (phase II) study phases (Fig.6.6). These peaks are found in all subjects at 
varying urinary concentrations post ingestion of CVs. There also appeared to be a time-
course decline in signal intensity of these peaks at later sample time-points. 
 
Fig. 6.6 Representative 600 MHz 
1
H NMR spectra of human urine from restricted CV 
(bottom: Phase I pre-dose) and high CV diets (top: Phase II pre-dose). 
A: δ2.83; B: δ2.81; C: δ2.78; D: δ2.75. 
2.83ppm
2.81ppm
2.78ppm
2.75ppm
citrate
Phase II Pre-dose subject 12
Phase I Pre-dose subject 12
A
B C
D
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6.5.1.1 Principal Components Analysis all 
1
H-NMR spectra 
Following pre-processing, baseline correction, phasing, correction to the internal 
standard TSP, pre-processed data was bucketed into 0.001ppm buckets and normalised 
to total spectral area. Data points in the region δ 4.5-5.5 were removed to eliminate 
artefacts associated with varying water suppression.  
 
PCA analysis of this entire dataset revealed no clustering of samples based upon class 
and the dataset was characterised by intersubject variations rather than a significant 
variation due to the dietary interventions applied (Fig. 6.7). This is to be expected in 
human datasets where dietary interventions produce largely subtle effects. The next step 
of investigation is to perform supervised discriminant analysis. 
 
Outliers identified in the PCA scores plot were shown to be due to the presence of 
ethanol in two different pre-dose samples by analysis of the corresponding loadings 
plot. Subjects were asked to abstain from alcohol during the study period. This suggests 
a certain level of non-compliance of these subjects to the dietary restrictions. Outliers 
were removed from all subsequent chemometric analyses.  
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Fig. 6.7 PCA scores plot demonstrating that variation within the NMR spectra X matrix 
multidimensional space is dominated by intersubject variation with no clear grouping 
based on sample class. Q
2
: 1.3 relatively low cross validation of the model for 
biological matrices and the R
2
: 0.32 shows relatively poor explanation of variance in the 
X matrix by this model. Outliers were removed prior to further chemometric analyses.
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6.5.1.2 O-PLS-DA  
Proton NMR spectra for each study phase in all time points were pair-wise compared 
using O-PLS-DA analysis to determine any significant changes between the run-in 
normal restricted CV diet (Phase I), the high CV diet (Phase II) and the final washout 
period of restricted CV intake (Phase III). Every phase was compared with each other 
using ―Unit Variance‖ (1/standard deviation) scaling. Differentiation and variation in 
metabolites was observed in the O-PLS-DA regression coefficient plot. 
 
O-PLS-DA coefficient plots of phase I vs. phase II urine samples normalised to total 
area consistently revealed a discriminatory set of three singlet peaks at δ2.755, δ2.781 
and δ2.809, these resonances being typical of bis-allylic compounds (see Fig. 6.8). 
These three singlets were found by comparison of any of the phase II time-points with 
any of the phase I or phase III time-points urine samples and were highly discriminant 
of the high CVs period and were therefore considered statistically significant (Q
2Ŷ: 
0.46; R
2Ŷ: 0.72) biomarkers of CV intake.   
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Fig. 6.8 O-PLS-DA coefficient plot; phase I predose (low CV) vs. Phase II predose 
(high CV) human urine samples showing the singlet resonances characteristic of Phase 
II. (Q
2Ŷ: 0.46; R2Ŷ: 0.72). 
 
The signal orientation indicates the higher (positive orientation) or lower (negative 
orientation) concentration of characteristic metabolites in phase II. The colour of the 
signal reflects the significance of the correlation with diet (red indicates highest 
significance and blue indicates low significance).  
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6.5.1.3 STOCSY  
In an attempt to further elucidate the molecular structure of these discriminatory signals, 
a STOCSY analysis was performed on each of these three peaks. This revealed 
correlations between the three singlet peaks identified by O-PLS-DA particularly 
between the singlet peak at δ2.781 and δ2.809, with less significant correlation with 
δ2.755 (Fig. 6.9). There was also some evidence of significant correlations with small 
intensity peaks further up field at δ3.083, δ3.104 and δ3.288. This suggested a structural 
similarity between the individual singlet peaks or a shared/similar metabolic 
origin/pathway. The weaker correlations were perhaps indicative of less abundant 
metabolites derived from a similar metabolic origin or perhaps structural elements 
related to the diagnostic singlet peaks at lower field. However, low peak intensity and 
significant overlap of peaks of other urinary constituents in the area of the spectrum 
prevented correct identification of splitting pattern by STOCSY analysis alone. 
 
Fig. 6.9 STOCSY analysis of peak 2.78ppm normalised to total area showing 
correlation between the singlet peaks of interest. Arrows indicates peak from which the 
analysis was driven from. 
2.81ppm
2.78ppm
2.75ppm
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6.5.2 NMR spectral biomarker identification 
To identify the unknown singlet resonances associated with CV consumption, 
1
H-NMR 
databases, literature and in-house sources were initially explored for metabolites with 
similar resonances, peak intensities, and splitting patterns. This failed to identify a 
potential candidate with a singlet splitting pattern and chemical shift in this area of the 
NMR spectra. Pair-wise time course O-PLS-DA analysis of phase II samples revealed a 
decrease over-time of the singlet resonances following cessation of the CV 
consumption, consistent with the notion that they are diagnostic biomarkers of CV 
intake.    
 
6.5.2.1 Mercapturate synthesis and extraction 
It is known from previous studies 
93
 that urinary biomarkers characteristic of CV 
consumption in humans are the mercapturic acid conjugates of the isothiocyanates 
sulforaphane and sinigrin, derived from glucosinolates found in broccoli and Brussels 
sprouts respectively. In order to eliminate these candidate compounds as the 
discriminating signals, a mercapturate synthesis reaction was performed. Following 
synthesis the samples were reduced to dryness and the samples reconstituted in D2O 
prior to 400MHz 
1
H-NMR analysis. The samples showed the chemical shift of the 
acetyl group of the acetyl-cysteine, a singlet at δ2.03. Complex multiplets arising from 
the magnetically non-equivalent protons surrounding the chiral carbon of the cysteinyl 
conjugate were also detected. The β-CH2 representing the AB of the ABX of an ABX 
spin-system around the dissymmetric chiral centre could be seen at δ3.31 and the α-CH 
(the X of the ABX) could be observed at δ4.47 (Fig. 6.10).  
 
Additionally urine samples were subjected to a mercapturate extraction protocol as 
described in section 6.4.5, however it was found the extracted mercapturates from the 
urine were below the concentration limits of detection and structural assignment 
capability of 
1
H-NMR analysis under the current conditions.  
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Fig. 6.10 400MHz NMR spectrum of synthetic sulphoraphane-mercapturate conjugate.  
A: Terminal methyl group of sulforaphane; B: AB of ABX chiral spin system; C: X 
constituent of ABX spin system; D: Terminal acetyl group of N-acetyl-cysteine. 
Remaining signals within the spectra correspond to the structure of sulforaphane. A well 
resolved peak of the terminal methyl group can be seen at δ2.98.  
 
The mercapturate conjugate extractions, examined with reference to the sulforaphane-
mercapturic acid conjugate (SFMA) synthesis, failed to show any evidence of the 
singlet peaks of interest at δ2.81, δ2.78 and δ2.75 and these candidate biomarkers were 
eliminated.  Detailed analysis of the raw urine spectra failed to show any evidence of 
the expected mercapturate signatures.  
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C
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6.5.2.2 Authentic Standard spiking experiments 
The three singlet peak biomarkers of CV consumption were at first assumed to be 
characteristic of independent small molecular weight metabolites. The relative position 
in the 
1
H-NMR spectra between δ2.75-2.81 and the absence of any further structural 
information suggested chemically isolated methyl groups producing a singlet splitting 
pattern. On this basis, a list of small molecular weight metabolites with biological 
plausibility was generated and authentic standard compounds were spiked into phase I 
control urine to attempt to identify singlet peaks. These analyses failed to identify any 
similarity in chemical shift between the unknowns and standards. However, the 
chemical shifts of both methanesulfinic acid and methanesulphonic acid suggested an S-
methyl-sulphoxide functional group may be a possibility for the unknown singlet peaks 
associated with CV consumption (Table. 6.3). 
  
Table 6.3 Chemical shifts of potential sulphur/nitrogen containing compounds with 
biological relevance and a singlet splitting pattern. 
The similarity in chemical shift of both methanesulfinic acid and methanesulphonic acid 
suggested an S-methyl-sulphoxide functional group for the unknown singlet peaks 
associated with CV consumption.  
 
  
Standard compound Chemical shift (ppmδ)
Dimethyl disulphide 2.43
Dimethyl sulphide 2.16
Methyl sulphoxide 3.02
Dimethyl sulphoxide 2.71
Methyl amine 2.57
Dimethyl amine 2.34
Trimethyl amine 2.87
Methanesulfinic acid 2.69
Methyl thiocyanate 2.65
Methanesulphonic acid 2.812
Dimethylsulphone 2.93
Dimethyl sulphate 3.69
N-Methylthiourea 2.961
Methylisothiocyanate 3.278
Methyldithiocarbamate 2.998
S-Methyl methanethiosulfonate MMTS 2.764, 3.31
Dimethylglycine 2.912, 3.723
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6.5.2.3 Improved Peak Alignment and Normalisation 
Interrogation of the raw NMR spectra identified a singlet peak in the phase II urines 
which showed evidence of pH shifting or a poor alignment of spectra. This peak was 
exclusive to the CV consumption sample class and it was therefore important to attempt 
to correctly align this peak prior to chemometric analysis. A superior data preprocessing 
step RSPA or recursive segment-wise peak alignment 
153
 was utilised to improve peak 
alignment within the NMR spectra. This was further improved by using a superior 
normalisation step by normalising to the probabilistic quotient 
154
. Improved pre-
processing, followed by re-calculation of the O-PLS-DA (Fig. 6.11) and STOCSY 
models identified a further singlet biomarker diagnostic of CV consumption at δ2.83. 
This indicated the presence of 4 distinct metabolites with potentially a shared metabolic 
origin and shared structural elements associated with CV consumption in the range 
δ2.75-2.83. The statistical correlation of these 4 peaks was further confirmed by 
STOCSY analysis (Fig. 6.12). Excision of the 4 unknown singlet peaks from the NMR 
spectra and recalculation of the O-PLS-DA model produced a strong correlation of 
peaks located further up field of the 4 singlets. This indicated that peaks in the region 
δ3-3.5 were also significant discriminators of CV consumption and could provide 
further structural information on the unknown metabolites identified at δ2.75-2.83. 
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Fig. 6.11 Following RSPA and normalisation to probabilistic quotient, O-PLS-DA 
identified a previously poorly aligned singlet peak at δ2.83 additionally characteristic of 
CV consumption. A: δ2.83; B: δ2.81; C: δ2.78; D: δ2.75.
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Fig. 6.12 STOCSY analysis confirms statistical correlations between the four unknown 
singlets and with extra connectivity with peaks between δ3-3.5. 
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6.5.2.4 
1
H–1H J-resolved spectra and COSY of Phase II urine 
The identity of the NMR spectral features identified as diagnostic of CV consumption 
between ~δ3-3.5 was difficult to ascertain by interrogation of the standard 1-
dimensional spectrum. The splitting pattern of these spectral features was confounded 
by spectral overlap of metabolites in greater abundance within the urine. However, the 
identity of these peaks is essential for correct structural identification of the unknown 
metabolite(s). The problem of structural identity and identification of splitting pattern in 
this crowded area of the spectrum was approached using a 2D 
1
H-
1
H J-Res NMR 
experiment. This two dimensional NMR experiment separates the chemical shift in one 
dimension from the scalar couplings on the second, providing a visualisation of the 
underlying J-couplings of 
1
D peaks in a two dimensional plot.  
 
The membership of convoluted peaks to a functional group can be ascertained and the 
splitting patterns visualised along with the potential to observe J-couplings of an 
unknown set of spectral features. In order to concentrate the biomarker identified as 
characteristic of CV consumption, the scores plot of a simple PCA plot incorporating 
only the X matrix data for the 4 unknown singlet peaks was performed to identify the 
subject and urine sample containing the greatest concentration of the unknown singlets. 
This was found to be the predose sample of participant number 12. Ten ml of this 
sample was lyophilised by freeze-drying and reconstituted in 1ml of H2O. The sample 
was then loaded onto an SPE column, and eluted with a methanol gradient. The 
majority of the unknown singlet peaks were found to be in the 5% methanol fraction. 
This SPE sample was subsequently utilised for improved two dimensional NMR 
experimentation. 
 
The J-Res experiment confirmed the identity of the unknown peaks in this crowded area 
of the spectra to be the peaks of an ABX spin system and also the similarity in J-
coupling between an A (δ3.10) B (δ3.27) and X representing a doublet of doublets 
further up field at (δ4.38) (Fig. 6.13). However the X doublet of doublets at δ4.38 was 
not identified in the O-PLS-DA loadings coefficient plot the proximity of this peak to 
that of water resulted in its removal due to varying solvent suppression. Analysis of the 
raw NMR spectra identified this doublet of doublets at δ4.38 confirming its presence in 
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the phase II urine samples. The J-Res spectrum provided J-couplings of 13.43Hz 
between the A and B of the spin system and a value of 2.87Hz between the A and X and 
10.56Hz between the B and X (Fig. 6.14). This pattern of J-couplings was shared 
between all three spectral features suggesting membership of all three spectral features 
to the same ABX spin system. 
 
Following the evidence of a similarity in chemical shift to the S-methyl-sulphoxide 
groups of methanesulphinic acid and methanesulphonic acid, the J-res NMR experiment 
was suggestive of a sulphur containing amino acid. It is known from the literature that 
CVs ubiquitously contain a methylated cysteine; SMCSO 
275
.  
 
NMR prediction using the ACD labs software confirmed that the splitting patterns and 
presence of an a chiral centre, and therefore an ABX spin system in both SMCSO and 
its principal mammalian metabolite NAc-SMCSO are supported by the findings of the 
J-Res experiment 
276, 277
. Correlations between the A, B and X of the spin system were 
subsequently confirmed using a COSY experiment (Fig. 6.15). 
 
Evidence of correlations exists between the NMR spectral features at δ3.10 and δ3.30 
and the doublet of doublets at δ4.38. However there appears to be further correlations of 
the signals at δ3.3 with another spectral feature at δ3.50 and between the NMR signals 
at δ3.10 and δ3.85 confounding a facile interpretation. This could possibly be explained 
by the presence of structural features of one of the other unknown metabolites 
associated with CV consumption with similar structure. 
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Fig. 6.13 400MHz 2D 
1
H-
1
H J-Res NMR experiment. Deconvolution of the NMR 
spectral features identified as characteristic of CV consumption between δ3-3.50 
provides evidence of an ABX spin system indicative of an unknown chiral metabolite.  
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Fig. 6.14 Comparison of the J-couplings demonstrates shared scalar coupling constants 
between the protons of the ABX spin system of the unknown metabolite diagnostic of 
CV consumption.  
This confirms the membership of the spectral features identified by O-PLS-DA to the 
same metabolite. 13.43Hz between the A and B of the spin system, 2.87Hz between the 
A and X and 10.56Hz between the B and X. 
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Fig. 6.15 2D COSY confirmation of the ABX spin system identified by J-res 
spectroscopy.  
Evidence of correlations exists between the NMR spectral features at δ3.10 and δ3.30 
and the doublet of doublets at δ4.38, however there appears to be further correlations of 
the signals at δ3.30 with another spectral feature at δ3.50 and between δ3.10 and δ3.85 
confounding facile interpretation. However this could be possibly explained by the 
presence of structural features of one of the other unknown metabolites associated with 
CV consumption with similar structure.  
δ3.1
δ3.3
δ4.3
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6.5.2.5 
13
C HSQC and HMBC of solid phase extract of Phase II urine 
Two dimensional heteronuclear NMR experiments were used to provide further 
structural information on the tentative singlet biomarkers and ABX spin system(s) 
identified within the high CV consumption study phase. The 
13
C Heteronuclear Single 
Quantum Coherence (HSQC) experiment provided a carbon shift of the carbon isotope 
directly bonded to proton(s) of the unknown singlet peaks and the protons of the ABX 
spin system identified in the 
1
H NMR spectra of the urine. This analysis can provide 
further information on the chemical environment of the proton(s) in question and by 
comparison of the carbon shifts with 
13
C NMR databases and comparison of 
13
C 
chemical shifts of authentic standards. 
13
C HSQC of the four singlet peaks provided 
1
H-
13C shifts of δ2.75: δ39.6, δ2.78: δ40.2, δ2.81: δ40.1 and δ2.83: δ40.7 (Table 6.4). 
Furthermore the 
13C shifts of around ~δ 40 provided by the HSQC experiment are 
suggestive of a close proximity of the protons to either a sulphur or nitrogen.  
 
Based on the HSQC 
13
C shifts the 4 singlet peaks are suggestive of closely related or 
very similar compounds sharing a common origin or metabolic pathway. This is 
supported by STOCSY analysis. The variation of the HMBC values for the other four 
singlet peaks suggests the four singlets diagnostic of CV consumption represent four 
separate metabolites all with a similar structure and shared metabolic origin. As 
preliminary evidence suggests that the functional group responsible for the four singlet 
peaks are methyl protons from an S-methyl-sulphoxide functional group, this lends 
weight to the idea that one of the singlets is a vegetable derived metabolite and the other 
3 singlet peaks are metabolites of this as yet unknown compound. This variation in 
13
C 
around δ55.7 suggests that the R-group in proximity to the distant carbon are varying 
subtly (Fig. 6.16). The 
13
C shifts of the signals thought to be responsible for the ABX 
spin system were of a lower intensity due to the complex splitting pattern and reduction 
in number of protons responsible for the signal and were therefore just above the 
threshold of noise. However a similarity of the HMBC 
13
C shifts for the unknown 
singlets and the HSQC of the ABX signals exists. In particular the HMBC for δ3.1 of 
δ180.1 suggests proximity to a 13C of a carboxylic acid group supporting evidence of an 
amino-acid like metabolite(s). 
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Table 6.4  Summary of 
13
C shifts for both the HSQC and HMBC experiments.  
Due to the low sensitivity of HSQC and HMBC the strongest heteronuclear signals were 
observed for the methyl groups of the unknown singlets. The 
13
C shifts of the signals 
thought to be responsible for the ABX spin system were of a lower intensity due to the 
complex splitting pattern and reduction in number of protons responsible for the signal 
and were therefore found to be just above the threshold of noise. 
 
1
H-NMR unknowns O-PLS-DA
1 H-NMR (δ PPM) splitting pattern HSQC (δ 
13C) HMBC (δ 13C) 
2.83 singlet 40.7 55.7
2.81 singlet 40.1 60.5
2.78 singlet 40.2 61.1
2.75 singlet 39.6 63.1
3.32 ABX 60.5 39.5; 57.1
3.28 ABX 62.1 40.2; 69.6
3.1 ABX 61.7 69.2; 180.1
3.12 ABX 47.8 55.1
3.15 ABX 44.4 59.8
4.38 doublet of doublets 69.1 180.7
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Fig. 6.16 Top: 
1
H-
13
C HSQC of 5% methanol SPE fraction of Phase II predose 
urine, the 4 singlet peaks share a similar 
13C shift of around δ39.6-40.2 suggestive of 
the chemically isolated S-methyl-sulphoxide group.  
Bottom: 
1
H-
13
C HMBC of 5% methanol SPE fraction of Phase II predose urine,  
variations in 
13
C shift can be seen for the four singlet peaks δ63.0, δ60.9, δ60.5, δ55.7; 
hypothesised to be a variation in R group adjacent to the long range carbon shift. 
Citrate is shown for reference purposes. 
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6.5.2.6 Cruciferous vegetable extraction: Analysis by 2D NMR experiment 
Extractions of both broccoli and Brussels sprouts were performed to assess a potential 
plant origin of the 
1
H-NMR biomarkers associated with CV consumption and also to 
attempt to identify hydrolysis products from mastication of plant tissue, effect of low 
pH on plant enzyme activity, the effect of cooking on hydrolysis product formation, 
comparison of different extraction strategies and to observe the formation of volatile 
compounds. Both broccoli and Brussels‘ sprouts samples were homogenised in either 
phosphate buffer or a 50:50 mixture of acetonitrile:D2O and left to ferment at either 
physiological (37.5°C) or room temperature for 2 hours. Human saliva or HCl was also 
added to recreate the conditions in the human mouth and gut respectively.  
 
Vegetable extracts were allowed to ferment to encourage the formation of enzymatic 
degradation products particularly of glucosinolates and SMCSO. Following 
fermentation of the vegetable extracts, phosphate buffered extractions were filtered and 
D2O and TSP an internal standard were added prior to 
1
H NMR analysis. Acetonitrile 
extractions were filtered and then lyophilised after snap-freezing prior to resolubilising 
in D2O.   
 
Vegetable extract 
1
H-NMR spectra were significantly improved by the application of 
the CPMG pulse sequence which reduced the broadening of the baseline due to 
proteinaceous and other macromolecular contaminants and improved signal strength of 
the low molecular weight components. 
   
There was an enormous wealth of information provided by the 
1
H-NMR analysis of the 
vegetable extractions due to the abundance of carbohydrates, amino acids, organic acids 
and phenolic compounds found within the aqueous extract of the vegetable matrix (Fig. 
6.17, Table 6.5).  Identification of NMR spectral features was initially made using the 
plant metabolomics assignments available within the literature and online databases 
147, 
148, 274, 278
. The use of acetonitrile as an extraction solvent was found to be more stable 
than phosphate buffered extractions. This was possibly due to the infiltration of soluble 
enzymes and was in accordance with previous reports of vegetable extraction strategies 
279
. No obvious changes could be seen in the raw spectra due to changing pH or addition 
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of saliva. However differences were seen between the different vegetables in the 
phenolic region and between fresh and microwaved vegetables with a reduction in 
unmetabolised SMCSO and glucobrassinin in fresh vegetables subjected to phosphate 
buffer extraction. 
  
Due to the abundance of signals throughout the 
1
H-NMR spectra, there was significant 
overlap between signals, particularly within the region associated with carbohydrate 
resonances. This initially hampered peak identification but was clarified by the 
application of several two-dimensional NMR experiments which greatly increased 
resolution and de-convoluted the 
1
H NMR spectra. A combination of 
1
H–1H J-resolved, 
correlation spectroscopy (COSY), total correlation spectroscopy (TOCSY), 
heteronuclear multiple bond correlation (HMBC) and heteronuclear single quantum 
coherence spectroscopy (HSQC) were applied to accurately identify less well known or 
unknown resonances within the one dimensional spectra (Table. 6.5). For example 2D-
TOCSY was used to confirm the presence of chlorogenic acid. Correlations could be 
seen between the two doublet peaks at δ6.93 and δ7.20 in this spectrum. Furthermore 
the shifts 
13
C by HSQC analysis were found to match those found in the literature 
148
 
(Fig. 6.18) 
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Table 6.5  Assignment of aqueous CV extraction metabolites confirmed by comparison 
of 
13
C shifts with literature sources. 
 
1H-NMR Assignments 1H-NMR δ (splitting pattern) 13C δ
Isoleucine  δ 0.94 (t)  24.41
δ 1.02 (d) 19.77
δ 1.98 (m) 26.7
Valine δ 1.00 (d) 17.4
δ 1.05 (d) 20.7
Lactate δ 1.34 (d) 22.4
Alanine  δ 1.48(d)  18.9
Arginine  δ 1.65 (m)  26.7
δ 1.72 (m) 26.7
δ 3.54 (t) 48.7
γ-aminobutyrate δ 1.90 (m) 30.3
δ 2.30 (t) 37.4
δ 3.01 (dd) 41.8
Acetic acid δ 1.93 (s) 26.3
Acetoacetate δ 2.27 (s) 32.2
Citrate δ 2.74 (d) 48.3
δ 2.56 (d) 48.3
Succinate δ 2.41 (s) 36.8
Sulforaphane δ 2.98 (s)   39.5
δ 4.7 (s)
δ 3.2(s)
δ 3.3(m)
δ 4.98(d)
δ5.23(t)
Methyl-methanethiosulphonate δ 2.76 (s) 39.31
δ 3.51 (s) 53.69
S-methyl-L-cysteine sulfoxide δ 2.83 (s) 40.8
 δ 3.32(m) 57.1
δ 4.1(m) 78.2
Choline δ 3.24 (s) 56.9
β-glucose δ 4.58 (d) 98.8
Fructopyranose δ 3.73 (d) 66.6
Sucrose δ 5.40 (d) 95
δ 4.17 (d) 79.8
Malic acid δ 4.34 (dd) 73.4
 δ 2.74 (dd) 44.7
δ 2.68 (dd) 44.7
α-glucose δ 5.18 (d) 94.9
Fumaric acid δ 6.56 (s) 138.2
trans-sinapoyl malate δ 7.01 (s) 119.9
chlorogenic acid δ6.97(d) 118.6
δ7.22(d) 122.4
glucobrassinin δ7.33(d) 132.2
δ7.38(t) 130.8
δ7.43(t) 132.2
phenylpropanoid δ 7.74 (d) 121.6
kaempferol δ 7.87 (t) 144.7
adenine δ 8.2 (s) 144.1
δ 8.21 (s) 145.2
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Fig. 6.17 Top: Aliphatic region of CPMG fresh Brocolli acetonitrile extraction.  
Assignments were made using a combination of 2D-NMR experiments and comparison 
with literature sources and authentic standards. A significant peak of SMCSO can be 
seen at δ2.83. Bottom: Phenolic region common plant phenolics including 
unmetabolised glucobrassinin. Unknown phenolics possibly include anthocyanins, 
quercitin compounds, and unknown phenylpropanoids.  
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Fig. 6.18 2D-TOCSY spectrum of fresh broccoli aqueous acetonitrile extraction 
confirming the presence of chlorogenic acid.  
Correlation can be seen between the two doublet peaks at δ6.93 and δ7.2 (arrows). 
Identifications were augmented with 
13
C confirmation. 
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1
H–1H J-resolved spectra proved a useful experiment for deconvolution of the crowded 
areas of the spectrum, reducing complex multiplets to single resonances and separating 
chemical shifts from their respective coupling constants in a two-dimensional plot 
280
.  
 
Complimentary to 
1
H–1H J-resolved spectra, the COSY experiment was utilised to 
understand the relationship between mutual spin-spin couplings and confirm the 
membership of spin systems to a particular molecule. The COSY experiment was 
further augmented by the TOCSY pulse sequence which showed spin systems of 
coupled protons within the same molecule over a greater distance. 
 
The combination of HMBC and HSQC heteronuclear spectroscopy proved very useful 
for both identification of unknowns within the phenolic region and more importantly for 
the identification of SMCSO within the plant extracts (table 6.5). The typical singlet 
resonance of the methyl group of SMCSO at δ2.83 was clearly observed in the 1H-NMR 
spectra of both the broccoli and Brussels‘ sprouts vegetable extracts. This corresponded 
to one of the four similarly shifted unknown singlet resonances observed in the human 
urine following CV consumption.  
 
Comparison of HSQC spectra of both the vegetable extractions and human urine 
demonstrated the similarity in 
13C of δ40.2 of the singlet at δ2.83 in the vegetable 
extract, not only to the unknown singlet in urine but also to the other three unknown 
singlets in the human urine (Fig. 6.19). This finding was enhanced using HMBC 
experimentation which gave long range correlations between the 
13
C identified by 
HSQC with another 
13C within the same molecule at δ55.7. Comparison of the HMBC 
experiments of the vegetable extracts and human urine revealed the same 
13
C chemical 
shift of δ55.7 for the singlet peak δ2.83 in human urine (Fig. 6.19).  
 
However the other four unknown singlet resonances observed in the high CV 
consumption urine showed slight chemical shift variation in this long range 
13
C 
resonance δ2.81 (δ60.5), δ2.78 (δ60.9), δ2.78 (δ63.0). These results suggested that the 
1H NMR singlet peak δ2.83 which statistically discriminates the high CV consumption 
study phase was of exogenous CV derived origin and that structural similarity in the 
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functional group for the 
13
C resonance δ40.2 exists between the four unknown singlet 
resonances. This is most likely due to a strong similarity in the functional group 
responsible for all of the four unknown singlet resonances. It could also be due to the 
presence and varying abundance of diastereoisomers of distinct metabolites. However it 
is known that the L-isomer of SMCSO predominates in nature and not the racemate 
275
. 
The difference in 
13
C shift in the HMBC experiment suggests that the neighbouring 
carbons of each singlet peak is being altered by different R groups adjacent to the 
carbon identified by this long range correlation.  
 
The 
13
C-
1
H heteronuclear experiments provided clear evidence that the four singlet 
resonances are most probably four distinct molecules which are closely related in 
structure. The singlet resonance at δ2.83 is present in both the aqueous vegetable 
extraction and high CV consumption human urine and likely represents unmetabolised 
excretion of a vegetable derived compound. The differences seen in the HMBC 
13
C 
resonances of the four singlet peaks associated with CV consumption could therefore 
potentially be mammalian derived metabolites of the CV derived compound and the 
relatively small differences in both the 
1
H and 
13
C  shifts is due to as yet unidentified R 
groups on each of the other four biomarkers observed in urine. Assuming that δ2.83 
does indeed represent the unmetabolised SMCSO, the four singlet resonances are most 
likely to represent methyl protons adjacent to the sulphoxide group of SMCSO or a 
closely related molecule. Variation in chemical shift of the remaining unknown singlets 
is probably due to different R groups arising from common routes of mammalian 
elimination of methylated sulphur containing amino acids. Principally SMCSO is 
cleaved and enters the urea pool (~50%), but as is common with many amino acids, it is 
also N-acetylated (~30%), and converted to thiopyruvates and thioacetates by the 
process of deamination (~8%) 
276, 277
.  
 
The HMBC experiment confirmed that the unknown singlet at δ2.83 δ40.7 was the 
same compound seen in the aqueous extract of broccoli as the multiple bond coherence 
value was of the same value (δ55.7) in both urine and broccoli. This suggested that the 
metabolite in urine was indeed of plant origin. 
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Fig. 6.19 Top: 
1
H-
13
C HSQC of fresh broccoli acetonitrile extraction; Bottom: 
1
H-
13
C 
HMBC of fresh broccoli acetonitrile extraction.  
1
H and 
13
C shifts match those seen in human urine diagnostic of CV consumption. This 
suggests a CV origin of one of the unknown NMR singlets at δ2.83. Citrate is shown for 
reference purposes 
δ 2.83 δ 40.2
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6.5.2.7 Synthesis of SMCSO and mammalian metabolites 
SMCSO was synthesised by selective oxidation of the sulphur of SMCS authentic 
standard (according to the protocol of Synge RLM et. al. 1954). In order to fully 
characterise this synthetic standard the same 2D NMR experiments were performed on 
the synthetic standard to confirm the identification made in the urine samples. Initially a 
1D standard experiment was performed to monitor the synthesis and the relative 
positions of the singlet peak and ABX spin systems within the spectra. This result was 
augmented using the homonuclear J-resolved spectrum to separate chemical shift from 
scalar couplings, an HSQC experiment to confirm the carbon 13 chemical shifts of the 
carbons from the methyl group singlet, and the two carbons of the ABX spin system. 
This confirmation was further augmented by performing an HMBC experiment to 
identify the long range proton-
13
C couplings and to match these to the NMR 
experiments performed in urine and vegetable extract experiments (Fig. 6.20).  
 
The N-acetylation of SMCSO with acetyl chloride and ice cold NaOH resulted in a 
number of contaminants which complicated the spectra (Fig. 6.21). The reaction of 
acetyl chloride with water results in a highly exothermic reaction producing HCl, acetic 
acid and sodium acetate. There was also the formation of NaCl and evidence of the 
presence of some of the solvents used within the reaction such as ethanol, chloroform 
and hexane in spite of lyophilising the synthesis by freeze drying prior to 
1
H NMR 
acquisition. The salt content of the synthesis proved challenging for the acquisition of 
good quality spectra as a high concentration of monovalent ions can affect probe tuning 
and sensitivity, an increased pulse length is required leading to a smaller bandwidth of 
excitation and can lead to a reduction in the homogeneity of the applied pulse with 
molecules in the centre of the sample experiencing a weaker RF-field.  
 
An attempt to lyophilise again under high temperature, low pressure conditions (60ºC) 
in a speedvac to remove solvent contaminants, followed by reconstitution in 50:50 
H2O:acetonitrile and an SPE using an acetonitrile gradient, succeeded in removing 
solvent but failed to desalt. Following the SPE, the concentration of N-acetyl-SMCSO 
in all fractions was unfortunately reduced below NMR detection limits required for two 
dimensional NMR experimentation.  
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The presence of contaminants was surmounted by performing the two dimensional 
NMR experiments, J-res, COSY, HSQC and HMBC. The presence of the singlet peak 
at δ2.78 was confirmed with the correct 13C shift of δ 40.2 and the 13C shift of the ABX 
spin system at δ3.1 of δ61.7 (Fig. 6.22). The HMBC experiment also confirmed the 13C 
shift of the NAc-SMCSO methyl group of δ61.1. In the absence of an authentic NAc-
SMCSO standard, the two dimensional NMR evidence presents confirmation of identity 
but is by no means conclusive. According to 
277
, the majority of SMCSO is cleaved to 
form urea and inorganic sulphate (~50%) the majority of which occurs in the first 24hrs 
(~59%) with a complete recovery within 14 days (~96%). Since the human volunteers 
in the CVs study consumed 500 g of CV per day, their intake of SMCSO was estimated 
to in the order of 218 mg per day 
4
. A change in excretion of urea in the human 
volunteer study would be difficult to detect assuming the subjects were consuming only 
~218mg of SMCSO a day.  
 
The next major route of metabolism is by N-acetylation (~30%), followed by 
unmetabolised excretion (~12%) and by deamination (8%). The height and significance 
of the peak for NAc-SMCSO at δ2.78, when compared to the peak at δ2.83 for 
unmetabolised SMCSO, is compatible with N-acetylation being the primary route of 
excretion of SMCSO. 
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Fig. 6.20 400MHz 1D-NOESY of SMCSO synthetic standard spiked into Phase I 
predose urine.  
AB protons can be seen at δ3.32 and the corresponding X proton at δ4.3.  
Inset: 400MHz 
1
H-
13
C HSQC of SMCSO synthetic standard the methyl proton singlet at 
δ2.83 13C δ40.2 matches the chemical shifts observed in both CV aqueous extracts and 
within human urine as a biomarker of CV consumption.   
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Fig. 6.21  400MHz 1D-NOESY of NAc-SMCSO synthetic standard.  
Levels of salts affected acquisition and other solvent contaminants confounded 
interpretation of the NMR spectrum. Unreacted SMCSO can be seen as can an overlap 
of the singlet at δ2.78. 
δ 2.76
δ 2.78
δ 2.83
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Fig. 6.22 Top right: 400MHz 
1
H-
13
C HSQC of NAc-SMCSO synthetic standard;  
the methyl proton singlet at δ2.78 13C δ40.2 matches the chemical shifts observed 
within the CV biomarker in human urine.  
Bottom right: 400MHz 
1
H-
13
C HMBC of NAc-SMCSO synthetic standard. The methyl 
proton singlet at δ2.78 13C δ61.2 matches the chemical shifts of the long range 13C of 
the unknown singlet δ2.78 in human urine.  
δ 2.78 δ40.2
δ 2.76
δ 2.78
δ 2.83
δ 2.78 δ61.2
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6.5.3 Effect of meat consumption on human urinary metabolic profile. 
6.5.3.1 PCA and PLS-DA analysis 
To attempt to model a metabolic trajectory following meat meal and caffeine 
consumption PCA modelling was performed on unit variance scaled data of all study 
phases. This included all time-points pre-dose, 0-10 h.p.d, 10-24 h.p.d and 24 h.p.d. 
urine samples.  Analysis of the scores plot revealed a clustering of the 0-10 h.p.d. dose 
group and some clustering could be seen based upon other timepoints (Fig. 6.23). 
Loadings attributable to dietary time-point were widely scattered and therefore it was 
difficult to extract urinary metabolite changes responsible for the grouping seen in the 
scores plot along the second principal component.  
 
Enhancement of separation was attempted using PLS-DA modelling which achieved 
improved separation between all dietary time-points in the first two PLS-DA 
components (Fig 6.24). Validation of the PLS-DA model showed that using two PLS-
DA components it was possible to predict red meat meal consumption with 41% of 
these predictions being significant at the 99% confidence interval. Analysis of the PLS-
DA loadings plot revealed variables corresponding to the urinary metabolites, carnitine, 
taurine, glycine, alanine, and histidine responsible for discrimination between the 0-10 
h.p.d and the other time points and hippurate and TMAO discriminatory of the 10-24 
h.p.d. timepoint. This was suggestive of a metabolic trajectory of the meat meal over the 
48 hour time course with evidence of bacterial co-metabolites in the  10-24 h.p.d.   
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Fig. 6.23 Scores maps showing t[1]/t[2] PCA scores (Q
2
: 0.37 R
2
: 0.46) from the 
1
H-
NMR spectra (Unit Variance scaled) of all study phases showing clustering of samples 
based upon time-point. 
-160
-140
-120
-100
-80
-60
-40
-20
0
20
40
60
80
-100 0 100
predose
0-10 h.p.d.
10-24 h.p.d.
24-48 h.p.d.
 202 
 
 
Fig. 6.24 Scores maps showing t[1]/t[2] PLS-DA scores (Q
2
: 0.41 R
2
: 0.49) from the 
1
H-NMR spectra (Unit Variance scaled) of all study phases showing clustering of 
samples based upon time-point.  
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6.5.3.2 Time course pair wise O-PLS-DA 
In order to further improve the observed separation in the PCA and PLS-DA models of 
all phases, O-PLS-DA was applied to produce a regression model to distinguish 
sequential timepoints within each individual study phase. This described the maximum 
separation between each timepoint. The loadings revealed marked time-course 
differences between pre-dose urine samples and all time points following meat 
consumption and caffeine intake.   Many metabolites could be very clearly established 
as being postprandial markers of meat consumption (Fig. 6.25). Pre-dose urine samples 
were characterised by higher urinary concentrations of hippurate, DMA and N-
acetylcysteine. Major differences following meat consumption in the 0-10 hours urine 
collection were increased excretion of creatine, creatinine, carnitine, taurine, N-acetyl-5-
hydroxytryptamine, 1- 3- methylhistidine, acetylcarnitine, carnosine and several other 
amino acids; glycine, glutamine, alanine, threonine and histidine. Ten to twenty four 
hours following meat consumption and caffeine intake, urinary excretion of bacterial 
co-metabolites TMAO, p-cresol sulphate, phenylacetylglutamine and to a lesser extent 
hippurate increased (Fig. 6.26). However the excretory levels of the metabolites 
identified in the 0-10 hours urine collection are all significantly decreased in the O-PLS-
DA model. After twenty four to forty eight hours post meat consumption and caffeine 
intake, urinary excretion of phenylacetylglutamine and TMAO decreased. 
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Fig. 6.25 Effect of red meat consumption on urinary metabolite profile.  
Time course pair-wise O-PLS-DA Loadings plot in the aliphatic region of the spectrum 
showing clear statistical significance of amino acid metabolites characteristic of the 0-
10 h.p.d time point following red meat consumption. The model shows excellent 
predictive strength and fit with a Q
2Ŷ: 0.8 and R2Ŷ: 0.95.  
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Fig. 6.26 Effect of meat consumption on urinary metabolite profile.  
Time course pair-wise O-PLS-DA Loadings plot in the aromatic region of the spectrum 
showing significance of bacterially derived co-metabolites in the 10-24 h.p.d time point 
following red meat consumption.  
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STOCSY analysis of the triplet of phenylacetylglutamine at δ7.36 revealed a correlation 
with not only itself but also with p-cresol sulphate, and to a lesser extent p-
hydroxyphenylacetate and hippurate. This statistical correlation supports the gut 
microbial origin of these aromatic compounds based on the strong statistical 
correlations observed. (Fig.  6.27).   
 
Fig. 6.27 STOCSY analysis of the triplet peak of phenylacetylglutamine δ7.36  
demonstrating statistical relationships of bacterial co-metabolites in the phenolic region 
of the spectrum identified in the time-course O-PLS-DA.  
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6.5.3.3 Effect of cruciferous vegetable dietary intervention on meat and 
caffeine alterations of metabotype. 
To examine the effect of CV consumption on meat and caffeine alterations of 
metabotype, pair-wise O-PLS-DA of each time point in each phase was performed. The 
dominant metabolite influencing separation of phase II with both phase I and III at all 
time points was consistently the characteristic singlet resonances associated with CV 
consumption (previously described). However following meat and caffeine 
consumption, increased urinary excretion of mannitol was shown to discriminate phase 
I 0-10 h.p.d from both phase II 0-10 h.p.d. and phase III 0-10 h.p.d.. This was also seen 
to a lesser extent to discriminate later time points in phase I from both phase II and III.  
Mannitol was confirmed by STOCSY analysis and from NMR databases of standard 
compounds. The splitting pattern, as observed in the O-PLS-DA coefficient plot and the 
raw spectra, was clearly attributable to mannitol (Fig. 6.28).  Time course overlay NMR 
spectra identified the presence of mannitol in all phases and time points.  The 
appearance of mannitol in the spectra was not anticipated, but has been previously 
reported as attributable to evidence of non-compliance due to consumption of chewing 
gum containing this sweetener 
96
. 
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Fig. 6.28  Expanded O-PLS-DA showing the characteristic splitting pattern of mannitol 
characteristic of the Phase I 0-10hrs time point.  
The presence of this metabolite was not anticipated and its significance in characterising 
the post meat meal/caffeine time point between the study phases is difficult to account 
for.  
Red: atom 2, blue: atom 3, green:atom 5. Two doublets attributable to atom 2 can be 
seen, a multiplet attributable to atom 5 and a doublet attributable to atom 3. Protons on 
atoms 7, 9 and 11 are symmetrically magnetically equivalent to 2, 3 and 5. 
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6.5.4 UPLC-MS biomarker identification 
6.5.4.1 MarkerLynx PCA analysis 
Evaluation of the UPLC-Mass Spectrometric data set was initially undertaken with a 
chemometric approach using the MarkerLynx software (Waters MS Technologies, 
Manchester, UK). MarkerLynx generates a PCA plot of the MS data where the 
intensities of peaks within a spectrum are reduced from multidimensional space to a two 
dimensional plot in order to visualise any clustering of points which may help to explain 
the variation within the data and to hopefully identify differences between the sample 
classes (Fig. 6.29). The data set was also reduced to a more manageable size, 
specifically to the 0-6 min fraction of the UPLC gradient, which usually contains more 
pertinent metabolic information than later fractions. The PCA analyses of the positive 
and negative ion mode data sets utilising in turn, pareto, mean centred and unit variance 
scaling unfortunately failed to identify any unsupervised chemometric clustering of the 
data and inter-sample variability proved to be more significant than any separations 
based on class.  
 
Fig. 6.29 Markerlynx PCA scores plot of positive mode UPLC-MS data. No underlying 
clustering of subjects within the data can be seen when observing variance in the X 
matrix of the 0-6mins retention time subset. There is evidence of a cluster of outlying 
samples (ringed) which represent a range of different subjects and sample classes. 
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6.5.4.2 Masslynx targeted analysis 
Further to the statistical analysis a targeted approach was also conducted which has 
been used previously in toxicology/ drug metabolism studies in rats 
281-283
.  A list of 
potential metabolites of interest was generated (Table. 6.6.). CV candidate molecules 
were selected based on the glucosinolates, isothiocyanates and their associated 
metabolites (inc. the mercapturates) from the literature. Post prandial biomarkers were 
selected based on the NMR findings and included meat meal metabolites (amino acids, 
bacterial co-metabolites), caffeine metabolites and the metabolites of the red meat 
carcinogens PhIP and MeIQx.  All of the potential metabolites of interest were profiled 
in both positive and negative modes. 
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Table. 6.6 Candidate metabolites of CV consumption generated by consideration of 
biological plausibility ranked by molecular weight including expected m/z of parent ion 
in both positive and negative modes. 
Candidate compound MW Neg mode Pos mode
4-Methoxyglucobrassicin 478.49 477.49 479.49
Neoglucobrassicin 478.49 477.49 479.49
Glucobrassicin 448.46 447.46 449.46
Glucoraphanin 436.49 435.49 437.49
Gluconasturtiin 423.45 422.45 424.45
Glucoiberin 422.47 421.47 423.47
Glucoibervirin 406.48 405.48 407.48
Progoitrin 388.39 387.39 389.39
5,6,11,12,17,18-hexahydrocyclononatriindole (CTr) 387.47 386.47 388.47
Gluconapin 372.39 371.39 373.39
Sinigrin 358.36 357.36 359.36
SF-NAc 341.28 340.28 342.28
4-Methoxyascorbigen 335.28 334.28 336.28
1-Methoxyascorbigen 335.28 334.28 336.28
IB-NAc 327.26 326.26 328.26
PEITC-Nac 327.24 326.24 328.24
MPITC-Nac 311.26 310.26 312.26
SFN-NAc 309.22 308.22 310.22
Ascorbigen 305.28 304.28 306.28
IBN-Nac 295.19 294.19 296.19
PEN-Nac 295.17 294.17 296.17
MPN-Nac 278.26 277.26 279.26
BITC-Nac 277.18 276.18 278.18
BTC-Nac 277.18 276.18 278.18
BEN-Nac 277.18 276.18 278.18
3,3'-Di-4-methoxyindolylmethane 276.30 275.30 277.30
3,3'-Di-1-methoxyindolylmethane 276.30 275.30 277.30
4-Methoxybrassinin 266.35 265.35 267.35
1-Methoxybrassinin 266.35 265.35 267.35
AITC-Nac 263.15 262.15 264.15
ATC-Nac 263.15 262.15 264.15
AEN-Nac 263.15 262.15 264.15
indolo(3,2b)carbazole (ICZ) 254.28 253.28 255.28
3,3'-Diindolylmethane 246.30 245.30 247.30
BC-Nac 245.11 244.11 246.11
Brassinin 3-S-methyldithiocarbamoyl aminomethyl indole 236.35 235.35 237.35
AC-Nac 231.08 230.08 232.08
4-Methoxyindole-3-acetonitrile 186.18 185.18 187.18
1-Methoxyindole-3-acetonitrile 186.18 185.18 187.18
sulforaphane 177.28 176.28 178.28
4-Methoxyindole-3-carbinol 177.17 176.17 178.17
1-Methoxyindole-3-carbinol 177.17 176.17 178.17
Iberin 163.26 162.26 164.26
Phenethyl isothiocyanate (PEITC) 163.24 162.24 164.24
Indole-3-acetonitrile 156.18 155.18 157.18
3-(methylthio)propyl-isothiocyanate (radish isothiocyanate) 147.26 146.26 148.26
Indole-3-carbinol 147.17 146.17 148.17
sulforaphane nitrile (5-methylsulfinylpentanenitrile) 145.22 144.22 146.22
Iberin nitrile 131.19 130.19 132.19
3-phenylpropionitrile 131.17 130.17 132.17
Goitrin ((R)-5-vinyl-2-oxazolidinethione) 129.18 128.18 130.18
Iberverin Nitrile 1-cyano-3-(methylthio)propane 114.26 113.26 115.26
Butenyl Isothiocyanate 113.18 112.18 114.18
butenyl thiocyanate 113.18 112.18 114.18
1-cyano-3,4-epithiobutane 113.18 112.18 114.18
Allyl Isothiocyanate 99.15 98.15 100.15
allyl thiocyanate 99.15 98.15 100.15
3,4-epithiobutanenitrile 99.15 98.15 100.15
Crambene (1-cyano-2-hydroxy-3-butene) 97.12 96.12 98.12
Alanine 89.09 88.09 90.09
butenyl cyanide 81.11 80.11 82.11
Allyl cyanide 67.08 66.08 68.08
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To determine the presence/absence of these various classes of metabolites, ions of the 
correct m/z were extracted from pre- and post-dose samples (where dose refers to CV or 
meat or caffeine). For example a comparison of extracted ion chromatograms (EICs) for 
sulforaphane-mercapturic acid would compare phase I pre-dose urine to phase II pre-
dose urine samples in an individual. Peaks occurring only in phase II pre-dose urine 
samples could be considered to be relevant to the consumption of CV. Peaks that 
consistently appeared in the post dose samples were considered to potentially contain 
metabolites of interest (Fig. 6.30). EIC peaks were integrated for each sample in every 
time-point and phase.  The relative integrals for each peak were then averaged and used 
to plot a bar chart showing a semi-quantitative overview of the excretion of the 
metabolite (Fig. 6.31). The relative integrals for each subject phase and time-point were 
adjusted for urinary volume.  The standard deviation for each metabolite was also 
calculated for every time-point and phase. It should be stressed that the identification of 
these potential metabolites is based upon appropriate molecular ion and biological 
plausibility. 
 
Potential metabolites for which there was a consistent extracted ion peak in the post 
dose time point/ phase included sulforaphane-NAc, allyl Isothiocyanate-NAc, caffeine, 
paraxanthine/theobromine/theophylline, 5-acetylamino-6-formylamino-3-methyluracil 
(AFMU). Signals indicative of tyrosine/mannitol/1-methylxanthine/ 7-methylxanthine, 
had similar MW and retention time and were therefore indistinguishable. The putative 
biomarkers also demonstrated evidence of time-course excretion profiles. The excretion 
of one of the potential metabolites of caffeine paraxanthine/theobromine/theophylline in 
particular demonstrated this over the 48 hours of urine sample collection throughout all 
phases of the study. 
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Fig. 6.30 Raw UPLC-MS total ion chromatograms (TICs) in positive mode for subject 
12 for both phase I and II predose urine samples.  
Comparison of extracted ion chromatograms in both Phase I and II predose samples 
showed a consistent peak at 4.32mins retention time. This can be considered a 
chromatographic peak diagnostic of Phase II predose urine samples. In this case the m/z 
263.1 (A & B) is the expected parent ion of allyl isothiocyanate-NAc cysteine 
conjugate. 
A=Extracted ion chromatogram for m/z 263.1   subject 12 phase II pre-dose urine. 
B=Extracted ion chromatogram for m/z 263.1   subject 12 phase I pre-dose urine;  
C=Chromatogram: Total ion count subject 12 phase II predose urine (high CV); 
D=Chromatogram: Total ion count subject 12 phase I predose urine (restricted CV);
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Fig. 6.31 Top: Semi-quantification of the relative integrals of 263.1m/z tentatively 
identified as allyl-isothiocyanate-mercapturate a known biomarker of CV consumption. 
Figure demonstrates a time-course excretory profile adjusted for urinary volume.  
Bottom: Time course excretory profile for of one of the potential metabolites of caffeine  
paraxanthine/theobromine/theophylline over the 48 hours of urine sample collection 
throughout all phases of the study. 
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6.5.4.3 XCMS
1
 statistical analysis 
The acquired UPLC-MS chromatograms were additionally evaluated using XCMS
1
 
157
. 
This programme performs peak picking in an automated and unbiased way. The 
programme uses the common MS netCDF file format that enables data export from any 
instrument platform. In this case the Waters LCT premier data (*.raw) files were 
converted to netCDF (*.cdf) using the databridge programme. Chromatograms were 
separated into their 12 separate sample classes for XCMS
1
 processing, via Phase I 
predose, 0-10hrs, 10-24hrs, 24-48hrs, Phase II predose, 0-10hrs, 10-24hrs, 24-48hrs, 
Phase III predose, 0-10hrs, 10-24hrs, 24-48hrs. Following file conversion the XCMS
1
 
parameters for the R language were entered into an automation script. The XCMS
1
 
group bandwidth was set to 60, the Extracted Ion Chromatogram maximum was set to 
250 and the width of overlapping m/z values was set to 0.5. All experimental iterations 
were performed on both the UPLC-MS positive and negative mode data sets 
(experimental iterations summarised in Table. 6.7.). XCMS
1
 utilises hundreds of 
endogenous metabolites as standards and calculates a non-linear retention time 
correction profile for each sample. 
 
Table. 6.7 Experimental iterations addressing primary study aims. All pair-wise 
comparisons were examined using the XCMS software on both the positive and 
negative UPLC-MS datasets. 
 
Experimental Iteration
Effect of CV consumption on metabotype
Phase I predose vs. Phase II predose
Phase II predose vs. Phase III predose
Effect of meat meal and caffeine on metabotype
Phase I predose vs. Phase I 0-10 h.p.d.
Phase III predose vs. Phase III 0-10 h.p.d.
Effect of CV on meat meal and caffeine  alterations of metabotype
Phase I 0-10 h.p.d. vs. Phase II 0-10 h.p.d.
Phase II 0-10 h.p.d. vs. Phase III 0-10 h.p.d.
Phase II predose vs. Phase II 0-10 h.p.d.
1H NMR unknowns O-PLS-DA
Urine
1H ppm splitting pattern HSQC HMBC
2.83 singlet 40.7 55.7
2.81 singlet 40.1 60.5
2.78 singlet 40.2 61.1
2.75 singlet 39.6 63.1
3.32 ABX 60.5 39.5 57
3.28 ABX 62.1 40.2 69.6
3.1 ABX 61.7 69.2 180.1
3.12 ABX 47.8 55.1
3.156 ABX 44.4 59.8
4.38 doublet of doublets 69.1 180.7
Broccolli extract
1H ppm splitting pattern HSQC HMBC
2.83 singlet 40.7 55.7 50.1
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Following processing and peak picking, mass spectral features were retrieved as a report 
in a text file which was imported into excel. The report provides a list of extracted ion 
chromatograms from lowest to highest p-value; it also provides ANOVA, t statistics, 
fold change between m/z intensities and the number of peaks in the raw chromatograms 
containing the feature of interest. 
 
The XCMS
1
 programme has proven successful in identifying significant mass spectral 
biomarkers of CV consumption.  As part of the experimental report XCMS
1
 provides 
extracted ion chromatograms (EIC) showing the significant discriminators between 
classes of comparisons which are ordered according to P statistics (from t-test) and their 
corresponding box and whisker plots visually describe the standard deviation, error, 
mean and median values for each EIC. The p-values indicate the statistical significance 
and the fold change of this feature from the baseline. 
 
Comparison of the Phase I predose vs. Phase II predose sample classes was processed in 
XCMS
1
 in positive mode. Chromatograms of 11 urine samples from the Phase I predose 
and 13 urine samples from the Phase II predose were obtained from the experimental 
comparison in XCMS
1
; six significant features were identified and of these M411T155, 
M263T260 and M357T229 (where M refers to m/z ratio and T to retention time in 
seconds) can be considered unique to Phase II and therefore CV consumption (Table. 
6.8). The other 3 represent significant statistical up-regulation within Phase II. 
Depending on the performance of the XCMS
1
 peak picking algorithm, and assuming 
there was relatively low chromatographic drift between samples within the limits of the 
XCMS
1
 alignment algorithm, features identified represent m/z values and retention 
times that differ from background noise and are therefore potential biomarkers of CV 
consumption. Peak selection problems can occur during the XCMS
1
 peak alignment 
procedure, due to retention drifts between samples and overlapping or wrongly aligned 
peaks with similar m/z and can cause the peak picking algorithm to fail. This was 
problematical with the Phase II predose vs. Phase II 0-10hrs and Phase I 0-10 hrs vs. 
Phase II 0-10 hrs experiments in the positive mode data and comparison of Phase I 
predose vs. 0-10hrs and Phase III predose vs. 0-10hrs in negative mode. Unfortunately 
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in both positive and negative modes the XCMS
1
 algorithm failed to identify any 
significant features associated with CV alterations of meat and caffeine metabolism. 
 
Table. 6.8 Effect of CV consumption on metabotype. Phase I predose vs. Phase II 
predose urine samples experimental iteration.  
Table shows the top 6 most statistically significant XCMS
1
 features (m/z and retention 
time in seconds) in positive mode ranked by p-value and showing fold change from 
baseline. 
 
 
 
An example of an EIC and box and whisker plot can be seen in Fig. 6.32. This 
significant feature; m/z 449.1 and retention time 173 seconds; represents the most 
statistically significant (based on p-value: 4.51E-07) biomarker of CV consumption in 
the negative mode dataset. 
The EIC presents the alignment and peak intensity of the raw chromatograms. There 
was a fold increase of 8.18 from the baseline in the Phase II pre-dose urine samples and 
this is highlighted by a significant upregulation of this feature in the phase II predose 
urine samples. There is also evidence of time-dependent reduction in excretion of this 
feature in the phase II urine samples with evidence of excretion in the 0-10 h.p.d. and 
10-24 h.p.d. urine samples which can be seen in the box and whisker plot with a visual 
representation of the standard deviation, error, mean and median values. 
  
UPLC-MS XCMS component
statistical significance (p value) m/z retention time (seconds) fold change from baseline
1.31E-06 277.1 77 8.2
1.84E-05 337.1 148 12.1
4.71E-04 411.1 155 8.1
0.00226 263.1 260 70
0.00239 357.1 229 3.5
0.0164 488.1 318 6.6
UPLC-MS-XCMS component Fold Change P value
M277T77 8.2 1.31E-06
M337T148 12.1 1.84E-05
M411T155 8.1 0.00047169
M263T260 70 0.002267304
M357T229 3.5 0.002394643
M488T318 6.6 0.016462155
 218 
 
 
 
Fig. 6.32 Example of an Extracted Ion Chromatograms (EIC) (A) and box and whisker 
plot (B) of significant feature; m/z 449.1 retention time 173 seconds;  
taken from the XCMS
1
 comparison of Phase I pre-dose vs. Phase II pre-dose urine 
samples in negative mode. This represents the most statistically significant biomarker 
based on p-value: 4.51E-07) of CV consumption. Red ringed box demonstrates 
significant up-regulation of this feature in the phase II predose samples 
A
Phase I predose vs Phase II predose significant features
EIC number name fold tstat pvalue anova mzmed mzmin mzmax rtmed rtmin rtmax npeaks
1 M449T173 10.91999 12.09921 3.67E-07 7.12E-56 449.1192 449.0647 449.1545 173.1314 171.6173 173.624 13
0-10 10-24 24-48 pre
PHASE IIIPHASE I PHASE II
0-10 10-24 24-48 pre0-10 10-24 24-48 pre
Time-point
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The presence and correct retention time of these extracted molecular ions was therefore 
manually confirmed within the raw chromatograms.  The relative ion intensities of each 
metabolite were compared to reveal differences and highlight potential biomarkers.   
 
Analysis of the positive and negative mode chromatograms revealed a total of 10 
statistically relevant putative biomarkers in the positive mode and 11 putative 
biomarkers in the negative mode data associated with CV dietary intervention based on 
their m/z ratio and retention time (Table. 6.9). The features represent either complete 
exclusivity to the CV vegetable consumption sample class or significant statistical up 
regulation within the class.  
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Table. 6.9 Showing statistically significant Extracted Ion Chromatograms (EICs) 
generated by the XCMS
1
 algorithm from the UPLC-MS data in both positive (10) and 
negative modes (11) which discriminate the high CV from the restricted CV dietary 
phases.   
Features are ordered by statistical significance (p-value). 
 
 
However, similarities have been observed in expected m/z ratio of the parent ions of 
known constituents/metabolites of CV vegetables and of putative biomarkers. Standard 
compounds acquisition was limited by financial considerations but many biologically 
plausible metabolites were acquired for each significant MS feature. De novo metabolite 
identification is challenging and was unfortunately beyond the scope of this thesis, 
Positive Mode XCMS significant features
M/z Retention time (sec) Fold Change P -value Experimental Iteration
277.1 77 8.26 1.31E-06 PIpre vs PIIpre
175.1 34 5.60 7.95E-06 PIIpre vs PIIIpre
337.1 148 12.14 1.84E-05 PIpre vs PIIpre
411.1 155 8.19 4.72E-04 PIpre vs PIIpre
210.1 55 1.90 5.39E-04 PIIpre vs PIIIpre
420.1 224 5.00 8.82E-04 PIIpre vs PIIIpre
132.1 33 5.40 1.10E-03 PIIpre vs PIIIpre
263.1 260 70.07 2.26E-03 PIpre vs PIIpre
357.1 229 3.57 2.39E-03 PIIpre vs PIIIpre
315.1 146 7.30 3.84E-03 PIIpre vs PIIIpre
488.1 318 6.63 0.0164 PIpre vs PIIIpre
Negative Mode XCMS significant features
M/z Retention time (sec) Fold Change P -value Experimental iteration
449.1 173 8.18 4.51E-07 PIpre vs PIIpre
259.1 172 22.66 1.07E-06 PIpre vs PIIpre
303.1 37 9.15 3.91E-06 PIpre vs PIIpre
275.1 77 17.44 6.34E-06 PIpre vs PIIpre
165.1 98 12.86 1.22E-05 PIpre vs PIIpre
211.1 98 5.79 5.27E-05 PIIpre vs PIIIpre
285.1 115 15.37 1.75E-04 PIpre vs PIIpre
151.1 37 8.93 2.32E-04 PI 0-10 vs PII 0-10
251.1 226 15.77 8.51E-04 PIpre vs PIIpre
261.1 262 8.79 2.71E-03 PIpre vs PIIpre
267.1 162 8.20 8.47E-03 PIpre vs PIIpre
 221 
 
however these routines have discovered spectral features associated with CV 
consumption. 
6.5.4.4 MS/MS fragmentation analysis of XCMS chromatographic features 
The most significant features identified by XCMS
1
 in human urine were characterised 
using MS/MS fragmentation analysis and initially the online MS/MS fragmentation 
databases such as Metlin (Scripps) and the human metabolome database (Hmdb, 
Genome Alberta) were utilised to attempt to identify the observed fragmentation 
patterns. 
  
MS/MS fragmentation analysis of the significant features identified by XCMS
1
 was 
obtained at a variety of collision energies to give high, medium and low energy 
fragmentation patterns, whilst retaining the parent molecular ion at lower ionisation 
energies. MS/MS fragmentation was performed using voltage ramping between 10-50v 
for each of the 19 significant MS features putatively identified in human urine in 
positive mode and for the 11 significant features positively identified in negative mode. 
The major fragments were tabulated and common mass losses were identified. An 
example is shown of XCMS
1
 spectral features diagnostic of meat and caffeine 
intervention in the positive mode subjected to tandem MS/MS fragmentation analysis 
(10-50V voltage ramp) (Table 6.10).  The major fragments produced at 10V, 30V and 
50V ionisation energies were tabulated; these were used for comparison to online 
tandem MS/MS metabonomic databases and standard compound fragmentation 
patterns. 
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Table. 6.10 Major MS/MS fragments of urinary XCMS
1
 features discriminatory of 
meat and caffeine intervention in positive mode (10-50V voltage ramp). 
Significant XCMS features positive mode
Meat and caffeine intervention ms/ms major fragments
m/z Retention time (sec) Fold Change P -value XCMS experiment 10v 30V 50V
299.1 56 5.82 2.00E-06 PI pre vs PI 0-10h 281.99 247.94 156.04
262.96 237.01 126.05
253.1 217.09 110.08
182.05 156.06
156.07 126.05
126.05 110.07
309.1 82 3.32 4.85E-06 PI pre vs PI 0-10h 292 277.2 263.11
277.2 271.25 154.05
271.18 263.1 110.08
263.09 223.97
201.95 201.95
156.07
142.95
122.1
110.08
413.1 192 3.55 3.09E-05 PI pre vs PI 0-10h 281.09 281.09 285.12
239.09
162.04
136.05
120.2
302.1 62 4.29 4.10E-05 PI pre vs PI 0-10h 232.9 269.08 186.93
164.92 227.1 164.92
143.03 186.9 143.05
126.06 171.06 126.05
106.95 164.92 86.05
143.05
126.05
114.06
106.95
565.1 155 5.11 5.00E-05 PI pre vs PI 0-10h 549.22 520.05 low ion count
539.21 485.05
404.01 390.02
302.02
279.13
558.1 317 3.74 1.94E-04 PI pre vs PI 0-10h 463.17 543.32 383.18
392.06 476.88 343.12
349.2 425.28
303.15 363.15
274.13 347.15
79 202.58
127.09
102.02
186.1 50 12.88 2.32E-06 PIII pre vs PIII 0-10h 169.03 169.04 84.08
144.02 144.06 98.97
130.05 140.07
126.07 130.05
99.97 126.07
84.95 114.01
101.97
99.97
84.08
205.1 42 6.00 2.86E-06 PIII pre vs PIII 0-10h 145.04 191.04 144.09
125.03 145.08 85.05
85.04 125.05
107.08
85.02
168.1 201 31.04 2.92E-06 PIII pre vs PIII 0-10h 153.09 153.09 153.09
128.96 128.95 138.06
96.97 96.96 113.01
90.21 86 110.96
86.05 84.1 98.02
96.96
89.93
85.98
70.95
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The most promising XCMS
1
 feature suggestive of the 
1
H-NMR findings at 151.1m/z 
negative mode was the correct m/z to potentially be the deanimated thiolactate of 
SMCSO; 3-methylthiolactic acid sulphoxide. MS/MS fragmentation of this unknown 
biomarker produced a fragmentation pattern similar to SMCS according to an 
experimental low energy fragmentation on the human metabolome database (Fig. 6.33). 
This XCMS
1
 significant feature also shows evidence of increasing excretory 
concentration in the negative mode when comparing phase I to phase II. Therefore 
perhaps there is an effect of CV consumption on level of excretion of this metabolite 
which could possibly be 3-methylthiolactic acid. Furthermore XCMS
1
 peak picked a 
significant feature 303.1m/z which, following fragmentation using a 10-30v voltage 
ramp, proved to be a dimer formation of 151.1m/z within the ion source. However, in 
the absence of an authentic standard or ease of synthesis, these identities were not 
confirmed. 
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Fig. 6.33 Top: MS/MS negative mode fragmentation analysis of XCMS
1
 significant 
feature 151.1m/z in human urine associated with CV consumption.  
A 10-40v voltage ramp was used for the fragmentation of this biomarker in urine. A 
putative fragmentation pattern is attempted to address the observed pattern in the 
absence of an authentic standard.  
Bottom: MS/MS negative mode fragmentation analysis of XCMS
1
 significant feature 
303.1m/z. A 10-50v voltage ramp was used for the fragmentation. This is believed to 
represent dimer formation of 151.1m/z in the ionisation source. 
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For example, the feature at 263.1 m/z, retention time 260 secs with a fold change of 
70.07, was associated exclusively with the CV dietary intervention predose urine 
sample. Online database searches on the Metlin database provided 24 matches but these 
were found to have little biological relevance. The Human Metabolome database 
(Hmdb, Genome, Alberta) provided 6 m/z matches which were biologically plausible, 
these included the following adducts; homovanillic acid sulphate (M+H
1+
); 3-
methylindole (2M+H
1+
); sorbitol-6-phosphate (M+H
1+
); L-propyl-L-phenylalanine 
(M+H
1+
); L-phenylalanyl-L-proline (M+H
1+
) and creatine (2M+H
1+
). 
 
Where database experimental fragmentation patterns were available, candidate 
metabolites were eliminated by comparison of fragmentation patterns to the MS/MS 
fragmentation patterns of the features identified in human urine. Based on database 
searches and the self generated candidate metabolites list available authentic standard 
compounds were acquired and dissolved in UPLC-MS grade H2O to a final 
concentration of 100mM.  In total 34 authentic standard compounds in positive mode 
(Table. 6.11) and 31 authentic standard compounds in negative mode were subjected to 
MS/MS fragmentation using the same experimental conditions, elution gradients and 
ionisation parameters (10-50V voltage ramp) as for the metabolites in urine for ease of 
comparison and reproducibility.  
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Table. 6.11 Standard compounds subjected to MS/MS fragmentation analysis (10-50V 
voltage ramp) in positive mode.  
The corresponding XCMS
1
 significant features in urine, fold change from baseline and 
p-values are included. Candidate compounds were generated based on biologically 
plausibility and database searches. Putative adduct formations were obtained from 
Human Metabolome database (Hmdb, Genome, Alberta) are also included.
 
XCMS feature Fold change p- value XCMS exp. Candidates Putative adduct formation (Hmdb)
M277T77 8.26 1.31E-06 PIpreVsPIIpre nicotinamide n-oxide 2M+H(1+)
2-hydroxybenzoic acid 2M+H(1+)
3-hydroxybenzoic acid 2M+H(1+)
M337T148 12.14 1.84E-05 PIpreVsPIIpre 3-hydroxymandelic acid 2M+H(1+)
homogentisic acid 2M+H(1+)
5-methoxysalicylic acid 2M+H(1+)
p-hydroxymandelic acid 2M+H(1+)
pyridoxamine 2M+H(1+)
M263T260 70.07 2.26E-03 PIpreVsPIIpre Homovanillic acid sulfate M+H(1+)
creatine 2M+H (1+)
M299T56 5.82 2.00E-06 PIpreVsPI0-10 homoanserine M+2Na-H(1+)
L-methionine 2M+H(1+)
urocanic acid 2M+Na(1+)
3-hydroxybenzoic acid 2M+Na(1+)
4-hydroxybenzoic acid 2M+Na(1+)
Enkephalin L M+ACN+2H(2+)
n-acetyl putrescine 2M+K(1+)
M310T82 3.32 4.85E-06 PIpreVsPI0-10 picolinic acid 2M+ACN+Na(1+)
nicotinic acid 2M+ACN+Na(1+)
M413T192 3.55 3.09E-05 PIpreVsPI0-10 3-hydroxyhippuric acid 2M+Na(1+)
alpha-hydroxyhippuric acid 2M+Na(1+)
methylisocitric acid 2M+H(1+)
L-Glutamine 2M+NH4(1+)
M302T62 4.29 4.10E-05 PIpreVsPI0-10 1-Methylnicotinamide 2M+3H2O+2H(2+)
Pantothenic acid 2M+2ACN+H(1+)
Tyramine 2M+3H2O+2H(2+)
M558T317 3.74 1.94E-04 PIpreVsPI0-10 Pyridoxal 5'-phosphate 2M+ACN+Na(1+)
M175T34 5.61 7.95E-06 PIIpreVsPIIIpre N-acetylputrescine M+2Na-H(1+)
Arginine M+H(1+)
N-Methyltryptamine M+H(1+)
3-hydroxyphenylacetic acid M+Na(1+)
M210T55 1.93 5.39E-04 PIIpreVsPIIIpre acetylcholine M+ACN+Na(1+)
Sulforaphane M+CH3OH+H(1+)
M420T224 5.83 8.82E-04 PIIpreVsPIIIpre N-acetylglutamic acid 2M+CAN+H(1+)
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Putative biomarkers of CV and meat and caffeine consumption were eliminated by the 
process of tandem MS/MS fragmentation analysis. Unfortunately even the more 
biologically relevant standard compounds were not comparable to the urinary mass 
spectral features by MS/MS fragmentation. The spectral feature m/z 263.1 identified by 
targeted analysis and XCMS
1
 statistical analysis in the positive mode dataset was 
thought to potentially be the N-acetyl-L-cysteine conjugate of the glucosinolate 
hydrolysis product allyl isothiocyanate due to a similarity in expected molecular ion, 
however this was found not to be the case as the standard compound produced a 
different fragmentation to the metabolite identified in urine. The MS/MS fragmentation 
in urine using a 10-50V produced characteristic fragments (m/z 147, 136, 130, 91 and 
84), however the AITC-NAc standard produced characteristic fragments corresponding 
to the NAc and allyl isothiocyanate respectively (m/z 164 and 100).  
 
With exhaustive resources and more comprehensive metabonomics mass spectral 
databases, the identity of the biomarkers identified could be confirmed; however within 
the confines of this study it was not possible. In order to augment the fragmentation 
analysis further standard compounds of interest were also subjected to MS/MS 
fragmentation analysis in both the positive and negative modes. These were compounds 
that did not necessarily match the expected molecular ion m/z of any of the significant 
spectral features identified by XCMS
1
 but were biologically plausible and available 
within the group (Table. 6.12). Furthermore, ion source adduct formation can be 
difficult to predict in urine and significant XCMS
1
 features could have potentially 
represented fragments of urinary metabolites. 
 
Literature searches for molecular ions and common fragments were also conducted and 
the results compiled to aid elucidation of the unknown mass spectral features. 
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Table. 6.12 Further candidate compounds of biological plausibility subjected to positive 
mode MS/MS fragmentation analysis (10-50V voltage ramp).  
Major tandem MS/MS fragments were recorded to facilitate similarity comparison with 
urinary spectral features identified by XCMS1 statistical analysis.  
 
 
Other compounds of interest major MS/MS fragments
voltage ramp 10-50V
Glutamine 84,130,147
N-acetylcysteine 76,122,146,164
carnitine 162
Mannitol 211,183,162,147,129,111,85,69
Caffeine 1,3,7-trimethylxanthine 181, 157,140,116,111,100,77
Paraxanthine 162,144,126,116,103,79
5-Acetylamino-6-formylamino-3-methyluracil 185,148,130,118,100,77
xanthine 137
1-methylxanthine 162,144,126,116,103,85
1-methyluric acid 157,140,118,116,111,100,91
chlorogenic acid 195,163,147
1,3,9-trimethylxanthine 185,162,144,126,85
indole-2-methylalcohol 163,148,130,118,111
indole-2-carbonyl acetate 189,144,111,72
indole-2-acetonitrile 185,157,130,111,100
catechin 291,139
Sulforaphane 140,114,79
AITC-Nac conjugate 164, 100
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6.5.4.5 XCMS
2
 analysis 
Whilst XCMS
1
 statistically assesses and ranks features in metabonomic UPLC-MS data, 
no information is provided on structural identity. XCMS
2
 provides an automatic search 
of tandem MS/MS fragmentation data against experimental MS/MS data from 
metabolites contained in the Metlin online database. Search hits are scored based on 
shared peak counts and provide information on shared fragment ions between the 
experimental MS/MS data and reference fragmentation patterns thereby identifying 
unknowns based on their fragmentation patterns. The greatest utility of the software is 
identifying structural similarity of unknowns with reference fragmentation patterns 
using a ‗similarity search‘ algorithm. This algorithm detects possible structural motifs in 
unknown metabolites which might produce characteristic fragment ions and neutral 
losses 
284
.  
 
Comparison of MS/MS data of the UPLC-MS biomarkers identified in urine did not 
result in any 100% search hits on the Metlin database however similarity was seen in 
some fragments and neutral losses (Table. 6.13) Unfortunately, the candidate 
compounds deduced from similarity search of the Metlin database are dominated by 
drug molecules, fatty acids, etc and are unlikely to be relevant here. The Metlin 
database is still in development, with 2175 MS/MS fragmentation patterns available 
presently. This is a time intense process and is slowly being augmented. 
 
The concept of XCMS
2
 is excellent for discovering structural similarity of unknowns 
and holds great future potential. All chromatographic features identified by XCMS
1
 in 
both positive and negative modes were submitted to tandem MS/MS fragmentation 
analysis and then compared to the Metlin database using XCMS
2
. 
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Table. 6.13 Subset of XCMS
2
 similarity search report from the experimental iteration 
of Phase I predose vs. Phase II predose showing the two putative biomarkers of 277.1 
m/z and 263.1m/z.  
The report compares the experimental MS/MS fragmentation data to experimental 
MS/MS data within the Metlin MS/MS database. Similarity is calculated based on m/z, 
retention time and similarity of both common fragments and common neutral losses. As 
can be seen similarity scores of common fragments and neutral losses are given along 
with the name of the compound on the Metlin database where an experimental MS/MS 
fragmentation exists. This experiment can provide more information on potential 
structures for unknown mass spectral biomarkers. 
 
 
m/z rtmin rtmax Experiment Collision Energy Fragment Score Neutral Score Common Neutral loss Common Fragment Compound Name Metlin Mass Collision Energy
277.0788 33.586 47.346 30 50 0 42.0457 84.0441 Tolbutamide 277.058639 40
277.1025 80.132 98.07 30 50 0 80.0623 136.076 Neostigmine 222.1368208 40
277.1025 80.132 98.07 30 50 0 27.011 91.054 Oleamide 117.057849 0
277.1025 80.132 98.07 30 50 0 43.971 136.076 Omeprazole 345.114714 0
277.1025 80.132 98.07 30 50 0 110.987 136.076 Sulfadoxine 310.073578 40
277.1025 80.132 98.07 30 50 0 42.0457 84.0441 Tolbutamide 277.058639 40
263.0175 150.555 164.081 30 50 0 0.0005 85.0301 Canrenoate 174.111676 10
263.0783 177.601 191.127 30 50 0 32.9882 91.0542 L-Thyronine 301.167794 10
263.0783 177.601 191.127 30 50 0 27.011 91.054 Oleamide 117.057849 0
263.0379 206.859 222.585 30 0 50 1.007 117.058 1-Acetylindole 159.0684 0
263.0379 206.859 222.585 30 0 100 1.007 131.037 alpha-Estradiol 133.0528 0
263.0379 206.859 222.585 30 50 0 17.026 101.071 Glutamine 146.069143 0
263.0379 206.859 222.585 30 50 0 0.984 101.071 Glutamine 146.069143 10
263.0379 206.859 222.585 30 50 0 32.9882 91.0542 L-Thyronine 301.167794 10
263.0379 206.859 222.585 30 50 0 48.0855 83.0549 Myristic Acid 280.24023 40
263.0379 206.859 222.585 30 50 0 75.9818 95.0132 N-Acetyl-D-galactosamine 194.042655 20
263.0379 206.859 222.585 30 0 50 1.007 43.0187 Norpseudoephedrine 151.099714 20
263.0379 206.859 222.585 30 50 0 27.011 91.054 Oleamide 117.057849 0
263.0379 206.859 222.585 30 0 50 1.007 43.0187 Phenylpropanolamine 151.099714 20
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6.6 Discussion 
6.6.1 S-Methyl-L-cysteine sulphoxide 
CVs are known to contain the sulphur containing phytochemical SMCSO  derived from 
amino acid biosynthesis 
285
. Within the plant tissues it forms 1-2% of the dry weight of 
many varieties of CVs and is therefore ubiquitous and abundant in these vegetables 
286
. 
 
The finding of SMCSO and its N-acetylated mammalian metabolite being diagnostic of 
subjects consuming 500g of CV per day over a period of 12 days is significant as a 
biomarker of consumption of CV. Unfortunately SMCSO is known to occur widely 
within the allium family (also known as methiin) as a plant secondary metabolite and 
component of the sulphur containing amino acid pool 
287
 and one of the reasons garlic 
and other alliums are the subject of investigation as functional foods. It is therefore not 
a plant metabolite exclusively obtained from the broccoli and Brussels sprouts. The fact 
that alliums were restricted during the study period suggests that the compound was 
indeed obtained from the high CV diet in Phase II as it is also found in abundance in 
both Brussels sprouts (~68mg/100g) and broccoli (~19.1mg/100g) and is ubiquitously 
present in vegetables of the family cruciferae.  
 
Evidence exists within the literature of biological activities of this sulphur containing 
amino acid within both in vitro and in vivo animal models. However the level of 
targeted research of SMCSO as an anti-carcinogenic compound appears to be limited 
and it has not been studied as a compound of biological significance in human in vivo 
studies within the context of diet and disease. The statistical significance of SMCSO 
and its N-acetylated metabolite as urinary biomarkers of CV consumption provides 
impetus for further study of the biological role and anti-carcinogenic potential of this 
plant secondary metabolite within humans. 
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6.6.2 Biosynthesis of SMCSO and role within the plant 
The biosynthetic pathway of sulphur containing cysteines within plants has been 
elucidated by chemical analysis and radiolabel feeding studies. These studies reveal an 
origin of SMCSO in plant sulphur metabolism, derived from SO4
2– which is the primary 
source of inorganic sulphur in plants, for the biosynthesis of cysteine, glutathione and 
subsequently SMCSO 
287
. The accumulation of SO4
2– in plant cells occurs in the root, 
where it is initially converted to 5-adenylylsulphate (APS) catalysed by the enzyme 
ATP sulphurylase in plastids. APS is enzymatically converted to an intermediate 
sulphite by APS reductase and finally to a sulphide by sulphide reductase. 
 
Cysteine is then formed by reaction of the sulphide with O-acetylserine by OAS-thiol-
lyase. The cysteine formed is then channelled into protein synthesis pathways and 
numerous plant secondary metabolic pathways. In the case of SMCSO, a methylation 
and oxidation step takes place. 
 
It is known that only the L stereoisomer of SMCSO occurs in nature. SMCSO 
represents the most ubiquitously and in some cases, such as Brussels sprouts, the most 
abundantly found sulphur containing amino acid in both vegetables of the cruciferae 
and alliums.  
 
The biological role of SMCSO and its cysteine-lyase mediated breakdown products 
following tissue disruption, is almost certainly as an antimicrobial, antifungal and 
antiparasitic. Its reactive intermediate products most probably act as enzyme inducers 
and inhibitors following herbivorous attack and mechanical damage. Interestingly, these 
same products appear to be beneficial to human health 
288
. 
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6.6.3 Experimental studies of SMCSO and potential biological roles within 
humans. 
Following mechanical disruption of CV tissue, cysteine sulfoxide lyases break down 
SMCSO into pyruvate, ammonia and methanesulfenic acid (MSI). Dependent on 
conditions the highly reactive methane sulfenic acid intermediate chemically 
disproportionates to a variety of metabolic endpoints, S-methyl methanethiosulfenate 
MMTSO, S-methyl methanethiosulfinate (MMTSI), MSI,  dimethyldisulfide and 
methanethiol 
289
. MMTSO formed from dimerization of methane sulfenic acid and the 
disproportionation of methyl methanethiosulphinate, is regarded as a form of 
phytoalexin which on wounding of the plant tissue prevents bacterial or yeast infections 
(Fig. 6.34.) 
290
. 
 
 
Fig. 6.34 Metabolic schematic demonstrating enzymatic hydrolysis of SMCSO by 
cysteine lyase following CV tissue disruption.  
Dependent on conditions such as pH and vegetable treatment the volatile dimethyl 
disulphide represents the metabolic endpoint by reaction of methane thiol or 
disproportionation of methane methylthiosulphinate (MMTSI). 
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MMTSI contains the thiosulphinate functional group R-S(O)-S-R, a commonality with 
the allicin compound found in garlic which is thoroughly researched and implicated in 
many of the health benefits of alliums found in animal studies. It is thought to be 
responsible for reducing atherosclerosis and fat deposition, normalising the lipoprotein 
balance, decreasing blood pressure, anti-thrombotic effects, anti-inflammatory activities 
and functions as an antioxidant 
287
. It is expected that MMTSI and MMTSO would 
share many of these biological effects and this is reflected by studies in the literature 
that confirm similar beneficial effects. 
 
Oral administration of SMCSO was found to mimic the effects of cabbage extract in 
suppressing hypercholesterolemia by upregulating cholesterol catabolism, namely 
cholesterol 7α-hydroxylase in hepatoma-bearing rats 291. 
 
Studies of the antimicrobial properties of SMCSO were performed against 15 species of 
bacteria and 4 species of yeasts using both cabbage and fermented cabbage (sauerkraut) 
292
. It was found that SMCSO itself and both dimethyl sulphide/dimethyl disulphide had 
a minimum inhibitory concentration (MIC) of 500ppm. It was also found that the 
breakdown products of SMCSO had antimicrobial activity. MMTSI had an MIC 
between 50-200ppm for all bacteria and between 6-10ppm for all species of yeast and 
MMTSO  also had a similar antimicrobial activity with an MIC of  20-100ppm for 
bacteria and between 50-200ppm for species of yeast 
292
. This suggests an antimicrobial 
role of this secondary plant metabolite for both disrupted and pathogenically invaded 
plant tissues and may also be a contributory factor to the beneficial properties of CV 
within the mammalian GI tract. 
 
The nutritional role of SMCSO seems to have been largely studied within Asian 
countries and in the developing world where CVs represent a significant component of 
diet 
291, 293
. These studies focus on upon both CVs and alliums and are motivated by a 
desire to utilise both CV‘s and alliums as functional foods. There is accumulated 
evidence to suggest a significant nutritional role of SMCSO as chemoprotective agent in 
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various aetiologies however these studies are largely in rat models and no in vivo human 
studies exist to confirm the observed beneficial effects 
294, 295
. 
Rats maintained on a hypercholesterolaemic diet which produced high cholesterol levels 
in both the blood plasma and liver showed a marked depression of both plasma and liver 
cholesterol levels particularly LDL and VLDL following addition of SMCSO to this 
diet 
296
. However this was not shown to be the case for other sulphur containing amino 
acids such as SMCS, cysteine, S-methylcysteine and S-methylmethionine which had 
little to no effect on hypercholesterolaemia.  
 
Antidiabetic and antihyperlipidaemic effects attributable to SMCSO have also been 
observed in experimental rats and are comparable to those of antidiabetic drugs 
glibenclamide and insulin and the antilipidaemic drug gugulipid  
293
. Sprague-Dawley 
rats made diabetic with the toxic glucose analogue Alloxan were orally administered 
with a 200mg/kg body weight dose of SMCSO for a 45 day period. This significantly 
reduced blood glucose and lipid levels in both serum and tissues. Also observed was an 
altered activity of liver hexokinase, glucose 6-phosphatase and HMG CoA reductase to 
normal levels. 
 
Lipid profiles in serum and tissues showed a reduced concentration of total cholesterol, 
triglycerides and phospholipids  
294
. Total lipoprotein lipase activity in the adipose 
tissues was also decreased with a subsequent decrease in the free fatty acid levels in 
serum and tissues. Increased excretion of bile acids and sterols was also observed 
following the SMCSO dosing regimen. The results of this study suggested that SMCSO 
causes reduction of endogenous lipogenesis, increased lipid catabolism and excretion of 
bile acids. This is thought to occur by interaction of the cysteine moiety of SMCSO 
inhibiting lipogenic enzymes within the liver as well as increasing activity of 
cholesterol 7α-hydroxylase 293, 294. 
 
It is also known that the reduction of SMCSO contributes to oxidation of the lipogenic 
coenzyme NADPH which may be contributing to the hypolipidaemia observed 
297
. 
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As much of the research focus has been upon the anti-carcinogenic activity of the 
glucosinolates and their hydrolysis products, the contribution of SMCSO to the 
beneficial effects of CV has largely been overlooked. The anti-mutagenic activity of 
SMCSO in isolation has been demonstrated utilising the mouse bone marrow 
micronucleus assay 
295
. ICR mice were treated with the tobacco carcinogen 
benzo[a]pyrene concurrently with SMCSO and its metabolite MMTSO known to form 
as a result of cysteine lyase activity following disruption of the plant cell wall.   
Observation of micronucleated polychromatic erythrocytes (MCPEs) revealed a 
0.5mmol of SMCSO and a 0.05mmol per kg bodyweight dose produced a reduction in 
micronucleus formation of 31% and 33% respectively 
295
. Higher doses of MMTSO 
(0.5mmol and 1.0mmol / kg body weight) however produced severe acute toxicity. This 
suggests that these two plant secondary metabolites of CV could contribute to the 
anticarcinogenic activity along with the hydrolysis products of glucosinolates. 
 
SMCSO has a propensity to form MMTSO under many conditions and would most 
likely occur in mammals. MMTSO can be formed by the action of the CV enzyme 
cysteine lyase in the presence of pyridoxal-5‘-phosphate as a cofactor. There is evidence 
to suggest MMTSO may also be formed by the gut microbiota, as evidence exists in 
ruminants where it was identified as the Kale anaemia cofactor in kale poisoning 
59
. 
Thermal hydrolysis of SMCSO in HCl to MMTSO and DMDS has also been 
demonstrated 
298
. Since SCMSO can readily form the active metabolite MMTSO, even 
without the action of the CV cysteine lyase, it suggests that in the context of this study 
(where the vegetables were microwaved, a cooking process known to disrupt tertiary 
protein structure and inactivate enzymatic activity) the beneficial health effects of 
SCMSO identified in the literature would still be likely to occur.   
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The degree of unsaturation of the sulphur atom in MMTSO may confer the ability to 
affect hepatic phase II enzyme protein expression although this is unclear. The 
nucleophilic centre of the thiosulphinate may also have the ability to scavenge 
electrophilic carcinogenic intermediates and inhibit genotoxic initiation 
295
. 
 
Despite extensive research on the organic sulphur-containing compounds (OSCs) in 
allium, focus has been on whole extracts of garlic and onions and upon the diallyl 
sulphides 
288
. Little research has been performed on SMCSO in isolation but it is 
thought to contribute to the health benefits of both alliums and brassica. However, 
SMCSO is also the only OSC in common between these two groups of vegetables. As 
allium vegetables were restricted in this study, the presence of SMCSO and its N-
acetylated metabolite can be attributable to CV consumption. 
 
On the basis of the statistically discriminating effect of SMCSO and its N-acetylated 
metabolite in human urine on the consumption of CVs and numerous links to beneficial 
health effects of this compound in animal models, it should certainly be considered for 
further study within the context of human in vivo and in  vitro cell studies. The known 
health benefits of CVs are almost certainly in part due to this plant secondary 
metabolite. It is surprising to note that in spite of the evidence of anticarcinogenic, 
antioxidant capacity, antihypercholesterolaemic, hypolipidaemic, antimicrobial and 
antidiabetic effects of SCMSO, this compound has not been more extensively studied in 
isolation especially in humans. This is even more remarkable when considering its 
abundance in both CVs and alliums and comparing the extensive number of 
publications on the glucosinolates and their hydrolysis products and of OSCs in alliums. 
 
MMTSO has also been shown to have a suppressive effect on the mutagen aflatoxin B1 
an indirect-acting carcinogen which induces clastogenic and aneugenic changes in 
mammalian cells 
23
. Aflatoxin B1 chromosome aberrations were observed in rat bone 
marrow cells and were found to be potently suppressed by MMTSO in the range 1-
20mg/kg body weight particularly if injected in a window of two hours before and after 
treatment with aflatoxin B1. MMTSO is thought to exhibit this anti-genotoxic effect by 
modulation of enzymatic sulfhydryl groups. This proposed mechanism of action was 
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identified by a similar effect on aflatoxin B1 induced chromosome aberrations by 
diphenyl disulphide 
23
; which is known to modify sulphydryl groups in proteins. Juices 
of both cabbages and onion were also shown to produce the same effect further 
strengthening the idea that SMCSO is a chemoprotective compound in the human diet 
23
.  
 
Furthermore, MMTSO isolated from cauliflower were also shown to modify the effect 
of azoxymethane on rat colon carcinogenesis upon dietary exposure 
299
. This effect was 
observable on biomarkers of cell proliferation in the rat model. Over the course of five 
weeks, rats were given a 15mg/kg body weight dose of azoxymethane and concurrently 
fed with 5mg/kg body weight MMTSO. This was shown to reduce the occurrence of 
aberrant cryptic foci in the rat colon 
299
. The biomarkers of colonic mucosal ornithine 
decarboxylase activity, silver stained nucleolar organiser regions per nucleus in colonic 
epithelium and polyamine levels in blood were significantly reduced by MMTSO 
inclusion in the diet of the rats. The incidence of intestinal neoplasms in a longer term 
study with azoxymethane was also shown to decrease in a dose dependent manner with 
MMTSO. Further to this study the same investigators co-administered MMTSO with 
sulindac a non-steroidal anti-inflammatory drug in rats 
300
. A synergistic effect of this 
combination was demonstrated in further suppressing aflatoxin B1 induced intestinal 
neoplasms in a long term 52 week study. This further strengthens the potential 
significance of SCMSO and MMTSO in the human diet. 
 
Radiolabelling studies of both SMSC and SMCSO carried out by 
276, 277
 provided 
evidence that no demethylation of either SMCS or SMCSO was observed when humans 
were dosed with known concentrations of either these plant derived amino acids. The 
primary route of excretion was found to be by cleavage to urea and inorganic sulphate 
(~50%), followed by N-acetylation (~30%), excretion of the unmetabolised SMCSO 
(~12%), and by deamination to the pyruvic acid derivative and finally 3-
methylthiolactic acid sulphoxide (~8%) (Fig. 6.35). In the studies presented here, 
1
H-
NMR spectroscopy succeeded in identifying both NAc-SMCSO and unmetabolised 
SMCSO in human urine. It can be reasonably hypothesised that the remaining unknown 
NMR singlets detected in this study may be the products of deamination; 3-
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methythiopyruvic acid sulphoxide and 3-methylthiolactic acid sulphoxide. Without 
absolute quantification, the proportional excretion of the metabolites of SMCSO are 
reflected in the peak heights in the 
1
H-NMR spectra; the dominant singlet peak at δ2.78 
shown to be NAc-SMCSO representing ~30% of SMCSO metabolism and the smaller 
peak at δ2.83 shown to be SMCSO representing ~12% of excreted SMCSO.  
 
Consumption of naturally occurring SMCSO in CV‘s may have an effect on the 
proportions of SMCSO metabolites in human urine compared to ingestion of SMCSO in 
isolation. The dosing of SMCSO or SMCS in a one-shot dosage by gelatine caps 
276, 277
, 
may lead to a rapid absorption and potential saturation of one of the metabolic 
pathways, the relatively slower release of dietary SMCSO obtained by CV consumption 
may have altered the proportions of metabolic endpoints and the rates of excretion. This 
could only be confirmed by quantification of the metabolites in human urine. Whether 
endogenous mammalian biosynthesis of SMCS and SMCSO occurs is unknown. SMCS 
and SMCSO are also not known to be recycled into the free cysteine amino acid pool 
and do not represent a dietary source of cysteine and are purely plant derived 
metabolites. 
 
Only the L-isomer of SMCSO is known to occur in nature, therefore the other two 
unknown peaks identified are unlikely to represent stereo isomers of SMCSO; these are 
most likely related metabolites of SMCSO. 
 
 240 
 
 
Fig.  6.35 Metabolic scheme showing the human metabolism of SMCSO.  
Radiolabelling studies identified urea and inorganic sulphate formation as the primary 
route of excretion (~50%), followed by N-acetylation (~30%), unmetabolised excretion 
(~12%) and finally by deamination (~8%).  Products ringed in solid-red were detected 
in human urine in the present study by 
1
H-NMR spectroscopy. Product ringed in 
dashed-red putatively identified by UPLC-MS analysis. 
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6.6.5. Effect of meat consumption on human urinary metabolic profile. 
Subtle variations in metabotype in human subjects following either a high meat, low 
meat or vegetarian diet have been previously described 
221
. Of particular interest are the 
metabolites, which were shown to be associated with a high meat diet. Many of these 
same metabolites were also observed in this study following consumption of a high-
meat content meal. The subjects in the present study abstained from meat for at least 24 
hrs prior to the meat meal on day 13 and post-prandial biomarkers of meat consumption 
were readily identified.  Alteration of urinary metabolic phenotype therefore occurred 
soon after the meat meal.  They included increased urinary excretion of creatine, 
creatinine, carnitine, taurine, N-acetyl-5-hydroxytryptamine, 1- 3- methylhistidine, 
acetylcarnitine, carnosine and several other amino acids; glycine, glutamine, alanine, 
threonine and histidine.  These meat-derived biomarkers declined in the subsequent 10-
24 hours urine collection. Most of these metabolites including many non-essential 
amino acids and some essential such as histidine and threonine are found in high 
abundance in meat and derive from a variety of metabolic pathways; for example, N-
acetyl-5-hydroxytryptamine produced during tryptophan metabolism.  This is likely to 
be representative of the digestive transit of meat from the higher duodenum and small 
intestine. 
 
Ten to twenty four hours following meat consumption, urinary excretion of TMAO, p-
cresol sulphate, phenylacetylglutamine and to a lesser extent hippurate increased. These 
are all known to be metabolites derived from the human gut microbiota. p-Cresol is 
formed from tyrosine via transamination to p-hydroxyphenylacetate by P.vulgaris then 
decarboxylation by C.difficile and lactobacillus species 
132
. High proportions of 
anaerobic gut microbes such as C.difficile and a depletion of P.vulgaris can indicate 
poor diet and can lead to a build up of p-hydroxyphenylacetate. The increase in urinary 
concentration of bacterial associated metabolites 10-24 hours post meat consumption is 
therefore consistent with gut physiology. The increase in bacterial co-metabolites seen 
in the 10-24 hour urine collection is reflective of tryptophan transamination, glycine 
benzoate conjugation (hippurate) and glutamine acetylation (phenylacetylglutamine) 
further along the digestive transit in the lumen of the lower small intestine and large 
intestine. The 24-48 hour urine collection shows a depletion of these phenolic bacterial 
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co-metabolites.  It has been suggested that the excretion of these metabolites serves as 
an alternative to urea for removal of waste nitrogen 
136
.  
 
In the 10-24 hours urine collection the concentration of TMAO is increased. TMAO is 
known to increase following meat and fish consumption. However TMAO is also 
derived from enteric bacteria from the parent molecule L-carnitine 
301
. The increased 
concentration of TMAO in the 10-24 hours post meat consumption urine suggests that it 
originates from gut microbes especially as it is associated with other microbial co-
metabolites seen in the O-PLS-DA coefficients plot. The temporal dependence of the 
appearance of these metabolites after meat consumption appears to demonstrate the 
series of metabolic events taking place when a meat meal passes through the digestive 
tract. High abundance components of meat are absorbed and excess is eliminated from 
the body by endogenous metabolism. Then after 10-24 hours bacterial co-metabolites 
derived from amino acid metabolism are observed arising from the lower small intestine 
and large intestine. 
 
Hippurate, phenylacetylglutamine and TMAO, all appear to be associated by time-
course O-PLS-DA analysis with 10-24 hours post meat consumption. STOCSY analysis 
of phenylacetylglutamine not only reveals a correlation with self but also with p-cresol 
sulphate and strongly with three unknown doublets at δ 7.69, δ 7.48 and δ 7.95 and to a 
lesser extent p-hydroxyphenylacetate and hippurate. This lends weight to the idea that 
these phenolic metabolites originate from particular species of the human gut 
microbiota. 
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6.6.6. Effect of cruciferous vegetable dietary intervention on meat and caffeine 
alterations of metabotype. 
A most perplexing finding distinguishing post meat meal urine sample classes was the 
presence of mannitol. Mannitol is an osmotic diuretic and weak renal vasodilator.  It is a 
stereoisomer of sorbitol and is an exogenous metabolite in humans, and its presence in 
the urine of these subjects is quite unusual. Mannitol is the most highly abundant sugar 
alcohol or polyol found in nature and is found in a wide variety of commonly consumed 
fruits and vegetables. Mannitol is primarily used as an artificial sweetener but also in 
the pharmaceutical industry as filler and to aid drug delivery across the blood-brain 
barrier. It is manufactured commercially by industrial hydrogenation or by fermentation 
of fructose, glucose or maltose by Lactobacillus intermedius. The meat meal was 
prepared using only high quality pure beef steak without any ‗fillers‘ such as mannitol 
which is commonly found as an additive in cheap meat patties. The subjects were also 
not provided with any artificial sweeteners or sugar with their coffee.  
 
Lactobacillus intermedius is not known to be part of the human gut microbiota, also 
none of this bacteria‘s substrates (for fermentation of mannitol) were present in the meat 
meal or the coffee given to the study subjects. The presence of mannitol in the urine is 
an enigma after discounting all potential sources from the study 
 
The fact that mannitol appears to be present at all time points suggests that it was 
deliberately introduced perhaps as a saliva inducer for the purposes of the caffeine 
kinetics analysis in the original study 
81
, in chewing gum or perhaps as a coffee 
sweetener for example. As the excretory half life of mannitol is only 100 minutes, it 
appears that mannitol was administered throughout the duration of the study. It could 
suggest that its presence is a spurious contaminant arising from the study. Mannitol is 
almost completely unmetabolised in humans, it has a bioavailability of only 7% and 
hepatic metabolism is negligible  
302
. Consumption of mannitol in sufficient quantity is 
known to produce a laxative effect by drawing water into the large intestine by osmosis. 
Mannitol is commonly used in clinical medicine as an indicator of renal function with a 
90% renal excretion. O-PLS-DA revealed an increased urinary excretion of mannitol in 
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phase I compared to both phase II and phase III. This indicates an unexplained effect on 
mannitol excretion following CV consumption.  
 
Several heterofermentative lactic acid bacteria (LAB) belonging to the genera 
Lactobacillus are known to produce mannitol from fructose, some of which are known 
to be human gut microbes. Mannitol is produced by the enzyme mannitol-2-
dehydrogenase (MDH) which catalyses the pyridine nucleotide dependent reduction of 
fructose. In particular the enzyme MDH has been purified and characterized from L. 
Brevis 
303
, L. Sanfranciscensis 
304
, Leuconostoc mesenteroides 
305
, and Lc. 
Pseudomesenteroides 
306
. 
 
STOCSY analysis of mannitol reveals correlations with other sugars such as glucose in 
the spectra. This suggests mannitol is perhaps less likely to be a contaminant as it 
correlates with other endogenous sugar metabolites. 
 
Interestingly outliers in chemometric models were found to be due to the characteristic 
1
H-NMR splitting pattern of ethanol in pre-dose urine samples. These outlying samples 
were removed to prevent poor modelling of the data. Study subjects were requested to 
abstain from alcohol during the study period however this finding suggests that study 
subjects did not adhere to dietary restrictions. This could perhaps shed light on the 
presence of mannitol as a contaminant.   
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6.6.4 UPLC Mass Spectral Metabonomic analysis  
 
UPLC-MS as a metabonomic analytical platform succeeded in detecting 19 statistically 
significant mass spectral features by m/z and retention time in positive mode, 11 
significant features in negative mode by use of the XCMS
1 
peak picking programme. 
Targeted analysis also succeeded in semi-quantifying a further 6 potential biomarkers in 
positive mode but failed to do so within the negative mode dataset. Identification of 
tentative biomarkers was attempted by online database searches which provided a 
wealth of potential candidates many of which were biologically plausible and a self-
generated list of potential metabolites based on metabolites of CVs, caffeine, meat and 
metabolites of the red-meat carcinogens. Authentic standards were subjected to MS/MS 
fragmentation analysis in positive mode (34) and in negative mode (31) and also further 
compounds of interest (17) at a range of ionisation voltages and compared to MS/MS 
fragmentation patterns of the unknown spectral features in human urine. Unfortunately 
this failed to fully confirm identity of the mass spectral biomarkers or to suggest any 
significant commonality in fragmentation pattern.  
  
Similarity of the tentative biomarker fragmentation patterns were also compared to 
experimental fragmentation patterns on both the Metlin (using the XCMS
2 
programme) 
and the HMDB. A metabolite of SMCSO; 3-methylthiolactic acid sulphoxide was a 
potential biomarker within the negative mode dataset, diagnostic of CV consumption. 
However in the absence of an authentic standard this was unconfirmed. In the absence 
of absolute confirmation of tentative biomarkers, the pattern of mass spectral features 
can be seen as ‗finger-print‘ of changes associated with both CV consumption and red-
meat/caffeine dietary intervention. 
 
The use of UPLC-MS data for global metabolic profiling has only been applied 
relatively recently and though perhaps less advanced than 
1
H-NMR spectroscopy, it has 
significant advantages and has met with success, notably within rat urine and plasma 
metabonomic datasets 
307, 308
 
150
. UPLC-MS utilizes high pressures combined with small 
capillary particle size for increased chromatographic resolution and boasts significant 
advantages; rapid screening, relatively high resolution and high throughput. However 
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UPLC-MS for metabonomic analysis suffers from some disadvantages; 
chromatographic and mass spectral drift, ion enhancement/suppression and 
reproducibility compared to NMR data. 
 
A significant challenge of interpretation of UPLC-MS data is its sheer size which makes 
manual analysis of raw data almost impossible.  The use of chemometric techniques 
particularly in the form of software packages such as XCMS
1
 
157
 and from 
instrumentation manufacturers (eg. Masslynx/MarkerLynx Waters) have proven useful 
for the discovery of biomarkers. HPLC-MS analysis was used recently to identify the 
neutral loss of 129 m/z mercapturates from acetaminophen in human urine 
272
 and holds 
promise for future human metabonomic studies. 
 
Recently new methods of UPLC-MS data treatment have been introduced which 
advocate the use of quality control samples placed within the 96-well plates of high 
throughput sample sets. The quality control sample would consist of a pooled urine 
sample from samples across the study to broadly reflect the different urinary 
components of participants throughout the study. These samples can then be treated as a 
quality control sample set that can be submitted to PCA analysis and further scrutiny in 
an effort to reduce any problem associated with reproducibility, chromatographic and 
spectral drift in large datasets. The run of quality control samples can be checked for 
any irregularity in retention time of peaks and intensities from the start of the run to the 
finish and the ion intensities for individual peaks can also be compared to ensure that 
analysis has performed properly throughout the run and validate the results obtained 
from the experimental dataset. 
Unfortunately when the CV urinary sample set was submitted to high-throughput 
UPLC-MS analysis this methodology was not implemented. The data analysis would 
most certainly have been improved by using this method and would have improved 
result assessment and validity 
309
 . 
 
Data-mining programs such as XCMS
1
 use special algorithms that filter and bin raw 
mass spectral data then extract chromatographic features identified by m/z ratio and 
retention time. The features are then aligned, normalized and a peak table created, 
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which can be subjected to further statistical analysis. XCMS uses a peak picking 
algorithm that identifies chromatographic features that represent the differences 
between sample classes and produces a list of Extracted Ion Chromatograms (EICs) and 
box and whisker plots and sorted in ascending order of confidence based on p-value and 
other statistical measures. However the XCMS
1 
can fail to work when peak alignment is 
poor due to spectral drift, this occurred within the positive mode dataset when 
examining the effect of CVs on meat and caffeine alteration of metabotype and failed to 
obtain adequate peak alignment. This could also be due to essentially no detectable 
difference between the Phase II 0-10hrs timepoint and the Phase I and III 0-10hrs 
timepoints other than the markers identified in the predose urine samples. The tentative 
biomarkers of CV consumption were selected based on their class exclusivity within the 
mass spectral data and by interpretation of the EIC, box and whisker plot, p-value and 
presence within the raw data. This relies on a degree of subjectivity and selection of 
significance, alignment and peak height within the EIC and exclusivity with the box and 
whisker plot. The purpose of this process was to identify ions of interest on which the 
investigations could focus attention as a possible source of biomarker information. 
 
Initial biomarker identification was based on knowledge of potential exogenous and 
endogenous candidate metabolites, database mining (ie. Human Metabolome Database, 
Hmdb, Genome Alberta) and fragmentation analysis. A further technique that could be 
attempted is use of a high resolution orbitrap mass spectrometer to obtain accurate mass 
atomic formulae of the unknown biomarkers in urine. Final confirmation is achieved 
using authentic standards but fragmentation of standard compounds failed to identify 
any of the unknown urinary biomarkers. The lack of absolute identification of unknown 
metabolites obtained from MS leads was disappointing. However identification was 
confounded by the number of standard compounds available within the scope of this 
thesis and the limitations of slowly developing metabonomic databases and is an 
ongoing challenge.  
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6.7 Conclusions 
In conclusion this human dietary intervention study succeeded in identifying 4 distinct 
urinary biomarkers of CV dietary intervention by 
1
H-NMR spectroscopy and a total of 
21 statistically significant urinary biomarkers and 2 putative biomarkers using a targeted 
approach by UPLC-MS analysis of both positive and negative mode datasets utilising 
various chemometric modelling techniques. 
 
1
H-NMR spectroscopy combined with the O-PLS-DA modelling proved particularly 
successful in identifying four distinct biomarkers of CV consumption. 
A combination of 
1
H-
1
H J-Res, COSY, 
13
C-
1
H HSQC, 
13
C-
1
H HMBC and TOCSY two 
dimensional NMR spectroscopy was indicative of two biomarkers of CV consumption; 
SMCSO and NAc-SMCSO.  The vegetable origin of this biomarker of CV consumption 
was confirmed by application of the same two dimensional NMR experiments to 
aqueous extracts of CVs. The identification of N-Acetylated-SMCSO was as the most 
significant biomarker of CV vegetable consumption, however due to contamination of 
the synthetic reaction this was highly indicative of the unknown singlet peak 2.78 in 
human urine but not truly conclusive. This problem could have been surmounted by the 
purchase of a custom synthetic standard compound of NAc-SMCSO, but this was not 
financially possible. The two remaining biomarkers of CV consumption could 
reasonably be hypothesised to be the thiopyruvate and thiolactate of SMCSO derived 
from deamination, although this was not confirmed.  
 
Targeted biomarker identification and the XCMS
1
 programme were successful in 
identifying 2 potential targeted biomarkers and 21 statistically significant tentative 
biomarkers of CV consumption in both the positive and negative mode UPLC-MS 
datasets. Problems arose in identification of these unknowns however, despite rigorous 
online database searches and the comparison of tandem MS/MS fragmentation patterns 
to that of promising biological candidate compounds. The availability and expense of 
standard compounds and the development of metabonomic mass spectral databases was 
highlighted as problematic to absolute identification of these unknowns. 
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The effect of red meat dietary intervention was demonstrated by 
1
H-NMR spectroscopy 
combined with supervised multivariate analyses. This corresponded to what appeared to 
be a digestive transit of the meat meal over the 48 hour urinary time course. These 
included post-prandial biomarkers of meat consumption such as excess amino acids 
with evidence of increased concentrations of bacterial co-metabolites which are 
associated with nitrogen removal in the gut. UPLC-MS analysis produced 9 statistically 
significant urinary biomarkers of meat consumption and 4 targeted approach putative 
biomarkers which bore expected molecular ion similarity to known metabolites of 
caffeine, however absolute identification proved problematic. 
 
The effect of CVs on meat and caffeine alterations metabolism was not satisfactorily 
addressed as the presence of mannitol a discriminatory of the post meal/ caffeine was 
entirely unanticipated and difficult to account for. Furthermore due to peak-picking 
difficulties in the XCMS
1
 programme only one biomarker addressing this experimental 
aim was discovered in the negative mode dataset. This feature had the expected m/z of 
the parent ion of deaminated SMCSO; 3-methylthiolactic acid however this could not 
be confirmed due to the lack of an authentic standard. 
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Chapter Seven: Overall Conclusions and Future Work 
The purpose of this thesis was to apply analytical techniques, including high-throughput 
1
H-NMR spectroscopy and UPLC-MS of biofluids coupled to multivariate statistical 
modelling, to examine the effects of nutritional intervention in three different 
experimental studies. Initially a study in experimental animals (rats) examined the effect 
of a dietary genotoxic carcinogen methyl eugenol on the metabolic phenotype. This was 
followed by a human dietary study examining the effect on metabolic phenotype of 
changing dietary fat composition and carbohydrate GI in subjects at risk of developing 
the metabolic syndrome; a condition considered a precursor to cardiovascular disease 
(CVD), type II diabetes and increased morbidity. Finally a further human study to 
determine the effects of CVs, meat meal and caffeine dietary interventions on the 
human metabolic phenotype, this represented a study examining dietary components 
reputed to be beneficial to human health. 
 
7.1 The application of metabonomics to examine the effects of ME 
dietary intervention in rats 
As a preliminary metabonomic study the effect of ME a known genotoxic carcinogen on 
the rat metabolic phenotype was investigated. This compound is of significant public 
health interest as it is widely consumed in many fruits, vegetables and spices and is used 
extensively as an additive in many foods, cosmetics and household items but has been 
shown to cause hepatic and gastric carcinogenesis in experimental animals. The study 
described in this thesis examined doses in F344 strain rats which were designed to more 
realistically reflect estimated human exposure levels (~1mg/kg bw/day), using doses in 
the range 1-50mg/kg bw/day in a 28 day dietary regimen; previous laboratory animal 
studies had used doses far in excess of this. 
The primary aim of this study was to assess any effect of methyl eugenol on the global 
rat metabolic phenotypes. It was hypothesised that any disruptions of normal 
homeostatic control in the rats suggesting a toxic, genotoxic or carcinogenic effect 
would be reflected in the urinary metabolite profile. The findings of this study 
confirmed that a dosing regimen of ME of human relevance over twenty-eight days with 
weekly sample collection did not produce any dramatic effect on the rat metabolic 
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phenotype. However there were subtle differences in urinary metabolic profile in the 
high dose group rats which were attributed to a putative urinary metabolite of ME, 
perhaps the sulphate or glucuronic acid conjugate of O-demethylated ME. The low 
urinary concentration of these discriminatory peaks in rats exposed to 50mg/kg bw/day 
made further structural elucidation by two-dimensional NMR experimentation 
problematic. However, attempts could be made in the future to concentrate urine 
samples from rats in this dosage group and combined with liquid chromatographic 
techniques and solid phase extraction may help to absolutely identify this putative 
urinary biomarker of ME exposure. 
There is considerable interest in the accurate biomonitoring of ME exposure in 
experimental animal toxicology studies and in human populations, in environmental 
toxicology and public health epidemiological studies. Good urinary biomarkers of ME 
could potentially be useful in high-throughput metabonomic studies of human 
populations. Average human exposure levels to ME (~1mg/kg bw/day), are likely to be 
below the detection limits of high-throughput urinary 
1
H-NMR spectroscopic analysis. 
The current study supports this position since the urinary concentration of potential 
biomarkers of ME in the rat urine samples was very low and the overlapping of 
constitutive metabolites in higher concentration confounded the data. However the use 
of targeted UPLC-MS analysis, which has higher resolution and sensitivity than 
1
H-
NMR spectroscopy may allow accurate identification of urinary biomarkers/metabolites 
of ME.    
As proof of principle, the application of metabonomic multivariate modelling of rat 
urinary metabotype successfully identified metabolic differences related to gender, age 
and a stress-response related to the use of the orogastric gavage. Clear evidence of 
sexual dimorphism in the urinary metabolic profile was identified in the F344 strain 
rats. Also evidence of age-related metabolic change in endogenous and bacterial co-
metabolites suggested increases in body weight, muscle mass, development of gut 
microbial populations and post-weaning adjustment of metabolism to an adult diet. 
Interestingly metabonomic approaches identified metabolic changes related to an 
induced acute stress-response in the experimental animals attributable to the orogastric 
gavage technique commonly used in toxicology studies. These findings demonstrated 
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the robustness of metabonomics for modelling changes in urinary metabolic 
phenotypes. However it also highlighted the potential influence of gender, age and 
method of administration in confounding results in dietary intervention studies. This has 
important implications in limiting inter-subject and experimental variation in animal 
studies despite using a relatively homogeneous population that is genetically and 
environmentally identical (F344). This must be considered when applying metabonomic 
methods to human dietary interventions where inter-subject and environmental 
variations are potentially more confounding. 
 
7.2 Application of the metabonomic approach to understanding human 
dietary intervention with varying composition of dietary fat and 
glycaemic index of carbohydrates in subjects at risk of developing 
metabolic syndrome    
The metabonomic strategies successfully applied in the preliminary animal study were 
utilised to examine a human dietary intervention urinary dataset. This study concerned a 
significant issue in public health, specifically the effects of human dietary intervention 
on subjects at risk of developing metabolic syndrome, a condition characterised by 
obesity, glucose intolerance, dyslipidaemia and hypertension. Also of interest was the 
influence of the gut microbiota on the development of this syndrome. Subjects 
diagnosed with MS are considered at increased risk of developing subsequent associated 
aetiologies of CVD, type II diabetes, cancer and increased morbidity and mortality.  
This study analysed urine and faecal water samples from a cohort of subjects (n=130) at 
risk of developing the MS. Two urine samples were collected from each subject; a 0 
week following a 4 week ―typical western‖ dietary regimen run-in and a 28 weeks 
collection. Subjects were divided into 5 dietary intervention groups; a control diet and 4 
other dietary groups where the composition and proportion of dietary fats and GI of 
carbohydrates had been altered. 
Application of unsupervised and supervised multivariate statistical analyses to this 
human dataset failed to identify any detectable effect of this dietary intervention on the 
human metabolic phenotype. This was reflected in poor modelling strengths of 
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chemometric models and a dominance of inter-subject variation in the dataset. No 
variation attributable to the effect of altering dietary fat composition and carbohydrate 
in human study subjects or discriminated between the different dietary classes was 
found. Collaborators at the University of Reading identified subtle changes in bacterial 
population numbers in the study subjects using FISH analysis. These bacterial 
population findings were regressed to the both the urinary and faecal water 
1
H-NMR 
spectroscopy datasets in an attempt to identify metabolic correlation particularly in the 
bacterial co-metabolites with the bacterial population findings. Unfortunately, this 
regression analysis also proved unsuccessful as only subtle variations were seen 
between the dietary classes in the bacterial numbers enumerated by FISH and this was 
confirmed by the spectral data regression analyses. 
In spite of attempts to improve data pre-processing, peak alignment and removal of 
outliers from the datasets no effect of dietary intervention was observed in this human 
study. 
This study was unsuccessful in terms of elucidating the effects of changing dietary fat 
and carbohydrate GI on human metabotype. However, the results of this study 
highlighted the inherent inter-subject variability in human populations and the 
subsequent confounding of metabonomic modelling of subtle dietary interventions. The 
subjects in this study were a particularly heterogeneous cohort. Both male and female 
subjects were recruited, with multi-racial backgrounds (although predominantly Asians) 
and variable age. Furthermore, the diagnostic criteria for recruitment were based on 
subjects at risk of developing MS and not a clinical diagnosis of the syndrome. The 
criteria consisted of a scoring system based on measures of blood pressure, glucose 
intolerance, central adipodisity, BMI and dyslipidaemia, family histories of type II 
diabetes, polycystic ovary syndrome, gestational diabetes and artherogenic lipid 
profiles. Dietary compliance was monitored by use of 4-week food diaries, therefore 
subjects may not have adhered to the dietary restrictions or recommended foodstuffs 
over the course of a 24 week dietary intervention. For the purpose of metabonomic 
analysis the experimental, environmental and inter-subject variability introduced 
particularly by the recruitment criteria proved problematic for robust modelling of the 
subtle dietary intervention effects.  
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7.3 Metabonomic analysis of the effects of CV dietary intervention on 
the human metabolic phenotype 
It was hoped that more rigorous control of inter-subject, environmental and 
experimental variation in human study subjects, which proved problematic in the 
previous human study, would enable the effects of dietary intervention to be observed in 
the metabolic profile. This human study examined the effect of CVs, known to be 
beneficial to human health and inversely associated with many forms of cancer, on the 
human metabolic profile. This study also examined the metabolic consequences of meat 
consumption and attempted to address any effect of CVs on alterations of meat and 
caffeine metabolism.  
In this study inter-subject variation was limited by recruiting male, Caucasian, non-
smoking individuals, of comparable age and also by restriction of prescription drugs, 
alcohol and other foodstuffs believed to possess strong biological properties such as 
alliums. In this instance, the metabonomic approach proved successful when applied to 
this human nutritional intervention data set. 
1
H-NMR spectroscopy combined with the 
O-PLS-DA chemometric technique proved particularly successful in identifying four 
distinct biomarkers of CV consumption and characterising time-course effects on 
metabolic phenotype following consumption of a red meat meal. The use of improved 
data pre-processing techniques RSPA and normalisation to the probabilistic quotient 
and a combination of 
1
H-
1
H J-Res, COSY, 
13
C-
1
H HSQC, 
13
C-
1
H HMBC and TOCSY 
two dimensional NMR spectroscopy confirmed the identity of two biomarkers of CV 
consumption namely SMCSO and NAc-SMCSO. Aqueous extracts of CVs 
demonstrated the dietary origin of SMCSO. The N-acetylated derivative of SMCSO, a 
common route of amino acid metabolism was also shown to be present in human urine 
as the most significant biomarker of CV vegetable consumption. This identification was 
not definitive, but was strongly indicative. The presence of NAc-SMCSO as the 
dominant biomarker of CV consumption is in accordance with the known excretory 
pathways of SMCSO; the two remaining biomarkers of CV consumption were 
hypothesised to be the thiopyruvate and thiolactate of SMCSO derived from 
deamination. Although not confirmed, such metabolites are predicted based upon this 
study and previous reported studies 
276, 277
.  
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The identification of NAc-SMCSO and unmetabolised SMCSO within human urine as 
biomarkers of CV consumption has potential utility in targetted epidemiological studies 
of diet, and perhaps cancer risk and population metabonomics. It could also be 
conceivably used to monitor adherence to a proscribed diet of CVs and/or alliums in 
human dietary intervention studies; this would certainly be preferable to the use of food 
diaries. The findings of this study should provide impetus for further study of SMCSO 
particularly within humans. The bulk of research on CVs has focused upon the 
glucosinolates and their hydrolysis products however SMCSO is reputed to be partly 
responsible for the health benefits of CVs 
295
.   
The effect of consumption of a red meat meal was clearly elucidated by 
1
H-NMR 
spectroscopy revealing an apparent digestive transit of the meat meal over the 48 hour 
time course with post-prandial biomarkers of meat consumption, excretion of excess 
amino acids, followed by evidence of bacterial co-metabolites associated with nitrogen 
removal in the gut. Each of these phases of digestive transit was identifiable in the time-
dependent urine samples. The effect of CVs on meat and caffeine metabolism was not 
satisfactorily addressed due in part to the presence of mannitol, which was entirely 
unanticipated and difficult to account for.  
The use of UPLC-MS global analysis in metabonomics is a relatively recent analytical 
platform when compared to 
1
H-NMR spectroscopy, particularly in human studies. 
However the use of targeted biomarker identification and the XCMS
1
 programme was 
successful in identifying 6 potential targeted biomarkers, 19 statistically significant 
tentative biomarkers in the positive mode and 11 tentative biomarkers in the negative 
mode datasets. The sensitivity of UPLC-MS allows identification of considerable 
numbers of class discriminating mass spectral features however significant problems 
remain in absolute identification of unknowns. The biomarkers identified by a mixture 
of targeted and statistical approaches can be considered a ‗fingerprint‘ of metabolic 
changes that characterise consumption of CVs, red meat and caffeine. In spite of 
identifying promising candidates based upon biological expectation and online database 
searches, none of the biomarkers were chemically confirmed. The ongoing development 
of metabonomic mass spectral databases will be a key limiting factor in the discovery 
process. 
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7.4 The future potential of metabonomics for nutrition studies 
There are currently concerted efforts being made to create standardised methods and 
databases focused on nutritional metabolite biomarker discovery and nutrigenomics 
310
. 
The limiting factor in utilisation of metabonomic technologies in biomarker discovery is 
the interpretation of datasets which can contain 2000+ metabolites 
311
 and the 
cataloguing and standardisation of methods between research groups is of the utmost 
importance particularly in the case of UPLC-MS analysis 
312
. These particular 
challenges were highlighted by the difficulty encountered in identifying 
1
H-NMR 
spectral biomarkers and even more so tentative biomarkers elucidated by UPLC-MS 
analysis.  
The use of stable non-invasive, robustly validated biomarkers of nutritional 
interventions particularly of foodstuffs of significant public health interest could be of 
enormous utility to the study of nutrition and its contribution to beneficial/detrimental 
health outcomes. The ability to gauge actual exposure of study participants to dietary 
components holds great future potential within human epidemiologic studies, to 
quantify absorbtion and exposure levels of dietary components in in vivo animal studies 
and to ensure dietary compliance in human nutritional intervention studies. The use of a 
robust stable urinary/serum biomarker has potential to improve or perhaps even negate 
the reliance upon inferior methods of dietary analysis such as food diaries, 24 hour diary 
recalls and food frequency questionnaires which are prone to inaccuracies 
84-55
.  
There are many studies in the scientific canon regarding the purported health benefits of 
components of the diet, particularly in the case of vegetables and fruits which are the 
subject of enormous research focus 
2,3,33-35
. However, the findings of these studies are 
potentially confounded by the difficulties and inaccuracies associated with dietary self-
reporting. The use of non-invasive biomarkers in biofluids which either predict or 
influences health, the exposure to dietary components or can influence the incidence or 
behaviour of a disease of dietary interventions could be used to improve the accuracy 
and validation of current dietary self-reporting methods. The use of dietary intervention 
biomarkers could be used in future studies and also in theory be performed post-
humously, the quantification of exposure levels to beneficial foodstuffs could lend 
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added weight to their findings and give an enhanced interpretation of true physiological 
effects of a dietary intervention 
313
. 
In future studies examining CVs an ideal study design would initially analyse the 
concentration of SMCSO in aqueous extracts of the CVs which are to be consumed, 
followed by subsequent blood serum and urine analysis from serially collected samples. 
This would provide a quantifiable account of the LADME of CVs and potentially 
alliums in human study participants or equally in animal studies.  
Currently, the biomarkers of CV consumption (SMCSO and NAc-SMCSO) discovered 
in the course of this thesis is being validated in the INTERMAP (INTERnational 
collaborative study of MAcronutrients, micronutrients and blood Pressure) 
epidemiology study 
314
.  INTERMAP is a multi-centre cross-sectional epidemiologic 
investigation designed to help clarify unanswered questions regarding the role of dietary 
factors in the development of unfavourable blood pressure (BP) levels in adults. 
Preliminary exploration of this large urinary dataset (n=4860) of individuals from the 
UK, US, Japan and China.  Based upon 24hour dietary recalls UK participants 
consuming CVs/alliums and non-consumers have been discriminated robustly by the 
excretion of SMCSO and NAc-SMCSO in all species of the cruciferae and alliums 
examined. This investigation will be further extended to all populations and by 
comparison of reported weight and type of vegetables of the cruciferae and alliums 
consumed to the excretory levels of these biomarkers in urine, to address accurate levels 
of LADME and an improved picture of the pharmacokinetics of bioactive food 
components. Quantified urinary concentrations of these biomarkers will also be 
regressed to systolic and diastolic blood pressure measurements, CVD and types II 
diabetes disease status and BMI.   
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7.5 Summary 
In summary, metabonomic approaches proved largely efficacious in the characterisation 
of nutritional intervention on the metabolic phenotype in both human and experimental 
animal studies. This study successfully identified 
1
H-NMR spectral biomarkers of both 
CV and meat consumption in human urine, tentative evidence of a urinary biomarker of 
ME exposure at a low dosage regimen (1-50mg/kg bw/day) and a discrimination of age, 
sex and dietary administration method in rat urinary metabolic profiles. In the 
preliminary human study, the limitation of experimental and intersubject variations was 
demonstrated to be of great importance in the robust modelling of metabonomic 
datasets, especially in human nutritional intervention studies where great environmental 
and genetic variations exist and therefore appropriate design of experiments is of prime 
concern.  
UPLC-MS analysis proved successful in the identification of biomarkers (36) of both 
CV and meat meal dietary interventions in human urine. The superior resolution and 
sensitivity of this analytical platform compared to 
1
H-NMR spectroscopy offers great 
potential for the identification of low molecular weight biomarkers in low concentration 
in human and experimental animal biofluids. Further statistical analyses may have been 
attempted to enhance interpretation of the mass spectral data such as statistical 
heterospectroscopy (SHY) correlation. SHY correlation coanalyses NMR and MS 
spectral data based upon intrinsic covariance correlations and can provide additional 
biological or structural information on unknown spectral features 
315
. However, the 
absolute chemical identification of UPLC-MS biomarkers of nutritional intervention 
proved problematic, highlighting the ongoing development of mass spectral databases 
as a limiting factor in the discovery process. Further mass spectral fragmentation 
analysis would be necessary for absolute chemical identification of the unknown 
biomarkers identified. 
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The analysis of metabolic consequences of exposure to dietary components is of great 
public health interest to the understanding of the complex relationship between diet and 
disease, particularly the identification of robust biomarkers of exposure and response in 
human and experimental animal biofluids. Biomarkers of nutritional intervention are of 
interest as they allow the biomonitoring of dietary interventions, absorption and 
exposure levels, the interrogation of epidemiological datasets of disease risk and 
outcomes and the identification of mechanisms of the beneficial/detrimental effects of 
components of the diet.  
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